O-glycoprotein-2-acetamido-2-deoxy-3-d-pyranosidase inhibitors

By designing new compounds that selectively inhibit O-GlcNAcase, the problem of non-selective O-GlcNAcase inhibitors in the prior art was solved, effective treatment of Alzheimer's disease and tau lesions was achieved, and intracerebral Glucose metabolism impairment.

CN118955490APending Publication Date: 2024-11-15BIOGEN MA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410813893.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-07-17
Filing Date
2019-03-13
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The presence of existing O-GlcNAcase inhibitors in higher eukaryotic tissues leads to challenges in regulating O-GlcNAcase for the treatment of Alzheimer's disease and related neurodegenerative diseases, especially due to their other functions Complex phenotypes caused by nonspecific inhibition of related enzymes.

Method used

A novel compound structure was developed to design compounds that selectively inhibit O-GlcNAcase by specific heteroaryl, thiazolyl and other substituents for the treatment of a variety of diseases associated with O-GlcNAcase modifications , including Alzheimer's disease and tau lesions.

Benefits of technology

This compound provides a potential treatment option by selectively inhibiting O-GlcNAcase, effectively preventing the high phosphorylation of tau protein, potentially alleviating the intracerebral glucose metabolism damage in Alzheimer's disease and related neurodegenerative diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955490A_ABST
    Figure CN118955490A_ABST
Patent Text Reader

Abstract

Described herein are compounds represented by formula (I ") or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising compounds or pharmaceutically acceptable salts thereof, and methods of making and using compounds or pharmaceutically acceptable salts thereof. The variables Ar, Ra, Rb, m, n, Y1, Y2, R3, and R4 are as defined herein. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application based on the invention patent application with application date of March 13, 2019, application number 201980019170.5 (PCT application number PCT / US2019 / 021995), and invention name: "O-glycoprotein-2-acetylamino-2-deoxy-3-D-pyranosidase inhibitor".

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims the U.S. Provisional Application No. 62 / 699,443 filed on July 17, 2018; U.S. Provisional Application No. 62 / 690,536 filed on June 27, 2018; and U.S. Provisional Application No. 62 / 642,932 filed on March 14, 2018; the entirety of each of which is incorporated herein by reference. Background Art

[0004] Numerous cellular proteins of the nucleus and cytoplasm are modified post-translationally by adding the monosaccharide 2-acetylamino-2-deoxy-β-D-pyranoglucoside (β-N-acetylglucosamine), which is connected by an O-glycosidic bond. This monosaccharide is commonly referred to as N-acetylglucosamine or O-GlcNAc connected by O-. The enzyme responsible for post-translationally connecting β-N-acetylglucosamine (GlcNAc) to specific serine and threonine residues of numerous nucleoplasmic proteins is O-GlcNAc transferase (OGTase). The second enzyme (called O-glycoprotein-2-acetylamino-2-deoxy-3-D-pyranoglucoside enzyme or O-GlcNAcase or OGA) removes this post-translational modification to release the protein, allowing the O-GlcNAc modification to undergo several dynamic cycles during the life of the protein.

[0005] O-GlcNAc-modified proteins regulate a wide range of important cellular functions, including, for example, transcription, proteasomal degradation, and cell signaling. O-GlcNAc is also present on many structural proteins, including the cytoskeletal protein "tau," which is responsible for stabilizing the critical cellular network of microtubules that are required for the distribution of proteins and nutrients in neurons. Importantly, tau has been clearly implicated in the etiology of several diseases, including tauopathies, Alzheimer's disease, Parkinson's disease, dementia, and cancer.

[0006] It is well established that Alzheimer's disease and many related tauopathies, including progressive supranuclear palsy (PSP) and amyotrophic lateral sclerosis (ALS), are characterized in part by the development of neurofibrillary tangles (NFTs). These NFTs are aggregates of paired helical filaments (PHFs) and are composed of abnormal forms of tau. In AD patients, tau is highly phosphorylated, thereby disrupting its normal function, forming PHFs and ultimately aggregating to form NFTs.

[0007] Six isoforms of tau are found in the human brain. In AD patients, all six isoforms of tau were found in NFTs, and all were clearly highly phosphorylated. Tau in healthy brain tissue has only 2 or 3 phosphate groups, while tau found in the brains of AD patients has an average of 8 phosphate groups.

[0008] The increase of phosphorylation level that occurs recently causes O-GlcNAc level to reduce, and on the contrary, the increase of O-GlcNAc level is relevant to the reduction of phosphorylation level.Shown, glucose utilization rate reduces and causes tau hyperphosphorylation in the brain.The progressive lesions of glucose transport and metabolism cause O-GlcNAc to reduce and the hyperphosphorylation of tau (and other albumen).Therefore, the inhibition of O-GlcNAcase that prevents the removal of O-GlcNac in tau to prevent the hyperphosphorylation of tau should compensate for the age-related lesions of glucose metabolism in the brain of healthy subjects and patients suffering from Alzheimer's disease or related neurodegenerative diseases.

[0009] However, the main challenge in developing inhibitors for blocking mammalian glycosidases (including O-GlcNAcase) functions is the presence of a large number of functionally related enzymes in higher eukaryotic tissues. Therefore, the application of non-selective inhibitors in studying the physiological effects of cells and organisms of a specific enzyme is complicated, because complex phenotypes are caused by the concomitant inhibition of these functionally related enzymes. In the case of β-N-acetylglucosaminidase, existing compounds for blocking O-GlcNAcase functions are non-specific and are used to effectively inhibit lysosomal β-hexosaminidase.

[0010] In view of the above technical challenges, and considering the potential of modulating O-GlcNAcase to treat AD, tauopathy, and other neurological diseases, there is still a need to develop potent and selective O-GlcNAcase inhibitors. Summary of the invention

[0011] Described herein are compounds useful for treating a variety of diseases, disorders, and medical conditions, including, but not limited to, those associated with proteins modified by O-GlcNAcase.

[0012] The first embodiment of the compound of the present invention is represented by the following structural formula:

[0013]

[0014] or a pharmaceutically acceptable salt thereof, wherein:

[0015] Ar is optionally substituted 5- to 10-membered heteroaryl, optionally substituted phenyl, or optionally substituted phenyl fused to an optionally substituted non-aromatic 5- to 6-membered heterocyclic ring;

[0016] Y 1 and Y 2 Each is CR c or N, where Y 1 or Y 2 At least one of them is N;

[0017] Z is CR 2 R 2 , C(=O), (CR 2 R 2 ) 2 , CH 2 C(=O) or C(=O)CH 2 ;

[0018] R a , R b and R c are independently -H, halogen, C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl or C 1 -C 4 Alkoxy, or R a and R b Together with its intervening carbon atom, it forms C 3 -C 6 Cycloalkyl;

[0019] m is 0 or 1;

[0020] n is 0 or an integer from 1 to 7;

[0021] When n is not 0, R 1 is independently at each occurrence a halo, C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 1 -C 4 Alkoxy or C 1 -C 4 Haloalkoxy;

[0022] R 2 is independently at each occurrence -H, halo, C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 3 -C 10 Cycloalkyl or C 3 -C 10 Halogenated cycloalkyl;

[0023] Or alternatively, two R 2 Together with the carbon atom to which it is attached, it forms C 3 -C 10 Cycloalkyl;

[0024] R 3 Yes - H or C 1 -C 4 alkyl; and

[0025] R 4 Yes - H, C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl or C 3 -C 6 Cycloalkyl;

[0026] Or alternatively, R 3 and R 4 Together with their intervening atoms they form an optionally substituted 5- to 7-membered heterocyclyl.

[0027] Provided herein are pharmaceutical compositions comprising at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

[0028] Also provided herein are methods of treating a subject having a disease or condition selected from a neurodegenerative disease, a tauopathy, diabetes, cancer, and stress, comprising administering to the subject an effective amount of a compound described herein or a pharmaceutically acceptable salt thereof, or an effective amount of a pharmaceutical composition comprising at least one compound described herein or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.

[0029] Also provided herein is a method of inhibiting O-GlcNAcase in a subject in need thereof, comprising administering to the subject an effective amount of a compound described herein or a pharmaceutically acceptable salt thereof, or an effective amount of a pharmaceutical composition comprising at least one compound described herein or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.

[0030] Also provided herein are methods of treating a disease or condition characterized by tau hyperphosphorylation in the brain, the method comprising administering to the subject an effective amount of a compound described herein or a pharmaceutically acceptable salt thereof, or an effective amount of a pharmaceutical composition comprising at least one compound described herein or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. DETAILED DESCRIPTION

[0031] Described herein are compounds useful for treating a variety of diseases, disorders, and medical conditions, including, but not limited to, those associated with proteins modified by O-GlcNAcase.

[0032] In a first embodiment, the compounds of the present invention are represented by the following structural formula:

[0033]

[0034] or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above in the Summary of the Invention.

[0035] In a second embodiment, the compounds of the present invention are represented by the following structural formula:

[0036]

[0037] or a pharmaceutically acceptable salt thereof, wherein R a , R b and R c are independently -H, halogen, C 1 -C 4 Alkyl or C 1 -C 4 A haloalkyl group, or R a and R b Together with its intervening carbon atom, it forms C 3 -C 6 Cycloalkyl; wherein the remaining variables are as defined in the first embodiment.

[0038] In a third embodiment, the compound of the present invention is represented by the following structural formula:

[0039]

[0040] or a pharmaceutically acceptable salt thereof; wherein each variable is as defined in the first embodiment or the second embodiment.

[0041] In a fourth embodiment, the compound of the present invention is represented by the following structural formula:

[0042]

[0043]

[0044] or a pharmaceutically acceptable salt thereof; wherein R a and R b Each independently is -H or C 1 -C 4 Alkyl; R 2 is independently at each occurrence -H, halo, C 1 -C 4 alkyl; and the remaining variables are as defined in the first, second or third embodiment.

[0045] In a fifth embodiment, the compound of the present invention is represented by the following structural formula:

[0046]

[0047]

[0048] or a pharmaceutically acceptable salt thereof; wherein R 2 is independently at each occurrence -H, halo, C 1 -C 4 alkyl; and the remaining variables are as defined in the first, second or third embodiment.

[0049] In a sixth embodiment, the compound of the present invention is represented by the following structural formula:

[0050]

[0051] or a pharmaceutically acceptable salt thereof; wherein R a and R b are each independently -H or methyl; R 1 Is a halogen, C 1 -C 4 Alkyl or C 1 -C 4 Haloalkyl; R 2 -H or C independently at each occurrence 1 -C 4 alkyl; and the remaining variables are as defined in the first, second, third, or fourth embodiment.

[0052] In a seventh embodiment, the compound of the present invention is represented by the following structural formula:

[0053]

[0054] or a pharmaceutically acceptable salt thereof; wherein R a and R b are each independently -H or methyl; R2 is independently -H or methyl at each occurrence; R 1 is -F or methyl; and the remaining variables are as defined in the first, second, third, fourth or sixth embodiment.

[0055] In an eighth embodiment, the compound of the present invention is represented by the following structural formula:

[0056]

[0057] or a pharmaceutically acceptable salt thereof; wherein Ar is as defined in the first embodiment, the second embodiment, the third embodiment, the fourth embodiment, the sixth embodiment or the seventh embodiment.

[0058] In a ninth embodiment, the compound of the present invention is represented by the following structural formula:

[0059]

[0060] or a pharmaceutically acceptable salt thereof; wherein Ar is as defined in the first embodiment, the second embodiment, the third embodiment or the fifth embodiment.

[0061] In a tenth embodiment, in a compound of the invention according to the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment, or a pharmaceutically acceptable salt thereof, Ar is optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted thiazolyl, optionally substituted phenyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted pyrazinyl, optionally substituted imidazo[1,2-a]pyridinyl, optionally substituted thieno[2,3-d]pyrimidinyl, or optionally substituted thieno[3,2-d]pyrimidinyl. In the compounds of the invention according to the first, second, third, fourth, fifth, sixth, seventh, eighth or ninth embodiment, or a pharmaceutically acceptable salt thereof, Ar is optionally substituted oxadiazolyl, optionally substituted 1,2,3-triazol-1-yl, optionally substituted triazolo[4,3-a]pyridin-3-yl or optionally substituted 1H-benzo[d]imidazol-1-yl.

[0062] In an eleventh embodiment, in the compounds of the invention according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiments, or a pharmaceutically acceptable salt thereof, Ar is optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted or optionally substituted In the compounds of the invention according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment, or a pharmaceutically acceptable salt thereof, Ar is optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted or optionally substituted

[0063] In a twelfth embodiment, in the compounds of the invention according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth or eleventh embodiments, or pharmaceutically acceptable salts thereof, Ar is optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted or optionally substituted In the compounds of the invention according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth or eleventh embodiment, or a pharmaceutically acceptable salt thereof, Ar is optionally substituted

[0064] In the thirteenth embodiment, in the compounds of the invention according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh or twelfth embodiments, or pharmaceutically acceptable salts thereof, Ar is optionally substituted with one or more groups selected from: C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 3 -C 6 Cycloalkyl, halogen, -CN, -NO 2 、-OR z 、-NR x R y 、-S(O) i R x 、-NR x S(O) i R y 、-S(O) i NR x R y 、-C(=O)OR x 、-OC(=O)OR x 、-C(=S)OR y 、-O(C=S)R x 、-C(=O)NR x R y 、-NR x C(=O)R y 、-C(=S)NR x R y 、-NR x C(=S)R y 、-NR x (C=O)OR y 、-O(C=O)NR x R y 、-NR x (C=S)OR y 、-O(C=S)NR x R y 、-NR x (C=O)NR x R y 、-NR x (C=S)NR x R y 、-C(=S)R x 、-C(=O)R x , phenyl and monocyclic heteroaryl;

[0065] in

[0066] C on Ar 1 -C 4 The alkyl substituent is optionally substituted with -CN, -NO 2 、-OR z 、-NR x R y 、-S(O) i R x 、-NR x S(O) i R y 、-S(O) i NR x R y 、-C(=O)OR x 、-OC(=O)OR x 、-C(=S)OR x 、-O(C=S)R x 、-C(=O)NR x R y 、-NR x C(=O)R y 、-C(=S)NR x R y -NR x C(=S)R y 、-NR x (C=O)OR y 、-O(C=O)NR x R y 、-NR x (C=S)OR y 、-O(C=S)NR x R y 、-NR x (C=O)NR x R y 、-NR x (C=S)NR x R y 、-C(=S)R x and -C(=O)R y , C 3 -C 6 Cycloalkyl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy and halomethoxy), monocyclic heteroaryl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy or halomethoxy) and phenyl (optionally substituted with one or more groups selected from: -CH 3, halomethyl, halo, methoxy, and halomethoxy);

[0067] C on Ar 3 -C 6 Cycloalkyl, phenyl and monocyclic heteroaryl substituents are optionally and independently substituted with: C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, halogen, -CN, -NO 2 、-OR z 、-NR x R y 、-S(O) i R x 、-NR x S(O) i R y 、-S(O) i NR x R y 、-C(=O)OR x 、-OC(=O)OR x 、-C(=S)OR x 、-O(C=S)R y 、-C(=O)NR x R y 、-NR x C(=O)R y 、-C(=S)NR x R y 、-NR x C(=S)R y 、-NR x (C=O)OR y 、-O(C=O)NR x R y 、-NR x (C=S)OR y 、-O(C=S)NR x R y 、-NR x (C=O)NR x R y 、-NR x (C=S)NR x R y 、-C(=S)R x and -C(=O)R x ;

[0068] Each R x and each R y Independently -H, C 1 -C 4 Alkyl or C3 -C 8 Cycloalkyl; wherein R x or R y C 1 -C 4 Alkyl or C 3 -C 8 The cycloalkyl group is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, C 3 -C 6 Cycloalkyl and phenyl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy or halomethoxy);

[0069] R z Yes - H, C 1 -C 4 Alkyl or C 3 -C 8 Cycloalkyl; wherein R z C 1 -C 4 Alkyl or C 3 -C 8 The cycloalkyl group is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, C 3 -C 6 Cycloalkyl and phenyl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy, and halomethoxy); and

[0070] i is 0, 1 or 2.

[0071] In a fourteenth embodiment, in the compounds of the invention according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth or thirteenth embodiments, or pharmaceutically acceptable salts thereof, Ar is optionally substituted with one or more groups selected from: C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 3 -C 6 Cycloalkyl, halogen, -CN, -OR z 、-NR x R y 、-C(=O)NR x R y 、-C(=S)NR x R y 、-O(C=O)NRx R y 、-O(C=S)NR x R y 、-C(=O)OR x 、-NR x C(=O)R y Phenyl, -C(=O)R x and optionally substituted monocyclic heteroaryl.

[0072] In a fifteenth embodiment, in the compounds of the invention according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth embodiments, or pharmaceutically acceptable salts thereof, Ar is optionally substituted with one or more groups selected from: C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 3 -C 6 Cycloalkyl, halogen, -OR z 、-C(=O)R x and optionally C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, halogen-substituted monocyclic heteroaryl.

[0073] In a sixteenth embodiment, in the compounds of the invention according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, or fifteenth embodiments, or pharmaceutically acceptable salts thereof, Ar is optionally substituted with one or more groups selected from: -CH 3 、-CH 2 CH 3 , halomethyl, cyclopentyl, cyclobutyl, halogen, -OR z 、-C(=O)R x and containing one or two heteroatoms selected from S and N and optionally C 1 -C 4 Alkyl-substituted 5-membered or 6-membered monocyclic heteroaryl; wherein R x Yes - H or C 1 -C 4 alkyl; and wherein R z is an optionally substituted C1 -C 4 alkyl.

[0074] In a seventeenth embodiment, in the compounds of the invention according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, or sixteenth embodiments, or pharmaceutically acceptable salts thereof, Ar is optionally substituted with one or more groups selected from: -CH 3 、-CH 2 CH 3 , -CHF 2 , -CF 3 , cyclopentyl, cyclobutyl, -F, -Cl, -Br, -OCH 3 、-C(=O)CH 3 In another embodiment, in the compounds of the invention according to the first embodiment, the second embodiment, the third embodiment, the fourth embodiment, the fifth embodiment, the sixth embodiment, the seventh embodiment, the eighth embodiment, the ninth embodiment, the tenth embodiment, the eleventh embodiment, the twelfth embodiment, the thirteenth embodiment, the fourteenth embodiment, the fifteenth embodiment or the sixteenth embodiment, or a pharmaceutically acceptable salt thereof, Ar is optionally substituted with one or more groups selected from: -CH 3 、-CH 2 CH 3 , -CHF 2 , -CF 3 , cyclopentyl, cyclobutyl, -F, -Br, -OCH 3 、-C(=O)CH 3 and thiazolyl.

[0075] In an eighteenth embodiment, the compound of the present invention is represented by the following structural formula:

[0076]

[0077] or a pharmaceutically acceptable salt thereof, wherein R 5 Select C at each occurrence 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 3 -C 6 Cycloalkyl, halogen, -CN, -NO 2 、-OR z 、-NR x Ry 、-S(O) i R x 、-NR x S(O) i R y 、-S(O) i NR x R y 、-C(=O)OR x 、-OC(=O)OR x 、-C(=S)OR y 、-O(C=S)R x 、-C(=O)NR x R y 、-NR x C(=O)R y 、-C(=S)NR x R y 、-NR x C(=S)R y 、-NR x (C=O)OR y 、-O(C=O)NR x R y 、-NR x (C=S)OR y 、-O(C=S)NR x R y 、-NR x (C=O)NR x R y 、-NR x (C=S)NR x R y 、-C(=S)R x 、-C(=O)R x , phenyl and monocyclic heteroaryl;

[0078] in

[0079] When R 5 It is C 1 -C 4 When alkyl, C 1 -C 4 The alkyl group is optionally and independently substituted with: -CN, -NO 2 、-OR z 、-NR x R y 、-S(O) i R x 、-NR x S(O) i R y 、-S(O) i NRx R y 、-C(=O)OR x 、-OC(=O)OR x 、-C(=S)OR x 、-O(C=S)R x 、-C(=O)NR x R y 、-NR x C(=O)R y 、-C(=S)NR x R y -NR x C(=S)R y 、-NR x (C=O)OR y 、-O(C=O)NR x R y 、-NR x (C=S)OR y 、-O(C=S)NR x R y 、-NR x (C=O)NR x R y 、-NR x (C=S)NR x R y 、-C(=S)R x and -C(=O)R y , C 3 -C 6 Cycloalkyl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy and halomethoxy), monocyclic heteroaryl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy or halomethoxy) and phenyl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy, and halomethoxy);

[0080] When R 5 It is C 3 -C 6 When cycloalkyl, phenyl or monocyclic heteroaryl is substituted, the cycloalkyl, phenyl or monocyclic heteroaryl is optionally and independently substituted by the following groups: 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, halogen, -CN, -NO 2 、-OR z 、-NR x Ry 、-S(O) i R x 、-NR x S(O) i R y 、-S(O) i NR x R y 、-C(=O)OR x 、-OC(=O)OR x 、-C(=S)OR x 、-O(C=S)R y 、-C(=O)NR x R y 、-NR x C(=O)R y 、-C(=S)NR x R y 、-NR x C(=S)R y 、-NR x (C=O)OR y 、-O(C=O)NR x R y 、-NR x (C=S)OR y 、-O(C=S)NR x R y 、-NR x (C=O)NR x R y 、-NR x (C=S)NR x R y 、-C(=S)R x and -C(=O)R x ;

[0081] Each R x and each R y Independently -H, C 1 -C 4 Alkyl or C 3 -C 8 Cycloalkyl; wherein R x or R y C 1 -C 4 Alkyl or C 3 -C 8 The cycloalkyl group is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, C 3 -C 6 Cycloalkyl and phenyl (optionally substituted with one or more groups selected from: -CH 3, halomethyl, halo, methoxy or halomethoxy);

[0082] R z Yes - H, C 1 -C 4 Alkyl or C 3 -C 8 Cycloalkyl; wherein R z C 1 -C 4 Alkyl or C 3 -C 8 The cycloalkyl group is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, C 3 -C 6 Cycloalkyl and phenyl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy, and halomethoxy); and

[0083] i is 0, 1 or 2; and

[0084] q is 0, 1, 2, or 3;

[0085] wherein the remaining variables are as defined in the first embodiment.

[0086] In a nineteenth embodiment, the compound of the invention is represented by one of the following structural formulas:

[0087]

[0088]

[0089] or a pharmaceutically acceptable salt thereof, wherein q is 0, 1, 2 or 3; and wherein the remaining variables are as defined in the eighteenth embodiment.

[0090] In a twentieth embodiment, the compound of the present invention is represented by one of the following structural formulas:

[0091]

[0092] or a pharmaceutically acceptable salt thereof, wherein the remaining variables are as defined in the eighteenth embodiment.

[0093] In a twenty-first embodiment, the compound of the present invention is represented by the following structural formula:

[0094]

[0095] or a pharmaceutically acceptable salt thereof, wherein the remaining variables are as defined in the eighteenth embodiment.

[0096] In a twenty-second embodiment, the compound of the present invention is represented by the following structural formula:

[0097]

[0098] or a pharmaceutically acceptable salt thereof, wherein the remaining variables are as defined in the eighteenth embodiment.

[0099] In a twenty-third embodiment, the compound of the present invention is represented by the following structural formula:

[0100]

[0101] or a pharmaceutically acceptable salt thereof, wherein the remaining variables are as defined in the eighteenth embodiment.

[0102] In the twenty-fourth embodiment, in the compounds of the invention according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, or twenty-third embodiments, or a pharmaceutically acceptable salt thereof, R 3 Yes -H,

[0103] In the twenty-fifth embodiment, in the compounds of the invention according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, or twenty-fourth embodiments, or a pharmaceutically acceptable salt thereof, R 4 Yes-CH 3 ,

[0104] In the twenty-fourth embodiment, in the compounds of the invention according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, or twenty-third embodiments, or a pharmaceutically acceptable salt thereof, R 5 Selected from C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 3 -C 6 Cycloalkyl, halogen, -CN, -OR z 、-NR x R y 、-C(=O)NR x R y 、-C(=S)NR x R y 、-O(C=O)NR x R y 、-O(C=S)NR x R y 、-C(=O)OR x 、-NR x C(=O)R y Phenyl, -C(=O)R x and optionally substituted monocyclic heteroaryl.

[0105] In the twenty-fifth embodiment, in the compounds of the invention according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, or twenty-fourth embodiments, or a pharmaceutically acceptable salt thereof, R 5 Selected from C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 3 -C 6 Cycloalkyl, halogen, -OR z、-C(=O)R x and optionally C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, halogen-substituted monocyclic heteroaryl.

[0106] In the twenty-sixth embodiment, in the compounds of the invention according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, or twenty-fifth embodiments, or a pharmaceutically acceptable salt thereof, R 5 Selected from -CH 3 、-CH 2 CH 3 , halomethyl, cyclopentyl, cyclobutyl, halogen, -OR z 、-C(=O)R x and containing one or two heteroatoms selected from S and N and optionally C 1 -C 4 Alkyl-substituted 5-membered or 6-membered monocyclic heteroaryl; wherein R x Yes - H or C 1 -C 4 alkyl; and wherein R z is an optionally substituted C 1 -C 4 alkyl.

[0107] In the twenty-seventh embodiment, in the compounds of the invention according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, or twenty-sixth embodiments, or a pharmaceutically acceptable salt thereof, R 5 Selected from -CH 3 、-CH 2 CH 3 , -CHF 2 , -CF3 , cyclopentyl, cyclobutyl, -F, -Br, -Cl, -OCH 3 、-C(=O)CH 3 and thiazolyl.

[0108] In the twenty-eighth embodiment, in the compounds of the invention according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, or twenty-seventh embodiments, or a pharmaceutically acceptable salt thereof, R 5 Selected from -F, -Br and Cl.

[0109] In the twenty-ninth embodiment, in the compounds of the invention according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh or twenty-eighth embodiments, or a pharmaceutically acceptable salt thereof, R a and R b One of them is -H and the other is selected from -CH 3 , -CF 3 and -OCH 3 .

[0110] In a thirtieth embodiment, in the compounds of the invention according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, or twenty-ninth embodiment, or a pharmaceutically acceptable salt thereof, n is 0 or 1.

[0111] In one embodiment, the compound of the invention may be any of the compounds described herein in the working examples, including salts and neutral forms thereof.

[0112] As used herein, the term "alkyl" refers to a fully saturated branched or straight chain hydrocarbon moiety. Unless otherwise indicated, an alkyl group contains 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, more preferably 1 to 6 carbon atoms or most preferably 1 to 4 carbon atoms. Representative examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl.

[0113] As used herein, the term "alkoxy" refers to the group -OR, wherein R is alkyl or cycloalkyl, as that term is defined above. Non-limiting examples of alkoxy include: -OCH 3 、-OCH 2 CH 3 、-OCH 2 CH 2 CH 3 、-OCH(CH 3 ) 2 、-OCH(CH 2 ) 2 , -O-cyclopropyl, -O-cyclobutyl, -O-cyclopentyl and -O-cyclohexyl.

[0114] The number of carbon atoms in a group is indicated herein by the prefix "C x-xx ", where x and xx are integers. For example, "C 1-4 The term "alkyl" refers to an alkyl group having 1 to 4 carbon atoms.

[0115] As used herein, the term "halogen" or "halo" may be fluorine, chlorine, bromine or iodine.

[0116] As used herein, the term "haloalkyl" refers to an alkyl group, as defined herein, substituted with one or more halo groups, as defined herein.

[0117] As used herein, the terms "heterocyclyl", "heterocyclyl group" and "heterocyclic", "heterocyclic ring" are used interchangeably and refer to a saturated, unsaturated, non-aromatic, monocyclic or bicyclic (e.g., fused) ring system having 3 to 12 ring members, or in particular 3 to 6 ring members or 5 to 7 ring members, at least one ring member is a heteroatom, and up to 4 (e.g., 1, 2, 3 or 4) ring members may be heteroatoms, wherein the heteroatoms are independently selected from O, S and N, and wherein C may be oxidized (e.g., C(═O)), N may be oxidized (e.g., N(O)) or quaternized (e.g., N + ), and S can be optionally oxidized to sulfoxide and sulfone. Examples of non-aromatic heterocyclic groups include aziridinyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuranyl, thiolanyl, imidazolidinyl, pyrazolidinyl, isoxazolidinyl, isothiazolidinyl, piperidinyl, tetrahydropyranyl, thiolanyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, dithianyl, azepanyl, oxetanyl, thiolanyl, dihydrofuranyl, imidazolinyl, dihydropyranyl, hydantoinyl, pyrrolidonyl, tetrahydrothiopyranyl, tetrahydropyridinyl and thiopyranyl, etc. Examples of bicyclic non-aromatic heterocyclic systems include benzo[1,3]dioxolyl, tetrahydroindolyl and 2-azaspiro[3.3]heptyl, etc.

[0118] As used herein, the terms "heteroaryl", "heteroaryl group", "heteroaromatic" and "heteroaromatic ring" are used interchangeably and refer to an aromatic 5-12 membered monocyclic or bicyclic ring system having 1 to 4 heteroatoms independently selected from O, S and N, and wherein N may be oxidized (e.g., N(O)) or quaternized, and S may be optionally oxidized to sulfoxides and sulfones. "Heteroaryl" includes heteroaromatic groups fused to phenyl or non-aromatic heterocyclic rings, such as tetrahydrofuran, pyran, pyrrolidine, piperidine, and the like. As used herein, the heteroaryl Ar may be attached to the remainder of the compounds of the invention at any ring with an open valence. Examples of heteroaryl groups include pyrrolyl, furanyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazinyl, thiazinyl, dioxinyl, triazinyl, tetrazinyl, azobenzene, oxazolyl, thiazolyl, 1-oxo-pyridinyl, thienyl, valerolactamyl, azaindolyl, benzimidazolyl, benzo[1,4]dioxinyl, benzofuranyl, benzisoxazolyl, benzisothiazolyl oxazolyl, benzothiadiazolyl, benzothiazolyl, benzothiophenyl, benzotriazolyl, benzoxadiazolyl, benzoxazolyl, cyclopentaimidazolyl, cyclopentatriazolyl, imidazo[1,2-a]pyridinyl, indazolyl, indolizinyl, indolyl, isoquinolinyl, oxazolopyridinyl, purinyl, pyrrolo[3,4]pyrimidinyl, pyridopyrazinyl, pyridopyrimidinyl, pyrrolo[2,3]pyrimidinyl, pyrrolopyrazolyl, pyrroloimidazolyl, pyrrolotriazolyl, quinazolinyl, quinolinyl, thiazolopyridinyl, naphthyridinyl, and the like.

[0119] As used herein, the term "optionally substituted phenyl fused to an optionally substituted non-aromatic 5-6 membered heterocyclic ring" refers to a fused ring system wherein the benzene ring is directly attached to the remainder of the compound.

[0120] As used herein, the term "cycloalkyl" refers to a fully saturated monocyclic or bicyclic (eg, fused) hydrocarbon group of 3-12 carbon atoms, 3-6 carbon atoms, or 5-7 carbon atoms.

[0121] As used herein, the term "halocycloalkyl" refers to a cycloalkyl group as defined herein substituted with one or more halo groups as defined herein.

[0122] As used herein, the term "fused ring system" is a ring system having at least two rings wherein the two rings share two adjacent ring atoms.

[0123] Substituted alkyl, phenyl, heteroaryl, non-aromatic heterocyclic or heterocyclic radicals are alkyl, phenyl, heteroaryl, non-aromatic heterocyclic or heterocyclic radicals having one or more substituents. Suitable substituents are those that do not significantly reduce the aromaticity of the radicals of formula (I'), (I), (I'), (Ia), (Ia'), (Ib), (Ib'), (Ia1), (Ia1'), (Ia2), (Ia2'), (Ia3), (Ia3'), (Ib1), (Ib1'), (II'), (IIa), (IIb), (IIa1), (IIa2), (IIa3), (IIb1), (III), (IIIa), (IIIb), (IIIc), (I Substituents for the O-GlcNAcase inhibitory activity of compounds of formula (IId), (IIIe), (IIIe'), (IIIf), (IIIf'), (IIIg), (IIIg'), (IIIh), (IIIh'), (IIIi), (IIIi'), (IIIj'), (IIIk') (hereinafter collectively referred to as "Formulas (I) to (IIIk")") or their pharmaceutically acceptable salts. Examples of substituents suitable for alkyl, phenyl, heteroaryl, non-aromatic heterocyclic or heterocyclic groups include, but are not limited to, C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 3 -C 6 Cycloalkyl, halogen, -CN, -NO 2 、-OR z 、-NR x R y 、-S(O) i R x 、-NR x S(O) i R y 、-S(O) i NR x R y 、-C(=O)OR x 、-OC(=O)OR x 、-C(=S)OR y 、-O(C=S)R x 、-C(=O)NR x R y 、-NR x C(=O)R y 、-C(=S)NR x R y 、-NR x C(=S)R y 、-NRx (C=O)OR y 、-O(C=O)NR x R y 、-NR x (C=S)OR y 、-O(C=S)NR x R y 、-NR x (C=O)NR x R y 、-NR x (C=S)NR x R y 、-C(=S)R x 、-C(=O)R x , phenyl and monocyclic heteroaryl. 1 -C 4 The alkyl substituents are optionally substituted with -CN, -NO 2 、-OR z 、-NR x R y 、-S(O) i R x 、-NR x S(O) i R y 、-S(O) i NR x R y 、-C(=O)OR x 、-OC(=O)OR x 、-C(=S)OR x 、-O(C=S)R x 、-C(=O)NR x R y 、-NR x C(=O)R y 、-C(=S)NR x R y 、-NR x C(=S)R y 、-NR x (C=O)OR y 、-O(C=O)NR x R y 、-NR x (C=S)OR y 、-O(C=S)NR x R y 、-NR x (C=O)NR x R y 、-NR x (C=S)NRx R y 、-C(=S)R x and -C(=O)R y , C 3 -C 6 Cycloalkyl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy and halomethoxy), monocyclic heteroaryl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy or halomethoxy) and phenyl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy and halomethoxy). 3 -C 6 Cycloalkyl, phenyl and monocyclic heteroaryl substituents are optionally and independently substituted with: C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, halogen, -CN, -NO 2 、-OR z 、-NR x R y 、-S(O) i R x 、-NR x S(O) i R y 、-S(O) i NR x R y 、-C(=O)OR x 、-OC(=O)OR x 、-C(=S)OR x ,-O(C=S)R y 、-C(=O)NR x R y 、-NR x C(=O)R y 、-C(=S)NR x R y 、-NR x C(=S)R y 、-NR x (C=O)OR y 、-O(C=O)NR x R y 、-NR x (C=S)OR y 、-O(C=S)NR x R y 、-NR x(C=O)NR x R y 、-NR x (C=S)NR x R y 、-C(=S)R x and -C(=O)R x In these substituents, each R x and each R y Independently -H, C 1 -C 4 Alkyl or C 3 -C 8 Cycloalkyl, wherein R x or R y C 1 -C 4 Alkyl or C 3 -C 8 The cycloalkyl group is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, C 3 -C 6 Cycloalkyl and phenyl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halogen, methoxy or halomethoxy). In these substituents, R z Yes - H, C 1 -C 4 Alkyl or C 3 -C 8 Cycloalkyl, wherein R z C 1 -C 4 Alkyl or C 3 -C 8 The cycloalkyl group is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, C 3 -C 6 Cycloalkyl and phenyl (optionally substituted with one or more groups selected from: -CH 3 In these substituents, i is 0, 1 or 2.

[0124] The present invention also includes pharmaceutically acceptable salts of the compounds disclosed herein. In the case where the compounds provided herein have sufficient alkalinity or acidity to form stable non-toxic acid or base salts, it may be appropriate to prepare and administer the compounds in the form of pharmaceutically acceptable salts. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids that form physiologically acceptable anions, such as toluenesulfonates, mesylates, acetates, citrates, malonates, tartrates, succinates, benzoates, ascorbates, alpha-ketoglutarate or alpha-glycerophosphate. Inorganic salts may also be formed, including hydrochlorides, sulfates, nitrates, bicarbonates and carbonates.

[0125] Pharmaceutically acceptable salts can be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound (e.g., an amine) with a suitable acid; providing a physiologically acceptable anion. Alkali metal (e.g., sodium, potassium, or lithium) or alkaline earth metal (e.g., calcium) salts of carboxylic acids can also be prepared.

[0126] Pharmaceutically acceptable base addition salts can be prepared from inorganic bases and organic bases. Suitable bases include, but are not limited to, alkali metal hydroxides, alkaline earth metal hydroxides, carbonates, bicarbonates, and the like.

[0127] The disclosed compounds or their pharmaceutically acceptable salts may contain one or more asymmetric centers in the molecule. According to the present disclosure, any structure that does not specify stereochemistry is understood to include all various stereoisomers (e.g., diastereomers and enantiomers) in pure or substantially pure form and their mixtures (e.g., racemic mixtures or mixtures enriched in enantiomers). The method of preparing these optically active forms is well known in the art (e.g., splitting the racemic form by recrystallization techniques, synthesizing from optically active starting materials, by chiral synthesis or chromatographic separation using chiral stationary phases). The disclosed compounds may exist in tautomeric forms and mixtures, and separate individual tautomers are envisioned. In addition, some compounds may exhibit polymorphism.

[0128] When a specific stereoisomer (e.g., enantiomer, diastereomer, etc.) of a compound used in the disclosed methods is depicted by name or structure, the stereochemical purity of the compound is at least 60%, 70%, 80%, 90%, 95%, 97%, 99%, 99.5%, or 99.9%. "Stereochemical purity" means the weight percent of the desired stereoisomer relative to the total weight of all stereoisomers.

[0129] When the stereochemistry of a disclosed compound is named or depicted by a structure and the named or depicted structure encompasses more than one stereoisomer (e.g., as in a diastereomeric pair), it is understood to include one encompassed stereoisomer or any mixture of encompassed stereoisomers. It is further understood that the stereoisomeric purity of the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% by weight. In this case, the stereoisomeric purity is determined by dividing the total weight of the stereoisomer mixture encompassed by the name or structure by the total weight of all stereoisomer mixtures.

[0130] As used herein, the term "Peak 1" refers to the first avoided peak during the separation of enantiomers and / or diastereomers, followed by the subsequent avoided "Peak 2" and optionally "Peak 3" and "Peak 4".

[0131] In one embodiment, any position occupied by hydrogen is meant to also include enrichment of deuterium above the natural abundance of deuterium. For example, one or more hydrogen atoms are replaced with deuterium, the abundance of deuterium being at least 3340 times greater than the natural abundance of deuterium, which is 0.015% (i.e., at least 50.1% deuterium incorporated), at least 3500 (52.5% deuterium incorporated at each designated deuterium atom), at least 4000 (60% deuterium incorporated), at least 4500 (67.5% deuterium incorporated), at least 5000 (75% deuterium incorporated), at least 5500 (82.5% deuterium incorporated), at least 6000 (90% deuterium incorporated), at least 6333.3 (95% deuterium incorporated), at least 6466.7 (97% deuterium incorporated), at least 6600 (99% deuterium incorporated), or at least 6633.3 (99.5% deuterium incorporated). In one embodiment, hydrogen is present at its natural abundance at all positions. The compounds as described herein, or pharmaceutically acceptable salts thereof, may exist in tautomeric forms and mixtures, and separate individual tautomers are contemplated.

[0132] One aspect of the present invention includes a method for inhibiting glycosidases and / or glycosidase signaling pathways in a cell, the method comprising contacting the cell with an effective amount of a compound of any one of Formulas (I") to (IIIk') or a pharmaceutically acceptable salt thereof. The glycosidase is preferably a glycoside hydrolase, more preferably a family 84 glycoside hydrolase, even more preferably O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranoglucopyranosidase (O-GlcNAcase or OGA), most preferably mammalian O-GlcNAcase. In one embodiment, the cell is contacted in vitro or in vivo. In one embodiment, contacting the cell comprises administering the compound to a subject.

[0133] One aspect of the present invention includes a method for inhibiting glycosidases and / or glycosidase signaling pathways in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of Formulas (I") to (IIIk') or a pharmaceutically acceptable salt thereof, thereby activating the glycosidase in the subject. The glycosidase is preferably a glycoside hydrolase, more preferably a family 84 glycoside hydrolase, even more preferably O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranoglucopyranosidase (O-GlcNAcase or OGA), most preferably mammalian O-GlcNAcase.

[0134] One aspect of the present invention includes a method for promoting the survival of eukaryotic cells (e.g., mammalian cells) or extending the lifespan of cells, the method comprising administering to a subject a therapeutically effective amount of a compound of any one of Formulas (I") to (IIIk') or a pharmaceutically acceptable salt thereof, thereby promoting the survival of eukaryotic cells or extending the lifespan of cells.

[0135] One aspect of the present invention includes a method for treating a disease or condition caused, mediated and / or propagated by O-GlcNAcase activity in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of Formulas (I") to (IIIk') or a pharmaceutically acceptable salt thereof. Preferably, the disease or condition is a neurological disorder, diabetes, cancer or stress. More preferably, the disease or condition is a neurological disorder. In one embodiment, the neurological disorder is one or more tauopathies selected from the group consisting of acute ischemic stroke (AIS), Alzheimer's disease, dementia, amyotrophic lateral sclerosis (ALS), amyotrophic lateral sclerosis with cognitive impairment (ALSci), argyrophilic grain dementia, Bluit disease, corticobasal degeneration (CBP), dementia pugilistica, diffuse neurofibrillary tangles with calcification, Down's syndrome, epilepsy, familial British dementia, familial Danish dementia, and tauopathy. dementia, frontotemporal dementia with parkinsonism associated with chromosome 17 (FTDP-17), Gerstmann-Straussler-Scheinker disease, Guadeloupean parkinsonism, Hallevorden-Spatz disease (neurodegeneration with brain iron accumulation type 1), ischemic stroke, mild cognitive impairment (MCI), multiple system atrophy, myotonic dystrophy, Niemann-Pick disease (type C), globus pallidus-ponto-nigral degeneration, Parkinsonism-dementia complex of Guam, Pick's disease (PiD), postencephalitic parkinsonism (PEP), prion diseases (including Creutzfeldt-Jakob disease), Disease (GJD), variant Creutzfeldt-Jakob disease (vCJD), familial fatal insomnia, Kuru, progressive cortical gliosis, progressive supranuclear palsy (PSP), Steele-Richardson-Olszewski syndrome, subacute sclerosing panencephalitis, pure entanglement dementia, Huntington's disease, and Parkinson's disease.In another embodiment, the neurological disorder is one or more tauopathies selected from the group consisting of acute ischemic stroke (AIS), Alzheimer's disease, dementia, amyotrophic lateral sclerosis (ALS), amyotrophic lateral sclerosis with cognitive impairment (ALSci), argyrophilic grain dementia, epilepsy, mild cognitive impairment (MCI), Huntington's disease, and Parkinson's disease. In another embodiment, the neurological disorder is Alzheimer's disease.

[0136] One aspect of the invention includes a method of treating a disease or condition characterized by tau hyperphosphorylation (e.g., tau hyperphosphorylation in the brain) in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of Formulas (I") to (IIIk') or a pharmaceutically acceptable salt thereof. In one embodiment, the disease or condition is selected from acute ischemic stroke (AIS), Alzheimer's disease, dementia, amyotrophic lateral sclerosis (ALS), amyotrophic lateral sclerosis with cognitive impairment (ALSci), argyrophilic grain dementia, Britt's disease, corticobasal degeneration (CBP), dementia pugilistica, diffuse neurofibrillary tangles with calcifications, Down syndrome, epilepsy, familial British dementia, familial Danish dementia, frontotemporal dementia with Parkinsonism associated with chromosome 17 (FTDP-17), Jakob-Strauss-Kreuzfeldt disease, Guadeloupe Parkinsonism, Habermann-Strauss disease (neurodegeneration with type 1 brain iron accumulation), ischemic stroke, mild Cognitive impairment (MCI), multiple system atrophy, myotonic dystrophy, Nieto-Pitt disease (type C), globus pallidus-ponto-nigral degeneration, Guam Parkinsonism-dementia complex, Pick disease (PiD), postencephalitis Parkinsonism (PEP), prion diseases (including Creutzfeldt-Jakob disease (GJD), variant Creutzfeldt-Jakob disease (vCJD), familial fatal insomnia, kuru, progressive supranuclear gliosis, progressive supranuclear palsy (PSP), Stevens-Lee-Osborn syndrome, subacute In another embodiment, the disease or disorder is selected from acute ischemic stroke (AIS), Alzheimer's disease, dementia, amyotrophic lateral sclerosis (ALS), amyotrophic lateral sclerosis with cognitive impairment (ALSci), argyrophilic grain dementia, epilepsy, ischemic stroke, mild cognitive impairment (MCI), Huntington's disease and Parkinson's disease. In another embodiment, the disease or disorder is Alzheimer's disease.

[0137] As used herein, the terms "subject" and "patient" are used interchangeably and refer to mammals in need of treatment, such as companion animals (e.g., dogs, cats, etc.), farm animals (e.g., cows, pigs, horses, sheep, goats, etc.), and laboratory animals (e.g., rats, mice, guinea pigs, etc.). Typically, the subject is a human in need of treatment.

[0138] As used herein, the term "treating" or "treatment" refers to obtaining a desired pharmacological and / or physiological effect. The effect may be therapeutic, including partially or substantially achieving one or more of the following results: partially or completely reducing the extent of a disease, disorder, or syndrome; improving or modifying clinical symptoms or indicators associated with the disorder; and delaying, inhibiting, or reducing the likelihood of progression of a disease, disorder, or syndrome.

[0139] The term "effective amount" means an amount of a compound of any one of Formulas (I") to (IIIk') or a pharmaceutically acceptable salt thereof that produces beneficial or desired results when administered to a subject, for example, 0.1 mg to 1000 mg / kg body weight, wherein the beneficial or desired results include clinical results, i.e., reversing, alleviating, inhibiting, reducing or slowing the progression of a disease or condition that can be treated by a compound of any one of Formulas (I") to (IIIk') or a pharmaceutically acceptable salt thereof, and reducing the likelihood of recurrence of a disease or condition that can be treated by a compound of any one of Formulas (I") to (IIIk') or a pharmaceutically acceptable salt thereof (e.g., as determined by clinical symptoms). The expression "effective amount" also encompasses an amount effective for increasing normal physiological function.

[0140] Another embodiment of the present invention is a pharmaceutical composition comprising at least one compound as described herein or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.

[0141] Also included is the use of a compound of any one of formulas (I") to (IIIk') or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating one or more diseases or disorders described herein. Also included herein is a pharmaceutical composition comprising a compound of any one of formulas (I") to (IIIk') or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier for the preparation of a medicament for treating one or more diseases or disorders described herein. Also included is a compound of any one of formulas (I") to (IIIk') or a pharmaceutically acceptable salt thereof for treating a subject suffering from one or more diseases or disorders described herein. Also included is a pharmaceutical composition comprising a compound of any one of formulas (I") to (IIIk') or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier for the treatment of one or more diseases or disorders described herein.

[0142] The term "pharmaceutically acceptable carrier" refers to a non-toxic carrier, diluent, adjuvant, medium or excipient that does not adversely affect the pharmacological activity of the compound formulated therewith and is safe for human use. Pharmaceutically acceptable carriers that can be used in the compositions of the present disclosure include, but are not limited to, ion exchangers, aluminum oxide, aluminum stearate, magnesium stearate, lecithin, serum proteins (e.g., human serum albumin), buffer substances (e.g., phosphates), glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based materials (e.g., microcrystalline cellulose, hydroxypropyl methylcellulose, lactose monohydrate, sodium lauryl sulfate and cross-linked sodium carboxymethylcellulose), polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene glycol-polyoxypropylene block polymers, polyethylene glycol and lanolin.

[0143] Other excipients may also be included, such as flavoring agents; sweeteners; preservatives, such as methylparaben, ethylparaben, propylparaben and butylparaben. A more complete list of suitable excipients can be found in Handbook of Pharmaceutical Excipients (5th edition, a Pharmaceutical Press (2005)). Those skilled in the art will know how to prepare formulations suitable for various types of administration routes. Conventional procedures and ingredients for selecting and preparing suitable formulations are described in, for example, Remington's Pharmaceutical Sciences (2003, 20th edition) and The United States Pharmacopeia: The National Formulary (USP 24NF19), published in 1999.

[0144] The compounds of any one of Formula (I") to (IIIk') or a pharmaceutically acceptable salt thereof, or the compositions of the present teachings can be administered, for example, orally, parenterally, sublingually, topically, rectally, nasally, buccally, vaginally, transdermally, by patch, pump administration, or via an implanted reservoir, and the pharmaceutical compositions are formulated accordingly. Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, intranasal, intrapulmonary, intrathecal, rectal, and topical modes of administration. Parenteral administration can be achieved by continuous infusion over a selected period of time.

[0145] Other administration forms included in the present disclosure are described in WO 2013 / 075083, WO 2013 / 075084, WO 2013 / 078320, WO 2013 / 120104, WO 2014 / 124418, WO 2014 / 151142 and WO 2015 / 023915, the contents of which are incorporated herein by reference.

[0146] The useful dosage of the compound as described herein or its pharmaceutically acceptable salt can be determined by comparing their in vitro activity and in vivo activity in animal models. The method of extrapolating the effective dosage of mice and other animals to humans is known in the art; for example, see U.S. Patent No. 4,938,949, the entire text of which is incorporated by reference.

[0147] example

[0148] The following general reaction schemes (Schemes 1 to 4) provide details that can be used to prepare compounds of the invention. The necessary intermediates are commercially available in some cases or can be prepared according to literature procedures. The illustrative reaction schemes are not limited to the listed compounds or any specific substituents used for illustrative purposes. The substituent labels (i.e., R groups) as shown in the reaction schemes are not necessarily related to the substituent labels used in the claims, and for clarity, a single substituent is generally shown attached to the compound, where multiple substituents are allowed under the definition of any of Formulas (I") to (IIIk') above.

[0149] Solution 1

[0150]

[0151] Intermediate 1

[0152]

[0153] Tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate: To a solution of 2,2,6,6-tetramethylpiperidine (85.0 g, 602 mmol) in anhydrous THF (1000 mL) was added 2.5 M n-BuLi in hexanes (288 mL, 720 mmol) at 0°C under argon. The resulting mixture was stirred for 10 min. A solution of 4,4,5,5-tetramethyl-2-[(tetramethyl 1,3,2-dioxaborolan-2-yl)methyl]-1,3,2-dioxaborolan (161 g, 601 mmol) in THF (200 mL) was added at 0°C. After stirring for 15 minutes, the solution was cooled to -78 °C and then a solution of tert-butyl 3-oxopiperidine-1-carboxylate (100 g, 502 mmol) in THF (500 mL) was added dropwise. The reaction was stirred at -78 °C for 1 h and then at 0 °C overnight. 30% K 2 CO 3 (aq) solution (500 mL) and the organic layer was partitioned and the mixture was stirred for 2 h. 2 SO 4 Dry, filter, and concentrate in vacuo. 2 The residue was purified (ethyl acetate / pentane) to provide the title compound (121 g, 75%).

[0154] Intermediate 2

[0155]

[0156] tert-Butyl 3-(4-fluorobenzylidene)piperidine-1-carboxylate: 1-bromo-4-fluorobenzene (0.2 g, 1.14 mmol) was dissolved in dioxane (8.0 mL) and H 2 To the solution in O (2.0 mL) were added tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate (0.405 g, 1.26 mmol), Pd(dppf)Cl 2 (0.084 g, 0.114 mmol), Cs 2 CO 3 (0.745 g, 2.29 mmol). The mixture was stirred at 90 °C under N 2 The reaction mixture was filtered and concentrated in vacuo. 2 The residue was purified by (petroleum ether / EtOAc: 15 / 1) to afford the title compound (0.120 g, 36%). LCMS (ESI): [M+H]292.

[0157] Intermediate 3

[0158]

[0159] tert-Butyl 3-(4-fluorobenzyl)piperidine-1-carboxylate: To a solution of tert-butyl 3-(4-fluorobenzylidene)piperidine-1-carboxylate (0.120 g, 0.412 mmol) in MeOH (15.0 mL) was stirred at N 2 Pd / C (0.022 g, 10% on carbon) was added. The mixture was stirred at 20 °C under H 2 Stir at (15 psi) for 1 hour. Filter the mixture and concentrate in vacuo to provide the title compound (0.082 g, 68%). LCMS (ESI): [M+H]294.

[0160] Intermediate 4

[0161]

[0162] 3-(4-Fluorobenzyl)piperidine: tert-butyl 3-(4-fluorobenzyl)piperidine-1-carboxylate (0.082 g, 0.280 mmol) was added to a HCl / EtOAc solution (0.280 mmol, 8.0 mL). The mixture was stirred at 18°C ​​for 17 h. 4 OH(aq) adjusted the mixture to pH 8 and concentrated the mixture in vacuo to provide the title compound (0.054 g, 99%). LCMS (ESI): [M+H]194.

[0163] Example 1-1

[0164]

[0165] N-(5-((3-(4-fluorobenzyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: To a solution of 3-(4-fluorobenzyl)piperidine (0.054 g, 0.279 mmol) in MeOH (15.0 mL) was added N-(5-formylthiazol-2-yl)acetamide (0.095 g, 0.559 mmol) and a drop of AcOH. The mixture was stirred at 50 °C for 2 h. NaBH was added 3 CN (0.053 g, 0.838 mmol) was added and the mixture was stirred at 50° C. for 17 h. The product was purified by preparative HPLC {(column: Waters Xbridge PrepOBD C18 150x30 5u; conditions: water (0.04% NH 3 H 2 O + 10 mM NH 4 HCO 3)-MeCN; start at B: 35; end at B: 65; gradient time (min): 10; 100% B holding time (min): 2; flow rate (ml / min): 25} The mixture was purified to provide the title compound (0.038 g, 39%). LCMS: [M+H] 348. 1 HNMR: (400 MHz, methanol-d4) δ7.19 (s, 1H), 7.14-7.10 (m, 2H), 6.94 (t, J = 9.2 Hz, 2H), 3.65 (s, 2H), 2.83-2.75 (m, 2H), 2.48 (d, J = 6.8 Hz, 2H), 2.19 (s, 3H), 2.02-1.99 (m, 1H), 1.82-1.66 (m, 4H), 1.57-1.47 (m, 1H), 0.99-0.91 (m, 1H).

[0166] Example 1-2

[0167]

[0168] N-(5-((3-(pyridin-2-ylmethyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: To a suspension of 2-(3-piperidinylmethyl)pyridine HCl (0.035 g, 0.165 mol, hydrochloride) and N-[5-(chloromethyl)thiazol-2-yl]acetamide (0.032 g, 0.165 mmol) in MeCN (0.64 mL) was added triethylamine (0.05 g, 0.494 mol) and the mixture was warmed to 70 °C overnight. The reaction was cooled to room temperature and the mixture was diluted with EtOAc and washed with saturated NH 4 Cl (aqueous solution). MgSO 4 The organics were dried, filtered and concentrated in vacuo. The residue was purified by preparative HPLC {(column: Waters XSelect CSH PrepC18 5um OBD 19x100mm; conditions: water:MeCN gradient 5-55% ACN, 7 min gradient, 0.1 Vol% aluminum hydroxide modifier} to provide the title compound (0.015 g, 27%). LCMS (ESI): [M+H] 331. 1 HNMR:(500MHz,CDCl 3)δ11.76(br s,1H),8.45(dd,J=1.8,4.9Hz,1H),8.40(d,J=1.8Hz,1H),7.47(td,J=1.8,7. 9Hz,1H),7.21(dd,J=4.6,7.0Hz,1H),7.18(s,1H),3.70-3.59(m,2H),2.78(br d,J=9.2Hz,2H),2.60-2.53(m,1H),2.51-2.43(m,1H),2.31(s,3H),2.07-1.98 (m,1H),1.93-1.81(m,2H),1.66(m,2H),1.56-1.46(m,1H),1.02-0.91(m,1H).

[0169] Examples 1-3

[0170]

[0171] N-(5-((3-(3-methoxybenzyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 1-bromo-3-methoxybenzene and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 360. 1 HNMR: (400 MHz, methanol-d4) δ7.20 (s, 1H), 7.13 (t, J = 8.0 Hz, 1H), 6.71-6.69 (m, 3H), 3.75 (s, 3H), 3.71-3.65 (m, 2H), 2.84-2.78 (m, 2H), 2.48-2.46 (m, 2H), 2.19 (s, 3H), 2.04-1.99 (m, 1H), 1.88-1.66 (m, 4H), 1.58-1.48 (m, 1H), 1.00-0.92 (m, 1H).

[0172] Examples 1-4

[0173]

[0174] N-(5-((3-(4-methoxybenzyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 1-chloro-4-methoxybenzene and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 360.1 HNMR:(400MHz,CDCl 3 )δ12.43(s,1H),7.17(s,1H),7.04(d,J=8.4Hz,1H),6.80(d,J=8.4Hz,1H),3.77(s,3H),3.69-3.58(m,2H),2.79-2.67(m,2H), 2.51-2.37(m,2H),2.31(s,3H),2.00-1.85(m,1H),1.90-1.76(m,2H),1.71-1.57(m,2H),1.54-1.48(m,1H),0.94-0.86(m,1H).

[0175] Examples 1-5

[0176]

[0177] N-(5-((3-(3-fluorobenzyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 1-bromo-3-fluorobenzene and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 348. 1 HNMR: (400MHz, methanol-d4) δ7.26-7.20(m,2H),6.94(d,J=7.6Hz,1H),6.89-6.85(m,2H),3.69-3.61(m,2H),2.83-2.76(m,2H),2. 58-2.47(m,2H),2.19(s,3H),2.05-1.94(m,1H),1.87-1.76(m,2H),1.69-1.66(m,2H),1.57-1.48(m,1H),1.01-0.93(m,1H).

[0178] Examples 1-6

[0179]

[0180] N-(5-((3-((6-methoxypyridin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate and 2-chloro-6-methoxypyridine. LCMS (ESI): [M+H] 361. 1 HNMR:(400MHz,CDCl3 )δ12.41(br s,1H),7.44-7.40(m,1H),7.17(s,1H),6.64(d,J=7.2Hz,1H),6.51(d, J=8.0Hz,1H),3.88(s,3H),3.69-3.60(m,2H),2.83-2.77(m,2H),2.62 -2.50(m,2H),2.30(s,3H),2.16-2.12(m,1H),2.04-1.99(m,1H),1.87 -1.82(m,1H),1.68-1.62(m,2H),1.55-1.52(m,1H),1.01-0.92(m,1H).

[0181] Examples 1-7

[0182]

[0183] N-(5-((3-((2-methoxypyridin-4-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 4-bromo-2-methoxypyridine and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 361. 1 HNMR: (400 MHz, methanol-d4) δ7.95 (d, J=5.2 Hz, 1H), 7.19 (s, 1H), 6.77 (d, J=5.2 Hz, 1H), 6.59 (s, 1H), 3.86 (s, 3H), 3.67 (s, 2H), 2.82-2.74 (m, 2H), 2.51-2.49 (m, 2H), 2.19 (s, 3H), 2.07-2.00 (m, 1H), 1.93-1.84 (m, 1H), 1.82-1.77 (m, 1H), 1.69-1.67 (m, 2H), 1.59-1.55 (m, 1H), 1.03-0.96 (m, 1H).

[0184] Examples 1-8

[0185]

[0186] N-(5-((3-((5-methoxypyridin-3-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 3-bromo-5-methoxypyridine and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 361. 1 HNMR:(400MHz,CDCl 3 )δ11.18(br s,1H),8.14(d,J=2.4Hz,1H),8.00(s,1H),7.17(s,1H),6.98(s,1H),3.84(s,3H),3.64-3.63(m,2H),2.78-2.76(m,2H),2.5 3-2.46(m,2H),2.29(s,3H),2.02-1.98(m,1H),1.88-1.82(m,2H),1.67-1.63(m,2H),1.55-1.50(m,1H),0.96-0.94(m,1H).

[0187] Examples 1-9

[0188]

[0189] N-(5-((3-((4-methoxypyridin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 2-bromo-5-methoxypyridine and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 361. 1 HNMR: (400 MHz, methanol-d4) δ8.21 (d, J = 6.0 Hz, 1H), 7.21 (s, 1H), 6.81-6.78 (m, 2H), 3.85 (s, 3H), 3.71-3.67 (m, 2H), 2.86-2.77 (m, 2H), 2.63 (d, J = 7.2 Hz, 2H), 2.20 (s, 3H), 2.08-2.02 (m, 2H), 1.89-1.82 (m, 1H), 1.75-1.61 (m, 2H), 1.58-1.52 (m, 1H), 1.06-1.03 (m, 1H).

[0190] Examples 1-10

[0191]

[0192] N-(5-((3-((5-methoxypyridin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 2-bromo-5-methoxypyridine and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 361. 1 HNMR:(400MHz,CDCl 3 )δ12.31(br s,1H),8.20(d,J=2.8Hz,1H),7.16(s,1H),7.11-7.08(m,1H),7.03-7.01(m,1H),3.82(s,3H),3.67-3.60(m,2H),2.76(d,J=10.2Hz,2 H),2.74-2.60(m,2H),2.30(s,3H),2.03-2.00(m,2H),1.87-1.85(m,1H),1.65(d,J=9.6Hz,2H),1.62-1.02(m,1H),0.99-0.97(m,1H).

[0193] Examples 1-11

[0194]

[0195] N-(5-((3-((6-methoxypyridin-3-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 3-bromo-5-methoxypyridine and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 360. 1 HNMR: (400MHz, methanol-d4) δ7.87(d,J=2.0Hz,1H),7.49(dd,J=8.8,2.0Hz,1H),7.20(s,1H),6.71(d,J=8.4Hz,1H),3.86(s,3H),3.69-3.62(m,2H),2 .88-2.71(m,2H),2.46-2.44(m,2H),2.20(s,3H),2.07-1.97(m,1H),1.8 6-1.73(m,2H),1.72-1.62(m,2H),1.60-1.44(m,1H),1.05-0.88(m,1H).

[0196] Examples 1-12

[0197]

[0198] N-(5-((3-((5-fluoropyridin-3-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 3-bromo-5-methoxypyridine and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 349. 1 HNMR:(400MHz,CDCl 3 )δ11.88(br s,1H),8.30(s,1H),8.22(s,1H),7.21-7.17(m,2H),3.68-3.59(m,2H),2.77-2.74(m,2H),2.63-2.47(m,2H) ,2.31(s,3H),2.08-2.03(m,1H),1.93-1.83(m,2H),1.73-1.68(m,2H),1.56-1.50(m,1H),1.03-0.93(m,1H).

[0199] Examples 1-13

[0200]

[0201] N-(5-((3-((4-fluoropyridin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 2-bromo-4-fluoropyridine and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 349. 1 HNMR: (400 MHz, methanol-d4) δ8.46 (dd, J=8.8, 5.6 Hz, 1H), 7.23 (s, 1H), 7.14-7.11 (m, 1H), 7.09-7.06 (m, 1H), 3.71 (s, 2H), 2.88-2.81 (m, 2H), 2.75-2.72 (m, 1H), 2.22 (s, 3H), 2.12-2.09 (m, 2H), 1.93-1.90 (m, 1H), 1.71-1.54 (m, 3H), 1.12-1.07 (m, 1H).

[0202] Examples 1-14

[0203]

[0204] N-(5-((3-(3-methoxybenzyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)pyrrolidine-1-carboxylate, 1-bromo-3-methoxybenzene and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 346. 1 HNMR: (400 MHz, methanol-d4) δ7.23 (s, 1H), 7.15-7.11 (m, 1H), 6.77-6.66 (m, 3H), 3.83-3.66 (m, 5H), 2.73-2.55 (m, 5H), 2.52-2.40 (m, 1H), 2.29-2.23 (m, 1H), 2.19 (s, 3H), 1.99-1.87 (m, 1H), 1.56-1.46 (m, 1H).

[0205] Examples 1-15

[0206]

[0207] N-(5-((3-(4-methoxybenzyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)pyrrolidine-1-carboxylate, 1-chloro-4-methoxybenzene and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 346. 1 HNMR: (400 MHz, methanol-d4) δ7.24 (s, 1H), 7.07 (dd, J = 6.4, 2.0 Hz, 2H), 6.81 (t, J = 2.8 Hz, 1H), 6.79 (d, J = 2.0 Hz, 1H), 3.79-3.73 (m, 5H), 2.74-2.69 (m, 2H), 2.65-2.58 (m, 3H), 2.50-2.42 (m, 1H), 2.29-2.24 (m, 1H), 2.19 (s, 3H), 1.96-1.89 (m, 1H), 1.55-1.51 (m, 1H).

[0208] Examples 1-16

[0209]

[0210] N-(5-((3-(3-fluorobenzyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)pyrrolidine-1-carboxylate, 1-bromo-3-fluorobenzene and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 334. 1 HNMR:(400MHz,DMSO-d6)δ11.50(br s,1H),7.32-7.26(m,1H),7.22(s,1H),7.04-6.97(m,3H),3.72-3.63(m,2H),3.32(s,2H),2.69-2.58(m,2H) ,2.58-2.52(m,3H),2.45-2.35(m,1H),2.17-2.14(m,1H),2.10(s,3H),1.88-1.79(m,1H),1.45-1.37(m,1H).

[0211] Examples 1-17

[0212]

[0213] N-(5-((3-(4-fluorobenzyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)pyrrolidine-1-carboxylate, 1-bromo-4-fluorobenzene and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 334. 1 HNMR: (400 MHz, methanol-d4) δ7.23 (s, 1H), 7.18-7.15 (m, 2H), 6.97-6.93 (m, 2H), 3.82-3.72 (m, 2H), 2.71-2.67 (m, 5H), 2.67-2.64 (m, 1H), 2.28-2.26 (m, 1H), 2.19 (s, 3H), 1.98-1.94 (m, 1H), 1.54-1.50 (m, 1H).

[0214] Examples 1-18

[0215]

[0216] N-(5-((3-((6-methoxypyridin-2-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)pyrrolidine-1-carboxylate, 2-chloro-6-methoxypyridine and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 347. 1 HNMR: (400 MHz, methanol-d4) δ 7.55-7.50 (m, 1H), 7.25 (s, 1H), 6.76 (d, J = 6.8 Hz, 1H), 6.57 (d, J = 8.4 Hz, 1H), 3.85 (s, 3H), 3.84-3.74 (m, 2H), 2.80-2.68 (m, 6H), 2.36-2.37 (m, 1H), 2.19 (s, 3H), 2.03-1.96 (m, 1H), 1.62-1.54 (m, 1H).

[0217] Examples 1-19

[0218]

[0219] N-(5-((3-((2-methoxypyridin-4-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)pyrrolidine-1-carboxylate, 4-bromo-2-methoxypyridine and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 347. 1 HNMR: (400MHz, methanol-d4) δ7.97(d,J=5.6Hz,1H),7.23(s,1H),6.81(d,J=5.6Hz,1H),6.63(s,1H),3.86(s,3H),3.83-3.7 3(m,2H),2.73-2.69(m,5H),2.67-2.64(m,1H),2.29-2.27(m,1H),2.17(s,3H),2.19-2.00(m,1H),1.52-1.50(m,1H).

[0220] Examples 1-20

[0221]

[0222] N-(5-((3-((5-methoxypyridin-3-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)pyrrolidine-1-carboxylate, 3-bromo-5-methoxypyridine and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 347. 1 HNMR:(400MHz,CDCl 3 )δ12.36(s,1H),8.13(d,J=2.4Hz,1H),8.04(d,J=1.6Hz,1H),7.18(s,1H),6.99-6.98(m,1H),3.82(s,3H),3.80-3.7 1(m,2H),2.70-2.62(m,5H),2.53-2.44(m,1H),2.30(s,3H),2.29-2.25(m,1H),2.02-1.93(m,1H),1.54-1.46(m,1H).

[0223] Embodiment 1-21

[0224]

[0225] N-(5-((3-((4-methoxypyridin-2-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)pyrrolidine-1-carboxylate, 2-bromo-4-methoxypyridine and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 347. 1 HNMR: (400MHz, methanol-d4) δ8.22(d,J=6.0Hz,1H),7.24(s,1H),6.84(d,J=2.4Hz,1H),6.82-6.80(m,1H),3.86(s,3H),3.84-3. 75(m,2H),2.79(d,J=7.6Hz,2H),2.74-2.59(m,4H),2.34-2.29(m,1H),2.19(s,3H),2.03-1.92(m,1H),1.62-1.53(m,1H).

[0226] Examples 1-22

[0227]

[0228] N-(5-((3-((5-methoxypyridin-2-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)pyrrolidine-1-carboxylate, 2-bromo-5-methoxypyridine and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 347. 1 HNMR:(400MHz,CDCl 3 )δ11.55(br s,1H),8.21(d,J=2.8Hz,1H),7.19(s,1H),7.12-7.09(m,1H),7.05-7.03(m,1H),3.83(s,3H),3.80-3.71( m,2H),2.79(d,J=7.2Hz,2H),2.78-2.60(m,4H),2.31-2.29(m,4H),1.97-1.55(m,1H),1.54-1.52(m,1H).

[0229] Examples 1-23

[0230]

[0231] N-(5-((3-((6-methoxypyridin-3-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)pyrrolidine-1-carboxylate, 5-bromo-2-methoxypyridine and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 347. 1 HNMR: (400MHz, methanol-d4) δ7.92(d,J=1.6Hz,1H),7.53(dd,J=8.8,2.4Hz,1H),7.24(s,1H),6.72(d,J=8.8Hz,1H),3.86(s,3H),3.83-3.74 (m,2H),2.75-2.66(m,2H),2.66-2.57(m,3H),2.51-2.39(m,1H),2.30-2.25(m,1H),2.19(s,3H),2.00-1.91(m,1H),1.57-1.48(m,1H).

[0232] Examples 1-24

[0233]

[0234] N-(5-((3-((5-fluoropyridin-3-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)pyrrolidine-1-carboxylate, 3-bromo-5-fluoropyridine and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 335. 1 HNMR:(400MHz,CDCl 3 )δ12.44(br s,1H),8.29(d,J=2.8Hz,1H),8.25(s,1H),7.22-7.18(m,2H),3.80-3.71(m,2H),2.72-2.62(m ,5H),2.52-2.43(m,1H),2.30(s,3H),2.28-2.26(m,1H),2.02-1.94(m,1H),1.54-1.45(m,1H).

[0235] Examples 1-25

[0236]

[0237] N-(5-((3-((5-fluoropyridin-2-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)pyrrolidine-1-carboxylate, 2-bromo-5-fluoropyridine and N-(5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 335. 1 HNMR:(400MHz,CDCl 3 )δ11.55(s,1H),8.36(d,J=3.2Hz,1H),7.32-7.27(m,1H),7.19(s,1H),7.13-7.10(m,1H),3.80-3.72(m,2H) ,2.85-2.82(m,2H),2.74-2.61(m,4H),2.32-2.30(m,1H),2.29(s,3H),2.00-1.95(m,1H),1.57-1.51(m,1H).

[0238] Examples 1-26

[0239]

[0240] N-(5-((3-((6-(trifluoromethyl)pyrazin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 2-chloro-6-(trifluoromethyl)pyrazine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 400. 1 HNMR:(500MHz,CDCl 3 )δ11.56(br s,1H),8.78(s,1H),8.64(s,1H),7.18(s,1H),3.75-3.58(m,2H),2.95-2.68(m,3H) ,2.31(s,3H),2.23-2.09(m,2H),2.04-1.91(m,1H),1.74-1.52(m,4H),1.09(m,1H).

[0241] Examples 1-27

[0242]

[0243] N-(5-((3-(pyridin-3-ylmethyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide

[0244] The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 3-bromopyridine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H]331. 1 HNMR:(500MHz,CDCl 3 )δ11.79(br s,1H),8.54(dd,J=1.8,4.9Hz,1H),7.59(dt,J=1.8,7.6Hz,1H),7.19(s,1H),7.14(d,J=7.9Hz,1H),7.13-7.09(m, 1H),3.75-3.56(m,2H),2.89-2.76(m,2H),2.76-2.63(m,2H),2.32(s,3H),2.12(m,1H),2.08-2.01(m,1H),1.90(br t,J=10.4Hz,1H),1.78-1.62(m,2H),1.60-1.47(m,1H),1.12-0.96(m,1H).

[0245] Examples 1-28

[0246]

[0247] N-(5-((3-Benzylpiperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, bromobenzene and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 330. 1 HNMR:(500MHz,CDCl 3 )δ11.61(br s,1H),7.32-7.24(m,2H),7.22-7.08(m,4H),3.73-3.58(m,2H),2.80(brd ,J=7.9Hz,2H),2.60-2.51(m,1H),2.50-2.42(m,1H),2.31(s,3H),1.99(br t,J=10.4Hz,1H),1.93-1.86(m,1H),1.85-1.79(m,1H),1.71-1.62(m,2H),1.56-1.45(m,1H),1.00-0.87(m,1H).

[0248] Examples 1-29

[0249]

[0250] N-(5-((3-((6-methylpyridin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide

[0251] The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 2-bromo-6-methylpyridine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 345. 1 HNMR:(500MHz,CDCl 3)δ12.11(br s,1H),7.46(t,J=7.6Hz,1H),7.17(s,1H),6.95(d,J=7.3Hz,1H),6.91(d,J=7.3Hz,1H),3.64(q,J=14.0Hz,2H),2.79(br d,J=8.5Hz,2H),2.71-2.61(m,2H),2.52(s,3H),2.31(s,3H),2.16-2.06(m,1H),2.02(br t,J=10.1Hz,1H),1.86(br t,J=10.4Hz,1H),1.71-1.62(m,2H),1.59-1.46(m,1H),1.07-0.95(m,1H).

[0252] Examples 1-30

[0253]

[0254] N-(5-((3-((5-(trifluoromethyl)pyridin-3-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 3-bromo-5-(trifluoromethyl)pyridine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 399. 1 HNMR:(500MHz,CDCl 3 )δ11.74(br s,1H),8.73(s,1H),8.60(s,1H),7.70(s,1H),7.18(s,1H),3.74-3.58(m,2H),2.76(m,2H),2.71-2.63(m,1H) ,2.56(m,1H),2.31(s,3H),2.08(m,1H),1.90(m,2H),1.75-1.60(m,2H),1.59-1.48(m,1H),1.06-0.95(m,1H).

[0255] Example 1-31

[0256]

[0257] N-(5-((3-((5-methylpyridin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 2-chloro-5-methylpyridine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 345. 1 HNMR:(500MHz,CDCl 3 )δ11.94(br s,1H),8.35(s,1H),7.38(dd,J=1.8,7.9Hz,1H),7.17(s,1H),7.02(d,J=7.9Hz,1H),3.72-3.56(m,2H) ,2.84-2.73(m,2H),2.65(dq,J=7.3,13.6Hz,2H),2.31(s,3H),2.29(s,3H),2.14-1.97(m,2H),1.87(br t,J=10.4Hz,1H),1.70-1.61(m,2H),1.58-1.46(m,1H),1.06-0.95(m,1H).

[0258] Example 1-32

[0259]

[0260] N-(5-((3-((6-methoxypyrazin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 2-bromo-6-methoxypyrazine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 361.

[0261] Examples 1-33

[0262]

[0263] N-(5-((3-((6-methylpyrazin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 2-bromo-6-methylpyrazine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 346. 1HNMR:(500MHz,CDCl 3 )δ11.80(br s,1H),8.27(s,1H),8.21(s,1H),7.18(s,1H),3.70-3.59(m,2H),2.78(br s,2H),2.67(m,2H),2.54(s,3H),2.31(s,3H),2.18-2.00(m,2H),1.94-1.85(m,1H),1.65(m,2H),1.54(m,1H),1.13-0.96(m,1H).

[0264] Examples 1-34

[0265]

[0266] N-(5-((3-((4-methylthiazol-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 2-bromo-4-methylthiazole and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 351. 1 HNMR: (500MHz, methanol-d4) δ7.54(s,1H),7.04(s,1H),4.88-4.99(m,1H),4.46-4.56(m,2H),4.41(s,1H),3.51(br d,J=11.0Hz,2H),2.84-3.05(m,3H),2.74(br t,J=12.2Hz,1H),2.30-2.42(m,3H),2.18-2.25(m,4H),1.92-2.06(m,1H),1.87(br d,J=14.0Hz,1H),1.73(br d,J=13.4Hz,1H),1.22-1.39(m,1H).

[0267] Embodiment 1-35

[0268]

[0269] N-(5-((3-((5-methylthiazol-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 2-bromo-5-methylthiazole and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 351. 1 HNMR: (500MHz, methanol-d4) δ7.57(s,1H),7.40-7.46(m,1H),4.94-5.04(m,1H),4.53(s,2H),3.53(br d,J=10.4Hz,2H),2.95-3.06(m,2H),2.90(br s,1H),2.77(brt,J=11.9Hz,1H),2.45(d,J=1.2Hz,3H),2.18-2.29(m,4H),1.95-2.10(m,1H),1.83-1.94(m,1H),1.75(br d,J=13.4Hz,1H),1.42(s,1H),1.21-1.37(m,1H).

[0270] Embodiment 1-36

[0271]

[0272] N-(5-((3-((2-methylthiazol-4-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 4-bromo-2-methylthiazole and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 351. 1 HNMR: (500MHz, methanol-d4) δ7.57(s,1H),7.30(s,1H),4.52(br s,2H),3.44-3.56(m,2H),2.86-2.93(m,1H),2.70-2.82(m,6H),2.18-2.23(m,4H),1.94-2.03(m,1H),1.86(br d,J=13.4Hz,1H),1.76(br d,J=12.8Hz,1H),1.20-1.32(m,1H).

[0273] Example 1-37

[0274]

[0275] N-(5-((3-(thiazol-5-ylmethyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 5-bromothiazole and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 337. 1 HNMR: (500MHz, DMSO-d6) δ11.93(s,1H),8.91(s,1H),7.61(s,1H),7.22(s,1H),4.04(s,6H),3.50-3.64(m,3H),2.64-2.82( m,5H),2.52-2.56(m,1H),2.11(s,4H),1.91-2.00(m,1H),1.69-1.80(m,2H),1.57-1.65(m,2H),1.36-1.44(m,1H),0.94(br d,J=9.8Hz,1H).

[0276] Examples 1-38

[0277]

[0278] N-(5-((3-(thiazol-4-ylmethyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 4-bromothiazole and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 337. 1 HNMR: (500MHz, DMSO-d6) δ11.92(s,1H),8.99(d,J=1.8Hz,1H),7.30(d,J=1.8Hz,1H),7.21(s,1 H),4.04(s,5H),3.49-3.63(m,2H),2.59-2.74(m,5H),2.11(s,4H),1.87-1.99(m,2H),1.75(br t, J=10.4Hz, 1H), 1.58 (br d, J=10.4Hz, 2H), 1.34-1.44 (m, 1H), 0.92 (brd, J=9.8Hz, 1H).

[0279] Examples 1-39

[0280]

[0281] N-(5-((3-(thiazol-2-ylmethyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 2-bromothiazole and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 337. 1 HNMR: (500MHz, methanol-d4) δ7.66(d,J=3.7Hz,1H),7.44(d,J=3.7Hz,1H),7.21(s,1H),3.67(s,2H),2.96(d,J=7.3Hz,2H),2.83(br t,J=11.6Hz,2H),2.15-2.24(m,4H),2.01-2.12(m,2H),1.88(br t,J=10.4Hz,1H),1.68-1.81(m,2H),1.52-1.63(m,1H),1.07(brdd,J=11.6,2.4Hz,1H).

[0282] Embodiment 1-40

[0283]

[0284] N-(5-((3-(pyridin-4-ylmethyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide

[0285] The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 4-bromopyridine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H]331. 1 HNMR: (500MHz, methanol-d4)δ8.38(br d,J=5.5Hz,2H),7.23-7.29(m,2H),7.20(s,1H),3.66(s,2H),2.69-2.87(m,2H),2.49-2.68(m,2H),2.21(s,3H), 2.00-2.12(m,2H),1.93(td,J=7.0,3.1Hz,1H),1.76-1.87(m,1H),1.64-1.76(m,2H),1.46-1.62(m,1H),1.03(br d,J=9.8Hz,1H).

[0286] Example 1-41

[0287]

[0288] N-(5-((3-((6-ethylthieno[2,3-d]pyrimidin-4-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 4-chloro-6-ethylthieno[2,3-d]pyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 416. 1 HNMR: (500MHz, methanol-d4) δ8.81-8.90(m,1H),7.55(s,1H),7.32(dd,J=2.4,1.2Hz,1H),4.51(br d,J=6.1Hz,2H),3.53(br d,J=11.6Hz,2H),3.02-3.20(m,4H),2.92(br s,1H),2.79-2.88(m,1H),2.45(br s,1H),2.23(s,3H),1.96-2.10(m,1H),1.71-1.94(m,2H),1.34-1.44(m,5H),1.20-1.33(m,1H).

[0289] Example 1-42

[0290]

[0291] N-(5-((3-((6-ethylthieno[3,2-d]pyrimidin-4-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 4-chloro-6-ethylthieno[3,2-d]pyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 416. 1HNMR: (500MHz, methanol-d4) δ8.96-9.00(m,1H),7.51-7.61(m,1H),7.31-7.36(m,1H),4.90-4.94(m,2H),4.48-4.55 (m,2H),3.01-3.18(m,4H),2.83-2.97(m,2H),2.75-2.83(m,1H),2.21-2.24(m,4H),1.95-2.07(m,1H),1.90(br d,J=13.4Hz,1H),1.68-1.84(m,2H),1.35-1.50(m,5H),0.96(t,J=7.3Hz,1H).

[0292] Embodiment 1-43

[0293]

[0294] N-(5-((3-((2-methylthieno[3,2-d]pyrimidin-4-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 4-chloro-2-methylthieno[3,2-d]pyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 402. 1 HNMR: (500MHz, methanol-d4) δ8.33(d,J=5.5Hz,1H),7.56(s,1H),7.51(d,J=5.5Hz,1H),4.56(br d,J=14.0Hz,1H),4.49(d,J=14.0Hz,1H),3.60-3.74(m,1H),3.52-3.59(m,1H),3.11-3.18(m,1H),3.03-3. 11(m,1H),2.91-3.01(m,1H),2.79-2.90(m,2H),2.74(s,3H),2.66(s,3H),2.52-2.62(m,1H),2.23(s,4H).

[0295] Embodiment 1-44

[0296]

[0297] N-(5-((3-(Thieno[3,2-d]pyrimidin-4-ylmethyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 4-chlorothieno[3,2-d]pyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 388. 1 HNMR: (500MHz, methanol-d4) δ9.06 (s, 1H), 8.35 (d, J = 5.5Hz, 1H), 7.51-7.63 (m, 3H), 2.63-2.67(m,2H),2.53(s,1H),2.23-2.24(m,3H),1.97-2.11(m,2H),1.91(br d,J=14.0Hz,2H),1.78(br d,J=14.0Hz,1H),1.38-1.45(m,5H).

[0298] Embodiment 1-45

[0299]

[0300] N-(5-((3-((4-methylpyridin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 2-bromo-4-methylpyridine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 345. 1 HNMR: (500MHz, methanol-d4) δ8.60 (d, J = 6.1Hz, 1H), 7.77-7.83 (m, 2H), 7.59 (s, 1H), 3.42-3.59 (m, 2H),2.90-3.09(m,4H),2.83-2.88(m,1H),2.66(d,J=1.8Hz,4H),2.20-2.25(m,3H),2.00(br d,J=12.8Hz,1H),1.81(s,1H),1.79(br s,1H),1.24-1.44(m,1H).

[0301] Embodiment 1-46

[0302]

[0303] N-(5-((3-((3-(trifluoromethyl)pyridin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 2-bromo-3-(trifluoromethyl)pyridine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 399. 1 HNMR: (500MHz, methanol-d4)δ8.74(br dd,J=7.9,4.9Hz,1H),8.11(t,J=6.4Hz,1H),7.40-7.51(m,2H),3.48-3.61(m,3H ),2.79-3.05(m,6H),2.18-2.28(m,2H),1.94-2.10(m,1H),1.87(s,1H),1.84(br s,1H),1.72-1.82(m,1H),1.28-1.43(m,1H).

[0304] Embodiment 1-47

[0305]

[0306] N-(5-((3-((1-methyl-1H-pyrazol-3-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 1 from tert-butyl 3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1-carboxylate, 3-bromo-1-methyl-1H-pyrazole and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 334. 1 HNMR: (500MHz, methanol-d4) δ7.42(d,J=1.8Hz,1H),7.22(s,1H),6.04(d,J=1.8Hz,1H),3.80(s,3H),3.67(s,2H),2.86(br d,J=7.9Hz,2H),2.43-2.53(m,2H),2.18-2.22(m,3H),1.97-2.07(m,1H),1.82-1.92(m,1H),1.66-1.79(m,3H),1.51-1.60(m,1H),0.97(br dd,J=11.9,3.4Hz,1H).

[0307] Solution 2

[0308]

[0309] Intermediate 5

[0310]

[0311] tert-Butyl 3-((5-fluoropyrimidin-2-yl)methyl)pyrrolidine-1-carboxylate: NiCl 2 (glyme) (0.084 g, 0.384 mmol), 4-tert-butyl-2-(4-tert-butyl-2-pyridyl)pyridine and Ir{dF(CF 3 )ppy} 2 (dtbpy)PF 6 A solution of (0.086 g, 0.077 mmol) in DME (80 mL) was stirred for 2 h. 2 Purge for 15 min. Add the nickel solution to a mixture of tert-butyl 3-(bromomethyl)pyrrolidine-1-carboxylate (2.03 g, 7.68 mmol), 2-bromo-5-fluoro-pyrimidine (1.70 g, 9.61 mmol), tris(trimethylsilyl)silane (2.87 g, 11.5 mmol, 3.54 mL) and lithium hydroxide (0.736 mg, 30.7 mmol). 2 After purging the mixture (15 min), the reaction was irradiated with a blue LED (48 watts 450 hv) at 40°C overnight. Celite was added to the reaction, and the mixture was filtered and concentrated in vacuo. 2 The residue was purified (0-100% EtOAc:heptane) to provide the title compound (0.760 g). LCMS (ESI): [Mt-Bu]226. 1 HNMR:(500MHz,CDCl 3 )δ8.39(br d,J=9.46Hz,2H),3.30-3.46(m,2H),3.10-3.21(m,1H),2.85-2.96(m,3H), 2.54-2.66(m,1H),1.80-1.91(m,1H),1.42-1.57(m,1H),1.27-1.35(m,9H).

[0312] Intermediate 6

[0313]

[0314] 5-Fluoro-2-(pyrrolidin-3-ylmethyl)pyrimidine hydrochloride: A solution of HCl in dioxane (4.0 M, 6.75 mL, 27.0 mmol) was added to tert-butyl 3-[(5-fluoropyrimidin-2-yl)methyl]pyrrolidine-1-carboxylate (0.760 g, 2.70 mmol) in CH 2 Cl 2(40.0 mL). After 2 h, the solution was decanted. The residue was dissolved in MeOH and concentrated in vacuo to provide the title compound. LCMS (ESI): [M+H] 182.

[0315] Examples 2-1 and 2-2

[0316]

[0317] (R)-N-(5-((3-((5-fluoropyrimidin-2-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide and (S)-N-(5-((3-((5-fluoropyrimidin-2-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: the absolute configuration was assigned arbitrarily. N-[5-(chloromethyl)thiazol-2-yl]acetamide (0.428 g, 2.25 mmol) was added to a solution of 5-fluoro-2-(pyrrolidin-3-ylmethyl)pyrimidine hydrochloride (0.489 g, 2.25 mmol) and diisopropylethylamine (1.45 g, 11.2 mmol, 1.96 mL) in DMF (5.00 mL). After 2 h, the mixture was concentrated in vacuo. The residue was dissolved in CH 2 Cl 2 In the saturated NaHCO 3 (aqueous solution) and concentrated in vacuo. 2 (40g, 0-15% CH 2 Cl 2 The residue was purified by HPLC:MeOH) to afford the title compound (0.411 g, 54%) as a racemic mixture. Enantiomers were separated using chiral SFC. Column: CHIRALPAK AD-H 30x250 mm, 5 um. Method: 35% isopropanol with 0.1% diethylamine in CO2, 100 mL / min.

[0318] Peak 1: 0.137 g. LCMS: [M+H] 336. 1 HNMR:(500MHz,CDCl 3 )δ12.07(br s,1H),8.48-8.59(m,2H),7.22(s,1H),3.79(s,2H),3.05(d,J=7.32Hz,2H),2.74-2.88(m,2H),2.67-2.74(m,1H),2.58- 2.64(m,1H),2.35(dd,J=8.39,6.56Hz,1H),2.32(s,3H),1.98-2.07(m,1H),1.61(ddt,J=12.63,8.16,6.16,6.16Hz,1H). 8

[0319] Peak 2. 0.124 g. LCMS: [M+H] 336. 1 HNMR:(500MHz,CDCl 3 )δ11.56(br s,1H),8.53(s,2H),7.22(s,1H),3.79(s,2H),3.05(d,J=7.17Hz,2H),2.75-2.87(m,2H),2.68-2.74(m,1 H), 2.60 (td, J = 8.58, 6.03Hz, 1H), 2.32-2.37 (m, 1H), 2.32 (s, 3H), 1.99-2.08 (m, 1H), 1.57-1.65 (m, 1H).

[0320] Example 2-3

[0321]

[0322] N-(5-((3-((2-methoxy-3-methylpyridin-4-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 2 from tert-butyl 3-(bromomethyl)piperidine-1-carboxylate, 4-bromo-2-methoxy-3-methylpyridine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 376. 1 HNMR:(500MHz,CDCl 3 )δ7.79(d,J=5.49Hz,1H),7.21(s,1H),6.70(d,J=4.88Hz,1H),3.89(s,3H),3.67(s,1H),3 .60-3.70(m,1H),2.71-2.89(m,2H),2.47-2.60(m,2H),2.20(s,3H),2.12(s,3H),2.06(br t,J=11.29Hz,1H),1.79-1.93(m,2H),1.62-1.75(m,2H),1.46-1.60(m,1H),1.46-1.60(m,1H),0.94-1.12(m,1H).

[0323] Embodiment 2-4

[0324]

[0325] N-(5-((3-((5-methoxypyrimidin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 2 from tert-butyl 3-(bromomethyl)piperidine-1-carboxylate, 2-bromo-5-methoxypyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 362. 1 HNMR:(500MHz,CDCl 3 )δ11.71(br s,1H),8.33(s,2H),7.18(s,1H),3.90(s,3H),3.73-3.56(m,2H),2.95-2.70(m,4H),2.30(s,3H),2.27 -2.16(m,1H),2.06-1.93(m,1H),1.93-1.83(m,1H),1.73-1.62(m,2H),1.56(m,1H),1.11-0.94(m,1H).

[0326] Embodiment 2-5

[0327]

[0328] N-(5-((3-((5-fluoropyridin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 2 from tert-butyl 3-(bromomethyl)piperidine-1-carboxylate, 2-bromo-5-fluoropyridine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 349. 1 HNMR:(500MHz,CDCl 3 )δ12.58(brs,1H),8.44(d,J=3.1Hz,1H),7.58(br d,J=11.0Hz,1H),7.51(dt,J=3.1,8.2Hz,1H),7.29(dd,J=4.3,9.2Hz,1H),4.52-4.25(m,2H),3.70-3.43(m,2H),2.9 2-2.75(m,1H),2.63-2.41(m,2H),2.36(s,3H),2.24(m,1H),2.18-2.05(m,1H),2.05-1.83(m,3H),1.34-1.13(m,1H).

[0329] Embodiment 2-6

[0330]

[0331] (R)-N-(5-((3-((5-fluoro-4-methoxypyrimidin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 2 from tert-butyl (S)-3-(bromomethyl)piperidine-1-carboxylate, 2-chloro-5-fluoro-4-methoxypyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 380.

[0332] Embodiment 2-7

[0333]

[0334] (R)-N-(5-((3-((5-fluoro-4-methylpyrimidin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a similar manner to Scheme 2 from tert-butyl (S)-3-(bromomethyl)piperidine-1-carboxylate, 2-chloro-5-fluoro-4-methylpyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 381.

[0335] Embodiment 2-8

[0336]

[0337] (R)-N-(5-((3-((6-(difluoromethyl)pyridin-3-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a manner analogous to Scheme 2 from tert-butyl (S)-3-(bromomethyl)piperidine-1-carboxylate, 5-bromo-2-(difluoromethyl)pyridine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 381. 1 HNMR:(500MHz,CDCl 3 )δ11.58(br s,1H),8.43(d,J=1.8Hz,1H),7.62(dd,J=2.4,7.9Hz,1H),7.58-7.53(m,1H),7.18(s,1H),6.63(t,J=55.5Hz,1H),3.71-3.57(m,2H),2.75(br d,J=7.9Hz,2H),2.64(dd,J=7.6,13.7Hz,1H),2.54(dd,J=7.6,13.7Hz,1H),2.31(s,3H),2.06(br t,J=10.1Hz,1H),1.98-1.79(m,2H),1.73-1.58(m,2H),1.56-1.46(m,1H),1.09-0.89(m,1H).

[0338] Embodiment 2-9

[0339]

[0340] (R)-N-(5-((3-((5-(trifluoromethyl)pyrimidin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a manner analogous to Scheme 2 from tert-butyl (S)-3-(bromomethyl)piperidine-1-carboxylate, 2-bromo-5-(trifluoromethyl)pyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 400. 1 HNMR:(500MHz,CDCl 3 )δ11.58(br s,1H),8.90(s,2H),7.18(s,1H),3.72-3.59(m,2H),3.02-2.91(m,2H),2.80(br t,J=11.3Hz,2H),2.30(s,3H),2.06(br t,J=10.1Hz,1H),1.94(br t,J=10.1Hz,1H),1.74-1.65(m,2H),1.64-1.52(m,2H),1.15-1.01(m,1H).

[0341] Embodiment 2-10

[0342]

[0343] N-(5-((R)-1-((R)-3-((5-fluoropyrimidin-2-yl)methyl)piperidin-1-yl)ethyl)thiazol-2-yl)acetamide: The relative configuration is assigned arbitrarily. The title compound was prepared in a similar manner to Scheme 2 from tert-butyl (S)-3-(bromomethyl)piperidine-1-carboxylate, 2-bromo-5-(trifluoromethyl)pyrimidine and N-(5-(1-chloroethyl)thiazol-2-yl)acetamide. Chiral separation method: Column: CHIRALPAK IA 30x250mm, 5um; Method: 40% ethanol containing 0.1% diethylamine in CO 2 (flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi. The product is peak 1. LCMS (ESI): [M+H] 364. 1 HNMR:(500MHz,CDCl 3)δ11.34(br s,1H),8.53(s,2H),7.10(s,1H),3.91(q,J=6.7Hz,1H),2.91-2.79(m,3H),2.70(m,1H),2.30(s,3H) ,2.27-2.18(m,1H),2.14-2.01(m,2H),1.71-1.50(m,4H),1.39(d,J=6.7Hz,3H),1.08-0.96(m,1H).

[0344] Example 2-11

[0345]

[0346] N-(5-((S)-1-((R)-3-((5-fluoropyrimidin-2-yl)methyl)piperidin-1-yl)ethyl)thiazol-2-yl)acetamide: The relative configuration was assigned arbitrarily. Chiral separation method: Column: CHIRALPAK IA 30x250mm, 5um; Method: 40% ethanol containing 0.1% diethylamine in CO 2 (flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi. The product is peak 2. LCMS (ESI): [M+H] 364.

[0347] Example 2-12

[0348]

[0349] N-(5-((3-fluoro-3-((5-fluoropyrimidin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 2 from tert-butyl 3-(bromomethyl)-3-fluoropiperidine-1-carboxylate, 2-bromo-5-fluoropyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 368. 1 HNMR:(500MHz,CDCl 3 )δ12.24(s,1H),8.56(s,2H),7.23(s,1H),3.70-3.86(m,2H),3.30-3.52(m,2H),2.61-2.75(m,2H),2.51(br s,2H),1.80-1.89(m,1H),1.67-1.79(m,3H).

[0350] Example 2-13

[0351]

[0352] N-(5-((3,3-difluoro-5-((5-fluoropyrimidin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 2 from tert-butyl 5-(bromomethyl)-3,3-difluoropiperidine-1-carboxylate, 2-bromo-5-fluoropyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 386. 1 HNMR:(500MHz,CDCl 3 )δ12.23(br s,1H),8.54(s,2H),7.22(s,1H),3.72-3.88(m,2H),2.98-3.08(m,2H),2.91-2.95(m,2H),2.52 -2.65(m,1H),2.34-2.43(m,1H),2.11-2.21(m,1H),2.07(t,J=10.83Hz,1H),1.45-1.61(m,1H).

[0353] Example 2-14

[0354]

[0355] N-(5-((4,4-difluoro-3-((5-fluoropyrimidin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 2 from tert-butyl 3-(bromomethyl)-4,4-difluoropiperidine-1-carboxylate, 2-bromo-5-fluoropyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 386. 1 HNMR:(500MHz,CDCl 3 )δ12.25(br s,1H),8.32-8.35(m,1H),8.33(s,1H),6.99(s,1H),3.51-3.57(m,1H),3.43-3.48(m,1H),3.19(dd,J=14. 96,3.36Hz,1H),2.71-2.77(m,1H),2.55-2.68(m,3H),2.16-2.26(m,1H),2.13(s,3H),1.76-1.97(m,2H).

[0356] Example 2-15

[0357]

[0358] N-(5-((3-(pyridin-2-ylmethyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 2 from tert-butyl 3-(bromomethyl)pyrrolidine-1-carboxylate, 2-bromopyridine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 317. 1 HNMR:(500MHz,CDCl 3 )δ12.33(br s,1H),8.48-8.57(m,1H),7.59(td,J=7.63,1.83Hz,1H),7.21(s,1H),7. 14(d,J=7.78Hz,1H),7.11(ddd,J=7.48,4.88,1.07Hz,1H),3.73-3.84(m ,2H),2.87(d,J=7.48Hz,2H),2.60-2.80(m,4H),2.33-2.37(m,1H),2.32 (s,3H),1.96-2.05(m,1H),1.57(ddt,J=12.66,8.20,6.28,6.28Hz,1H).

[0359] Example 2-16

[0360]

[0361] N-(5-((3-Fluoro-3-((5-fluoropyrimidin-2-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 2 from tert-butyl 3-(bromomethyl)-3-fluoropyrrolidine-1-carboxylate, 2-bromo-5-fluoropyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 354. 1 HNMR:(500MHz,CDCl 3 )δ11.49(br s,1H),8.58(s,2H),7.23(s,1H),3.83(d,J=1.83Hz,2H),3.38-3.53(m,2H),3.08-3.22(m,1 H),2.79-2.94(m,2H),2.71(td,J=8.28,4.35Hz,1H),2.31-2.34(m,3H),2.11-2.31(m,2H).

[0362] Example 2-17

[0363]

[0364] N-(5-((4-((5-fluoropyrimidin-2-yl)methyl)-2-methylpyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a similar manner to Scheme 2 from tert-butyl 4-(bromomethyl)-2-methylpyrrolidine-1-carboxylate, 2-bromo-5-fluoropyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. The resulting enantiomers were separated using chiral SFC. LCMS (ESI): [M+H] 350. 1 HNMR: (400 MHz, methanol-d4) δ8.59-8.65 (m, 2H), 7.23 (d, J = 5.52 Hz, 1H), 4.03-4.09 (m, 1H), 3.55 (t, J = 14.56 Hz, 1H), 2.81-3.13 (m, 3H), 2.45-2.80 (m, 3H), 2.20 (d, J = 1.00 Hz, 3H), 2.07-2.16 (m, 1H), 1.60-1.86 (m, 1H), 1.16 (dd, J = 6.02, 8.28 Hz, 3H).

[0365] Example 2-18

[0366]

[0367] N-(5-(((2S,4S)-4-((5-fluoropyrimidin-2-yl)methyl)-2-methylpyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The relative and absolute configurations are assigned arbitrarily. Chiral separation method: Column: CHIRALPAK AD-H; Method: 40% ethanol containing 0.1% diethylamine in CO 2 (flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi. The product is peak 4. LCMS (ESI): [M+H] 350. 1 HNMR:(500MHz,CDCl 3 )δ12.28(br s,1H),8.52(s,2H),7.20(s,1H),4.05(dd,J=14.27,0.99Hz,1H),3.54(d,J=14.50Hz,1H),3.00-3.10(m,2H),2.87(dd,J=9.54,3.89Hz,1 H),2.59-2.69(m,1H),2.49-2.59(m,2H),2.33(s,3H),2.10(ddd,J=12.51,8.24,6.41Hz,1H),1.27-1.35(m,1H),1.17(d,J=5.95Hz,3H).

[0368] Example 2-19

[0369]

[0370] N-(5-(((2R,4R)-4-((5-fluoropyrimidin-2-yl)methyl)-2-methylpyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The relative configuration and absolute configuration are arbitrarily assigned.

[0371] Chiral separation method used: Column: CHIRALPAK AD-H; Method: 40% ethanol containing 0.1% diethylamine in CO 2 (flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi. The product is peak 3. LCMS (ESI): [M+H] 350. 1 HNMR:(500MHz,CDCl 3 )δ12.32(br s,1H),8.51(s,2H),7.20(s,1H),4.06(dd,J=14.19,0.92Hz,1H),3.53(d,J=14.19Hz,1H),3.14(dd,J=9.00,7.17Hz,1H),2.91-3.03(m,2H ),2.69-2.80(m,1H),2.57-2.66(m,1H),2.32(s,3H),2.06(t,J=9.00Hz,1H),1.72-1.79(m,2H),1.64-1.72(m,1H),1.15(d,J=6.10Hz,3H).

[0372] Example 2-20

[0373]

[0374] N-(5-(((2R,4S)-4-((5-fluoropyrimidin-2-yl)methyl)-2-methylpyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The relative configuration and absolute configuration are arbitrarily assigned.

[0375] Chiral separation method: Column: CHIRALPAK AD-H; Method: 40% ethanol containing 0.1% diethylamine in CO 2 (flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi. The product is peak 2. LCMS (ESI): [M+H] 350. 1 HNMR:(500MHz,CDCl 3)δ12.50(br s,1H),8.50(s,2H),7.19(s,1H),4.05(dd,J=14.11,1.14Hz,1H),3.53(d,J=14.34Hz,1H),3.14(dd ,J=9.08,7.10Hz,1H),2.96(d,J=7.02Hz,2H),2.74(ddqd,J=9.92,9.00,7.10,7.02,7.02,6.26Hz,1 H),2.62(ddq,J=7.78,7.78,6.10,6.10,6.10Hz,1H),2.30-2.34(m,3H),2.06(t,J=9.00Hz,1H),1. 76(ddd,J=12.97,7.78,6.26Hz,1H), 1.68(ddd,J=12.82,9.92,7.78Hz,1H), 1.15(d,J=5.95Hz,3H).

[0376] Example 2-21

[0377]

[0378] N-(5-(((2S,4R)-4-((5-fluoropyrimidin-2-yl)methyl)-2-methylpyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The relative configuration and absolute configuration are arbitrarily assigned.

[0379] Chiral separation method: Column: CHIRALPAK AD-H; Method: 40% ethanol containing 0.1% diethylamine in CO 2 (flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi. The product is peak 1. LCMS (ESI): [M+H] 350. 1 HNMR:(500MHz,CDCl 3 )δ12.46(br s,1H),8.50(d,J=0.61Hz,2H),7.18(t,J=0.99Hz,1H),4.03(dd,J=14.27,1.14Hz,1 H),3.53(d,J=14.50Hz,1H),2.99-3.08(m,2H),2.57-2.67(m,1H),2.55(ddq,J=9.4 6,6.41,6.10,6.10,6.10Hz,1H),2.47-2.52(m,1H),2.31(s,3H),2.08(ddd,J=12.4 7, 8.28, 6.41Hz, 1H), 1.29 (ddd, J = 12.66, 9.46, 7.32Hz, 1H), 1.15 (d, J = 6.10Hz, 3H).

[0380] Example 2-22

[0381]

[0382] N-(5-(((trans)-3-((5-fluoropyrimidin-2-yl)methyl)-4-methylpyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 2 from tert-butyl (trans)-3-(bromomethyl)-4-methylpyrrolidine-1-carboxylate, 2-bromo-5-fluoropyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 350. 1 HNMR:(500MHz,CDCl 3 )δ12.36(br s,1H),8.44(s,2H),7.12(s,1H),3.67(q,J=13.89Hz,2H),3.04(dd,J=13.89,5.95Hz,1H),2.89(dd,J=13.66,9.08Hz,1H),2.79(t,J=8.24Hz, 1H), 2.68 (t, J = 8.62Hz, 1H), 2.44 (dd, J = 9.08, 6.79Hz, 1H), 2.24 (s, 3H), 2.16-2.22 (m, 2H), 1.93 (spt, J = 6.99Hz, 1H), 0.90 (d, J = 6.71Hz, 3H).

[0383] Example 2-23

[0384]

[0385] N-(5-((5-((5-fluoropyrimidin-2-yl)methyl)-2-methylpiperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a similar manner to Scheme 2 from tert-butyl 5-(bromomethyl)-2-methylpiperidine-1-carboxylate, 2-bromo-5-fluoropyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. The cis and trans diastereomers were separated on silica gel. The resulting enantiomers were separated using chiral SFC.

[0386] Example 2-24

[0387]

[0388] N-(5-(((2R,5R)-5-((5-fluoropyrimidin-2-yl)methyl)-2-methylpiperidin-1-yl)methyl)thiazol-2-yl)acetamide: The absolute configuration was assigned arbitrarily. Chiral separation method: Column: CHIRALPAK IA 30x250mm, 5um; Method: 40% ethanol containing 0.1% diethylamine in CO 2 (flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi. The product is peak 1. LCMS (ESI): [M+H] 364. 1 HNMR: (400 MHz, methanol-d4) δ8.59 (d, J=0.75 Hz, 2H), 7.17 (s, 1H), 3.84 (dd, J=0.75, 14.05 Hz, 1H), 3.63 (d, J=14.31 Hz, 1H), 2.89-3.04 (m, 2H), 2.68-2.81 (m, 1H), 2.46-2.55 (m, 1H), 2.33-2.42 (m, 1H), 2.22-2.31 (m, 1H), 2.19 (s, 3H), 1.63-1.74 (m, 1H), 1.48-1.63 (m, 2H), 1.36-1.47 (m, 1H), 1.11 (d, J=6.53 Hz, 3H).

[0389] Example 2-25

[0390]

[0391] N-(5-(((2S,5S)-5-((5-fluoropyrimidin-2-yl)methyl)-2-methylpiperidin-1-yl)methyl)thiazol-2-yl)acetamide: The absolute configuration was assigned arbitrarily. Chiral separation method: Column: CHIRALPAK IA 30x250mm, 5um; Method: 40% ethanol containing 0.1% diethylamine in CO 2 (flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi. The product is peak 2. LCMS (ESI): [M+H] 364. 1HNMR: (400 MHz, methanol-d4) δ8.59 (d, J = 0.75 Hz, 2H), 7.17 (s, 1H), 3.79-3.89 (m, 1H), 3.62 (d, J = 14.31 Hz, 1H), 2.89-3.04 (m, 2H), 2.68-2.80 (m, 1H), 2.46-2.54 (m, 1H), 2.34-2.41 (m, 1H), 2.22-2.32 (m, 1H), 2.19 (s, 3H), 1.63-1.74 (m, 1H), 1.48-1.63 (m, 2H), 1.36-1.48 (m, 1H), 1.11 (d, J = 6.53 Hz, 3H).

[0392] Example 2-26

[0393]

[0394] N-(5-(((2S,5R)-5-((5-fluoropyrimidin-2-yl)methyl)-2-methylpiperidin-1-yl)methyl)thiazol-2-yl)acetamide: The absolute configuration was assigned arbitrarily. Chiral separation method: Column: CHIRALPAK IA 30x250mm, 5um; Method: 40% ethanol containing 0.1% diethylamine in CO 2 (flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi. The product is peak 1. LCMS (ESI): [M+H] 364. 1 HNMR: (400 MHz, methanol-d4) δ8.62 (d, J = 0.75 Hz, 2H), 7.21 (s, 1H), 3.99 (d, J = 14.81 Hz, 1H), 3.79 (d, J = 14.81 Hz, 1H), 2.72-2.86 (m, 3H), 2.11-2.33 (m, 5H), 1.87-1.97 (m, 1H), 1.63-1.74 (m, 2H), 1.28-1.44 (m, 1H), 1.21 (d, J = 6.02 Hz, 3H), 0.99-1.15 (m, 1H).

[0395] Example 2-27

[0396]

[0397] N-(5-(((2R,5S)-5-((5-fluoropyrimidin-2-yl)methyl)-2-methylpiperidin-1-yl)methyl)thiazol-2-yl)acetamide: The absolute configuration was assigned arbitrarily. Chiral separation method: Column: CHIRALPAK IA 30x250mm, 5um; Method: 40% ethanol containing 0.1% diethylamine in CO 2(flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi. The product is peak 2. LCMS (ESI): [M+H] 364. 1 HNMR: (400 MHz, methanol-d4) δ8.62 (s, 2H), 7.21 (s, 1H), 3.99 (d, J = 14.81 Hz, 1H), 3.79 (d, J = 14.81 Hz, 1H), 2.73-2.85 (m, 3H), 2.12-2.33 (m, 5H), 1.87-1.96 (m, 1H), 1.63-1.73 (m, 2H), 1.28-1.42 (m, 1H), 1.21 (d, J = 6.27 Hz, 3H), 0.99-1.15 (m, 1H).

[0398] Example 2-28

[0399]

[0400] N-(5-((5-((5-fluoropyrimidin-2-yl)methyl)-2-methylpiperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared from tert-butyl 3-(1-bromoethyl)piperidine-1-carboxylate, 2-bromo-5-fluoropyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide in an analogous manner to Scheme 2. The resulting enantiomers were separated using chiral SFC.

[0401] Example 2-29

[0402]

[0403] N-(5-(((S)-3-((R)-1-(5-fluoropyrimidin-2-yl)ethyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The relative and absolute configurations are assigned arbitrarily. Chiral separation method: Column: CHIRALPAK IG 30x250mm, 5um; 30% ethanol containing 0.1% DEA in CO 2 (flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi, column temperature 40° C. The product is peak 1. LCMS (ESI): [M+H]364.

[0404] Example 2-30

[0405]

[0406] N-(5-(((S)-3-((S)-1-(5-fluoropyrimidin-2-yl)ethyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The relative and absolute configurations are assigned arbitrarily. Chiral separation method used: Column: CHIRALPAK IG 30x250mm, 5um; 30% ethanol containing 0.1% DEA in CO 2 (flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi, column temperature 40° C. The product is peak 2. LCMS (ESI): [M+H]364.

[0407] Example 2-31

[0408]

[0409] N-(5-(((R)-3-((R)-1-(5-fluoropyrimidin-2-yl)ethyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The relative and absolute configurations are assigned arbitrarily. Chiral separation method: CHIRALPAK IG 30x250mm, 5um; 30% ethanol containing 0.1% DEA in CO 2 (flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi, column temperature 40° C. The product is peak 3. LCMS (ESI): [M+H]364.

[0410] Example 2-32

[0411]

[0412] N-(5-(((R)-3-((S)-1-(5-fluoropyrimidin-2-yl)ethyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The relative and absolute configurations are assigned arbitrarily. Chiral separation method: Column: CHIRALPAK IG 30x250mm, 5um; 30% ethanol containing 0.1% DEA in CO 2 (flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi, column temperature 40° C. The product is peak 4. LCMS (ESI): [M+H]364.

[0413] Example 2-33

[0414]

[0415] N-[5-[[(3S)-3-[(5-fluoropyrimidin-2-yl)methyl]-1-piperidinyl]methyl]thiazol-2-yl]acetamide: The title compound was prepared in an analogous manner to Scheme 2 from (R)-tert-butyl 3-(bromomethyl)piperidine-1-carboxylate, 2-bromo-5-fluoro-pyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 350. 1 HNMR:(500MHz,CDCl 3 )δ12.09(br s,1H),8.52(s,2H),7.18(s,1H),3.59-3.71(m,2H),2.86(d,J=6.71Hz,2H),2.81(br t,J=10.68Hz,2H),2.31(s,3H),2.18-2.28(m,1H),1.99-2.07(m,1H),1.90(b rt,J=10.38Hz,1H),1.64-1.73(m,2H),1.51-1.61(m,1H),1.00-1.09(m,1H).

[0416] Example 2-34

[0417]

[0418] N-(5-((3-((5-fluoropyrimidin-2-yl)methyl)-3-methylpiperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a similar manner to Scheme 2 from tert-butyl 3-(bromomethyl)-3-methylpiperidine-1-carboxylate, 2-bromo-5-fluoropyrimidine and N-(5-(chloromethyl)thiazol-2-yl)acetamide. LCMS: [M+H] 364. 1 H NMR (400 MHz, methanol-d 4 )δ8.57-8.63(m,2H),7.17(s,1H),3.85(d,J=14.31Hz,1H),3.59-3.70(m,1H),2.89-3.03(m,2H),2.74(br s,1H),2.45-2.56(m,1H),2.33-2.43(m,1H),2.26(ddd,J=3.76,7.53,11.29Hz,1H),2.19 (s,3H),1.64-1.74(m,1H),1.49-1.63(m,2H),1.39-1.48(m,1H),1.12(d,J=6.53Hz,3H).

[0419] Example 2-35

[0420]

[0421] N-(5-((3-((5-fluoropyrimidin-2-yl)methyl)-3-methylpyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 2 from tert-butyl 3-(bromomethyl)-3-methylpyrrolidine-1-carboxylate, 2-bromo-5-fluoropyrimidine and N-(5-(chloromethyl)thiazol-2-yl)acetamide. LCMS (ESI): [M+H] 350. 1 H NMR (400MHz, methanol-d4) δ8.64(d,J=0.75Hz,2H),7.21(s,1H),3.75(s,2H),3.01(s,2H),2.91(d,J=9.54Hz,1H),2.63(dt,J=2.26,7.0 3Hz, 2H), 2.34 (d, J = 9.54Hz, 1H), 2.20 (s, 3H), 2.13 (td, J = 7.28, 12.80Hz, 1H), 1.58 (ddd, J = 6.15, 7.22, 12.99Hz, 1H), 1.10 (s, 3H).

[0422] Example 2-36

[0423]

[0424] N-(5-((3-(1-(5-fluoropyrimidin-2-yl)ethyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 2 from tert-butyl 3-(1-bromoethyl)pyrrolidine-1-carboxylate, 2-bromo-5-fluoropyrimidine and N-(5-(chloromethyl)thiazol-2-yl)acetamide. LCMS (ESI): [M+H] 350. 1 H NMR (400MHz, methanol-d4) δ8.69(s,1H),8.63-8.77(m,1H),7.51-7.64(m,1H),4.50-4.70(m,2H),3.41-3.91(m,1H),2.6 9-3.26(m,4H),2.28-2.55(m,1H),2.22(d,J=4.02Hz,3H),1.91-2.12(m,1H),1.54-1.87(m,1H),1.26-1.42(m,3H).

[0425] Example 2-37

[0426]

[0427] N-(5-(((3S,4R)-3-((5-fluoropyrimidin-2-yl)methyl)-4-methylpiperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a manner analogous to Scheme 2 from tert-butyl trans-3-(bromomethyl)-4-methylpiperidine-1-carboxylate, 2-bromo-5-fluoropyrimidine and N-(5-(chloromethyl)thiazol-2-yl)acetamide followed by chiral separation; the absolute configuration was assigned arbitrarily. Chiral separation method used: Column: CHIRALPAK AD-H 30x250mm, 5um; Method: 40% ethanol in 0.1% diethylamine in CO 2 (flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi. The product is peak 1. LCMS (ESI): [M+H] 364. 1 H NMR (400MHz, methanol-d4) δ8.56(s,2H),7.15(s,1H),3.66(dd,J=0.75,14.05Hz,1H),3.47-3.57(m,1H),2.96-3.08(m,1H),2.86-2.95(m,1H),2.65(br s,1H),2.28-2.52(m,3H),2.20(s,4H),1.79(dt,J=3.64,7.34Hz,1H),1.52-1.72(m,2H),0.96(d,J=7.03Hz,3H).

[0428] Example 2-38

[0429]

[0430] N-(5-(((3R,4S)-3-((5-fluoropyrimidin-2-yl)methyl)-4-methylpiperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a similar manner to Scheme 2 from tert-butyl trans-3-(bromomethyl)-4-methylpiperidine-1-carboxylate, 2-bromo-5-fluoropyrimidine and N-(5-(chloromethyl)thiazol-2-yl)acetamide followed by chiral separation; the absolute configuration was assigned arbitrarily. The chiral separation used was: Column: CHIRALPAK AD-H 30x250mm, 5um; Method: 40% ethanol in 0.1% diethylamine in CO 2 (flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi. The product is peak 2. LCMS (ESI): [M+H] 364. 1H NMR (400 MHz, methanol-d4) δ 8.56 (s, 2H), 7.15 (s, 1H), 3.62-3.70 (m, 1H), 3.48-3.57 (m, 1H), 2.97-3.09 (m, 1H), 2.86-2.95 (m, 1H), 2.65 (br s, 1H), 2.27-2.50 (m, 3H), 2.20 (s, 4H), 1.80 (tt, J = 3.89, 7.40 Hz, 1H), 1.52-1.72 (m, 2H), 0.96 (d, J = 7.03 Hz, 3H).

[0431] Example 2-39

[0432]

[0433] N-(5-(((3S,4S)-3-((5-fluoropyrimidin-2-yl)methyl)-4-methylpiperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 2 from tert-butyl cis-3-(bromomethyl)-4-methylpiperidine-1-carboxylate, 2-bromo-5-fluoropyrimidine and N-(5-(chloromethyl)thiazol-2-yl)acetamide followed by chiral separation; the absolute configuration was assigned arbitrarily. Chiral separation method used: Column: CHIRALPAK AD-H 30x250mm, 5um. Method: 40% ethanol with 0.1% DEA in CO2 (flow: 100mL / min), ABPR 120 bar, MBPR 40psi. The product is Peak 1. LCMS (ESI): [M+H] 364. 1 H NMR (400 MHz, methanol-d4) δ 8.56 (s, 2H), 7.15 (s, 1H), 3.62-3.73 (m, 1H), 3.53 (br d, J = 14.05 Hz, 1H), 2.96-3.09 (m, 1H), 2.86-2.95 (m, 1H), 2.66 (br s, 1H), 2.28-2.54 (m, 3H), 2.20 (s, 4H), 1.74-1.87 (m, 1H), 1.50-1.73 (m, 2H), 0.96 (d, J = 7.03 Hz, 3H).

[0434] Example 2-40

[0435]

[0436] N-(5-(((3R,4R)-3-((5-fluoropyrimidin-2-yl)methyl)-4-methylpiperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a manner analogous to Scheme 2 from cis-tert-butyl 3-(bromomethyl)-4-methylpiperidine-1-carboxylate, 2-bromo-5-fluoropyrimidine and N-(5-(chloromethyl)thiazol-2-yl)acetamide followed by chiral separation; the absolute configuration was assigned arbitrarily. The chiral separation used was: Column: CHIRALPAK AD-H 30x250mm, 5um. Method: 0.1% DEA in 40% ethanol in CO 2 (flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi. The product is peak 2. LCMS (ESI): [M+H] 364. 1 H NMR (400 MHz, methanol-d4) δ 8.56 (s, 2H), 7.15 (s, 1H), 3.62-3.72 (m, 1H), 3.49-3.57 (m, 1H), 2.97-3.10 (m, 1H), 2.85-2.95 (m, 1H), 2.66 (br s, 1H), 2.28-2.52 (m, 3H), 2.20 (s, 4H), 1.75-1.89 (m, 1H), 1.51-1.73 (m, 2H), 0.96 (d, J = 7.03 Hz, 3H).

[0437] Example 2-41

[0438]

[0439] N-(5-((3-((5-fluoropyrimidin-2-yl)methyl)-2-methylpiperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 2 from tert-butyl 3-(bromomethyl)-2-methylpiperidine-1-carboxylate, 2-bromo-5-fluoropyrimidine and N-(5-(chloromethyl)thiazol-2-yl)acetamide. LCMS (ESI): [M+H] 364. 1 H NMR (400 MHz, CDCl 3 )δ11.42(br s,1H),8.44-8.59(m,2H),7.19(br d,J=8.03Hz,1H),3.58-3.92(m,2H),2.87(br d,J=7.28Hz,3H),2.47(br d,J=9.03Hz,3H),2.30(s,3H),1.15-1.46(m,3H),1.15-1.46(m,1H),1.03(br s,3H).

[0440] Example 2-42

[0441]

[0442] N-(5-((3-((5-fluoropyrimidin-2-yl)methyl)-2-methylpyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 2 from tert-butyl 3-(bromomethyl)-2-methylpyrrolidine-1-carboxylate, 2-bromo-5-fluoropyrimidine and N-(5-(chloromethyl)thiazol-2-yl)acetamide. LCMS (ESI): [M+H] 350. 1 H NMR (400 MHz, CDCl 3 )δ11.52(br s,1H),8.52(s,2H),7.22(br s,1H),4.05(br d,J=13.80Hz,1H),3.72(br s,1H),2.69-3.20(m,5H),2.36-2.59(m,1H),2.31(s,3H),1.79(br s,1H),1.59(br s,1H),1.11(br d,J=5.02Hz,3H).

[0443] Example 2-43

[0444]

[0445] N-(5-((4-((5-fluoropyrimidin-2-yl)methyl)-2-(trifluoromethyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared from tert-butyl 4-(bromomethyl)-2-(trifluoromethyl)pyrrolidine-1-carboxylate, 2-bromo-5-fluoropyrimidine and N-(5-(chloromethyl)thiazol-2-yl)acetamide in an analogous manner to Scheme 2. The resulting enantiomers were separated using chiral SFC.

[0446] Example 2-44

[0447]

[0448] N-(5-(((2R,4S)-4-((5-fluoropyrimidin-2-yl)methyl)-2-(trifluoromethyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The relative and absolute configurations are assigned arbitrarily. Column: CHIRALPAK AD-H 30x250mm, 5um; Method: 40% ethanol in 0.1% diethylamine in CO 2 (flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi. The product is peak 1. LCMS (ESI): [M+H] 404. 1H NMR (500 MHz, CDCl 3 )δ11.89(br s,1H),8.51(s,2H),7.21(s,1H),3.92-4.23(m,2H),3.30-3.40(m,1H),3.13-3.20(m,1H), 2.93-3.07(m,2H),2.77-2.90(m,1H),2.39(dd,J=10.07,8.85Hz,1H),2.32(s,3H),2.12(br dd, J=13.50, 6.94Hz, 1H), 1.77 (dt, J=13.58, 10.83Hz, 1H).

[0449] Example 2-45

[0450]

[0451] N-(5-(((2S,4R)-4-((5-fluoropyrimidin-2-yl)methyl)-2-(trifluoromethyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The relative and absolute configurations are assigned arbitrarily. Column: CHIRALPAK AD-H 30x250mm, 5um; Method: 40% ethanol in 0.1% diethylamine in CO 2 (flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi. The product is peak 2. LCMS (ESI): [M+H] 404. 1 H NMR (500 MHz, CDCl 3 )δ11.97(br s,1H),8.52(s,2H),7.22(s,1H),3.96-4.23(m,2H),3.30-3.43(m,1H),3.18(dd,J=8.01,6.48Hz,1H),2.93-3.09(m,2H),2.78-2.91 (m,1H),2.40(dd,J=10.07,8.85Hz,1H),2.30-2.36(m,3H),2.14(ddd,J=13.47,7.06,1.30Hz,1H),1.78(dt,J=13.54,10.78Hz,1H).

[0452] Example 2-46

[0453]

[0454] N-(5-(((2R,4R)-4-((5-fluoropyrimidin-2-yl)methyl)-2-(trifluoromethyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The relative and absolute configurations are assigned arbitrarily. Column: CHIRALPAK AD-H 30x250mm, 5um; Method: 40% ethanol in 0.1% diethylamine in CO 2 (flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi. The product is peak 3. LCMS (ESI): [M+H] 404. 1 H NMR (500 MHz, CDCl 3 )δ10.69(br s,1H),8.45(s,2H),7.19(s,5H),3.90-4.15(m,2H),3.14(qd,J=7.43,2.59Hz,1H),2.95-3.05(m,1H),2.78-2.94(m ,3H),2.67(td,J=9.77,6.10Hz,1H),2.23(s,3H),1.99(ddt,J=12.57,10.59,7.34,7.34Hz,1H),1.48-1.61(m,1H).

[0455] Example 2-47

[0456]

[0457] N-(5-(((2R,4S)-4-((5-fluoropyrimidin-2-yl)methyl)-2-(trifluoromethyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The relative and absolute configurations are assigned arbitrarily. Column: CHIRALPAK AD-H 30x250mm, 5um; Method: 40% ethanol in 0.1% diethylamine in CO 2 (flow rate: 100 mL / min), ABPR 120 bar, MBPR 40 psi. The product is peak 4. LCMS (ESI): [M+H] 404. 1 H NMR (500 MHz, CDCl 3 )δ10.73(br s,1H),8.45(s,2H),7.17-7.22(m,5H),3.90-4.15(m,2H),3.14(qd,J=7.43,2.75Hz,1H),2.97-3.04(m,1H),2.78-2 .95(m,3H),2.67(td,J=9.77,6.10Hz,1H),2.23(s,3H),1.99(ddt,J=12.59,10.49,7.38,7.38Hz,1H),1.57(m,1H).

[0458] Example 2-48

[0459]

[0460] N-(5-((5-((5-fluoropyrimidin-2-yl)methyl)-2-(trifluoromethyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a similar manner to Scheme 2 from tert-butyl 5-(bromomethyl)-2-(trifluoromethyl)piperidine-1-carboxylate, 2-bromo-5-fluoropyrimidine and N-(5-(chloromethyl)thiazol-2-yl)acetamide. The resulting isomers were separated using: Column: CHIRALPAK AD-H 30x250mm, 5um; Method: 30% isopropanol in 0.1% diethylamine in CO 2 Medium (flow rate: 100mL / min), ABPR 120 bar, MBPR 40psi.

[0461] Example 2-49

[0462]

[0463] Relative and absolute configurations are assigned arbitrarily; the product is peak 1. LCMS (ESI): [M+H] 487. 1 H NMR (500 MHz, CDCl 3 )δ12.15(br s,1H),8.52(s,2H),7.22(s,1H),3.93-4.18(m,2H),3.27-3.40(m,1H),2.80-2.91(m,2H),2.74-2.80(m,1 H),2.64-2.74(m,1H),2.31-2.36(m,3H),2.20-2.31(m,1H),1.94-2.03(m,1H),1.77-1.89(m,1H),1.62(br d,J=12.21Hz,1H),1.36-1.49(m,1H).

[0464] Example 2-50

[0465]

[0466] The relative and absolute configurations are assigned arbitrarily; the product is peak 2. LCMS (ESI): [M+H]487. 1 H NMR (500 MHz, CDCl 3)δ12.15(br s,1H),8.52(s,2H),7.22(s,1H),3.96-4.15(m,2H),3.25-3.39(m,1H),2.80-2.90(m,2H),2.74-2.80(m,1 H),2.65-2.73(m,1H),2.30-2.35(m,3H),2.21-2.29(m,1H),1.94-2.02(m,1H),1.78-1.89(m,1H),1.62(br d,J=12.21Hz,1H),1.37-1.49(m,1H).

[0467] Example 2-51

[0468]

[0469] N-(4-fluoro-5-((3-(1-(5-fluoropyrimidin-2-yl)ethyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a similar manner to Example 1-1 from 5-fluoro-2-(1-(pyrrolidin-3-yl)ethyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 368. 1 H NMR (400 MHz, methanol-d 4 )δ8.66(dd,J=0.88,1.63Hz,2H),3.82-3.96(m,2H),3.00-3.21(m,2H),2.81-2.96(m,1H),2.67-2.80(m,2H),2 .40-2.66(m,1H),2.19(d,J=4.77Hz,3H),1.72-1.83(m,1H),1.34-1.57(m,1H),1.30(dd,J=7.03,11.29Hz,3H).

[0470] Example 2-52

[0471]

[0472] N-(4-fluoro-5-((3-(1-(6-methoxypyrimidin-4-yl)ethyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 2 from 4-methoxy-6-(1-(pyrrolidin-3-yl)ethyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 380. 1 H NMR (400 MHz, methanol-d 4)δ8.69(s,1H),6.75-6.85(m,1H),4.38-4.66(m,2H),3.99(d,J=0.75Hz,1H),3.96-4.0 6(m,1H),3.96-4.06(m,1H),3.39-3.92(m,2H),3.13(td,J=1.63,3.26Hz,1H),2.84(br d,J=7.53Hz,2H),2.28-2.55(m,1H),2.18-2.25(m,3H),1.43-2.09(m,2H),1.30(dd,J=6.65,9.91Hz,3H).

[0473] Example 2-53

[0474]

[0475] N-(4-fluoro-5-(((2S,5R)-5-((5-fluoropyrimidin-2-yl)methyl)-2-methylpiperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Scheme 2 and using 5-fluoro-2-(((3R,6S)-6-methylpiperidin-3-yl)methyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 382. 1 HNMR: (400MHz, methanol-d 4 )δ8.66(d,J=1.00Hz,2H),3.72-3.96(m,2H),2.71-2.92(m,3H),2.13-2.38(m,2H),2.22(s,3H),1 .92-2.07(m,1H),1.63-1.77(m,2H),1.28-1.47(m,1H),1.22(d,J=6.27Hz,3H),1.00-1.16(m,1H).

[0476] Solution 3

[0477]

[0478] Intermediate 7

[0479]

[0480] (3S)-3-(Iodomethyl)piperidine-1-carboxylic acid tert-butyl ester: Dissolve (3S)-3-(Hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester (20.0 g, 92.9 mmol) in CH 2 Cl 2(25.0 mL) and triethylamine (11.3 g, 111.5 mmol, 15.5 mL) was added. The mixture was cooled to 0 °C and methanesulfonyl chloride (12.8 g, 111.5 mmol, 8.63 mL) was slowly added. After the addition was complete, the reaction was warmed to room temperature and stirred for 3 h. The reaction mixture was filtered through celite and washed with water (25 mL), saturated Na 2 CO 3 (aqueous solution) (25 mL), washed with Na 2 SO 4 The crude mesylate was dissolved in acetone (150 mL) and sodium iodide (27.85 g, 185.8 mmol) was added to the mixture; the mixture was then stirred overnight at reflux. The reaction mixture was cooled to room temperature, filtered, and concentrated in vacuo. The residue was dissolved in diethyl ether (300 mL) and washed with water (50 mL), saturated Na 2 CO 3 (aqueous solution) (40 mL), 5% Na 2 S 2 O 3 The solution was washed with 4% ethyl acetate (40 mL) and brine (40 mL). 2 SO 4 The solution was dried, filtered, and concentrated in vacuo to provide the title compound (23.90 g, 79%). 1 HNMR:(500MHz,CDCl 3 )δ3.93-4.27(m,1H),3.85(br d,J=13.43Hz,1H),3.09(br d,J=6.71Hz,2H),2.43-2.93(m,2H),1.93(brd,J=10.38Hz,1H),1.58-1.71(m,2H),1.40-1.54(m,10H),1.25(m,1H).

[0481] Intermediate 8

[0482]

[0483] (3R)-tert-Butyl 3-[(5-fluoropyrimidin-2-yl)methyl]piperidine-1-carboxylate: To a slurry of zinc powder (0.817 g, 12.5 mmol) in DMA (2 mL) was added a mixture of TMSCl / 1,2-dibromoethane (7 / 5 v / v, 0.24 mL) over a 10 minute period. The mixture was stirred for 15 minutes and a solution of (S)-tert-butyl 3-(iodomethyl)piperidine-1-carboxylate (3.25 g, 10.0 mmol) in DMA (5 mL) was slowly added. Stirring was continued for 2 hours. 2-Chloro-5-fluoro-pyrimidine (0.884 g, 6.67 mmol) and Pd(amphos)Cl were added to the mixture. 2 (0.473 g, 0.667 mmol). The mixture was heated at 80 °C overnight. After cooling to room temperature, the mixture was diluted with EtOAc and filtered through a pad of celite. The filtrate was washed with water and filtered through MgSO 4 Dry, filter, and concentrate in vacuo. 2 The residue was purified (0-100% EtOAc / heptane) to provide the title compound (1.78 g, 90%). LCMS (ESI): [(-t-Bu)M+H]240, [(-Boc)M+H]196. 1 HNMR:(500MHz,CDCl 3 )δ8.53(s,2H),3.74-4.08(m,2H),2.84-2.93(m,2H),2.76-2.83(m,1H),2.43-2.72(m,1H),2.11(m,1H),1.77(br d,J=10.99Hz,1H),1.62-1.70(m,1H),1.42(s,10H),1.17-1.31(m,1H).

[0484] Intermediate 9

[0485]

[0486] 5-Fluoro-2-[[(3R)-3-piperidinyl]methyl]pyrimidine hydrochloride: Acetyl chloride (15.8 g, 201.5 mmol, 14.4 mL) was added dropwise to vigorously stirred MeOH (110 mL) at 0°C over 10 min and the mixture was stirred for an additional 20 min. A solution of (3R)-tert-butyl 3-[(5-fluoropyrimidin-2-yl)methyl]piperidine-1-carboxylate (5.95 g, 20.15 mmol) in MeOH (30 mL) was added dropwise to a menthol HCl solution at 0°C. The resulting mixture was warmed to room temperature and stirred for an additional 2 h. The mixture was concentrated in vacuo to provide the title compound (4.60 g, 98%). LCMS (ESI): [M+H] 232.1 HNMR: (400 MHz, methanol-d4) δ 8.67-8.76 (m, 2H), 3.27-3.38 (m, 2H), 2.82-2.97 (m, 3H), 2.70-2.81 (m, 1H), 2.34-2.46 (m, 1H), 1.78-1.93 (m, 2H), 1.72 (s, 1H), 1.26-1.39 (m, 1H).

[0487] Example 3-1

[0488]

[0489] N-[5-[[(3R)-3-[(5-fluoropyrimidin-2-yl)methyl]-1-piperidinyl]methyl]thiazol-2-yl]acetamide: To a suspension of 5-fluoro-2-[[(3R)-3-piperidinyl]methyl]pyrimidine hydrochloride (7.90 g, 34.1 mmol) and N-[5-(chloromethyl)thiazol-2-yl]acetamide (6.83 g, 35.8 mmol) in MeCN (170 mL) was added triethylamine (10.35 g, 102 mmol, 14.2 mL); then it was warmed to 70 °C overnight. The reaction was cooled to room temperature, and the mixture was diluted with EtOAc and washed with saturated NH 4 Cl (aqueous solution). MgSO 4 The organics were dried, filtered and concentrated in vacuo. 2 (24 g, 0-100% EtOAc:iPrOH (3:1 v / v)-heptane) The residue was purified to provide the title compound (8.24 g, 69%). LCMS (ESI): [M+H]350. 1 HNMR:(500MHz,CDCl 3 )δ11.89(br s,1H),8.52(s,2H),7.18(s,1H),3.65(q,J=13.63Hz,2H),2.86(d,J=7.33Hz,2H ),2.77-2.84(m,2H),2.31(s,3H),2.18-2.28(m,1H),1.98-2.07(m,1H),1.90(br t,J=10.38Hz,1H),1.66-1.71(m,2H),1.51-1.61(m,1H),1.00-1.09(m,1H).

[0490] Example 3-2

[0491]

[0492] N-(5-((3-fluoro-5-((5-fluoropyrimidin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 3 from tert-butyl 3-fluoro-5-(iodomethyl)piperidine-1-carboxylate, 2-chloro-5-fluoro-pyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 368. 1 HNMR:(500MHz,CDCl 3 )δ11.96(br s,1H),8.54(s,2H),7.21(s,1H),4.66(tt,J=9.99,4.73Hz,0.5H),4.56(tt,J=9.96,4.7 7Hz,0.5H),3.68-3.82(m,2H),3.18(dt,J=9.99,4.92Hz,1H),2.88-3.00(m,3H),2.85(br d,J=10.53Hz,1H),2.34-2.40(m,1H),2.28-2.34(m,4H),2.12-2.20(m,1H),2.0 5(td,J=9.84,5.04Hz,1H), 1.90(t,J=10.68Hz,1H), 1.25(quin,J=11.48Hz,1H).

[0493] Example 3-3

[0494]

[0495] N-(5-((3,3-difluoro-4-((5-fluoropyrimidin-2-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 3 from tert-butyl 3,3-difluoro-4-(iodomethyl)pyrrolidine-1-carboxylate, 2-chloro-5-fluoro-pyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS: [M+H] 372. 1 HNMR:(500MHz,CDCl 3 )δ12.17(br s,1H),8.54(s,2H),7.23(t,J=0.84Hz,1H),3.82(t,J=0.92Hz,2H),3.34-3.40(m,1H),3.23-3.33(m,1H),3.14(t d, J=6.41, 3.36Hz, 2H), 3.04 (dd, J=15.03, 9.54Hz, 1H), 2.81-2.91 (m, 1H), 2.44-2.50 (m, 1H), 2.30-2.36 (m, 3H).

[0496] Embodiment 3-4

[0497]

[0498] (R)-N-(5-((3-((2-methylpyrimidin-4-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a similar manner to Scheme 3 from (S)-tert-butyl 3-(iodomethyl)piperidine-1-carboxylate, 4-chloro-2-methyl-pyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS: [M+H] 346. 1 HNMR:(400MHz,CDCl 3 )δ11.56(br s,1H),8.48(d,J=5.02Hz,1H),7.17(s,1H),6.94(d,J=5.27Hz,1H),3.57-3.71(m,2H),2.76(m,2H),2.70(s,3H),2 .57-2.68(m,2H),2.31(s,3H),2.06-2.18(m,2H),1.89(m,1H),1.67(m,2H),1.50-1.63(m,1H),0.99-1.11(m,1H).

[0499] Embodiment 3-5

[0500]

[0501] (R)-N-(5-((3-((5-(difluoromethyl)pyridin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a manner analogous to Scheme 3 from tert-butyl (S)-3-(iodomethyl)piperidine-1-carboxylate, 2-chloro-5-(difluoromethyl)pyridine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 381. 1 HNMR:(400MHz,CDCl 3 )δ11.97(br s,1H),8.64(d,J=1.25Hz,1H),7.74(d,J=7.76Hz,1H),7.23(d,J=8.03Hz,1H),7.17(s,1H),6.68( t,J=56.47Hz,1H),3.57-3.72(m,2H),2.70-2.85(m,4H),2.31(s,3H),2.03-2.19(m,2H),1.90(br t,J=10.29Hz,1H),1.67(m,2H),1.48-1.60(m,1H),0.99-1.13(m,1H).

[0502] Embodiment 3-6

[0503]

[0504] (R)-N-(5-((3-((5-(difluoromethyl)pyrimidin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a manner analogous to Scheme 3 from tert-butyl (S)-3-(iodomethyl)piperidine-1-carboxylate, 2-chloro-5-(difluoromethyl)pyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 382. 1 HNMR:(400MHz,CDCl 3 )δ11.69(br s,1H),8.80(s,2H),7.18(s,1H),6.73(t,J=55.22Hz,1H),3.59-3.71(m,2H),2.93(d,J=7.28Hz,2H),2.81(br t,J=9.91Hz,2H),2.30(s,3H),2.01-2.11(m,1H),1.93(t,J=10.29Hz,1H),1.52-1.74(m,4H),1.02-1.14(m,1H).

[0505] Embodiment 3-7

[0506]

[0507] (R)-N-(5-((3-(pyrimidin-2-ylmethyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a manner analogous to Scheme 3 from tert-butyl (S)-3-(iodomethyl)piperidine-1-carboxylate, 2-chloropyrimidine and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 331. 1 HNMR:(400MHz,CDCl 3 )δ11.39(br s,1H),8.67(d,J=5.02Hz,2H),7.18(s,1H),7.12(t,J=4.89Hz,1H),3.59-3.70(m,2H),2.79-2.91(m,4H),2.3 0(s,3H),1.97-2.04(m,1H),1.91(t,J=10.42Hz,1H),1.63-1.74(m,3H),1.52-1.62(m,1H),1.00-1.11(m,1H).

[0508] Embodiment 3-8

[0509]

[0510] (R)-N-(5-((3-((5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a manner analogous to Scheme 3 from tert-butyl (S)-3-(iodomethyl)piperidine-1-carboxylate, 2-bromo-5-fluoro-4-methoxy-6-methylpyrimidine and N-(5-(chloromethyl)thiazol-2-yl)acetamide. LCMS (ESI): [M+H] 394. 1 H NMR (500 MHz, CDCl 3 )δ11.74(br s,1H),7.18(s,1H),4.00(s,3H),3.65(s,2H),2.80-2.91(m,2H),2.66(d,J= 7.33Hz,2H),2.40(d,J=2.44Hz,3H),2.31(s,3H),2.17-2.27(m,1H),2.01(br t,J=10.38Hz,1H),1.85(br t,J=10.38Hz,1H),1.53-1.73(m,3H),0.97-1.07(m,1H).

[0511] Embodiment 3-9

[0512]

[0513] (R)-N-(5-((3-((5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a manner analogous to Scheme 3 from tert-butyl (S)-3-(iodomethyl)pyrrolidine-1-carboxylate, 2-bromo-5-fluoro-4-methoxy-6-methylpyrimidine and N-(5-(chloromethyl)thiazol-2-yl)acetamide. LCMS (ESI): [M+H] 380. 1 HNMR (500MHz, CDCl 3 )δ12.28(br s,1H),7.22(s,1H),4.00(s,3H),3.73-3.85(m,2H),2.82-2.92(m,3H),2.68-2.81(m,2H),2.52-2.62(m, 1H), 2.40 (d, J = 2.90Hz, 3H), 2.31 (m, 4H), 1.99-2.09 (m, 1H), 1.58 (ddt, J = 12.61, 8.14, 6.18, 6.18Hz, 1H).

[0514] Embodiment 3-10

[0515]

[0516] (R)-N-(5-((3-((4-methylpyrimidin-2-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a manner analogous to Scheme 3 from tert-butyl (S)-3-(iodomethyl)pyrrolidine-1-carboxylate, 2-bromo-4-methylpyrimidine and N-(5-(chloromethyl)thiazol-2-yl)acetamide. LCMS (ESI): [M+H] 332. 1 HNMR (600MHz, CDCl 3 )δ12.18(br s,1H),8.48(d,J=5.13Hz,1H),7.27-7.32(m,1H),6.98(d,J=5.14Hz,1H),3.84(br s,2H),2.93-3.04(m,3H),2.83(dt,J=14.95,7.38Hz,2H),2.66(brs,1H),2.49(s,3H),2.36-2.47(m,1H),2.31(s,3H),2.05(br dd, J=12.29, 5.87Hz, 1H), 1.64 (br dd, J=12.29, 6.24Hz, 1H).

[0517] Example 3-11

[0518]

[0519] (R)-N-(5-((3-((5-fluoro-4-methylpyrimidin-2-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a manner analogous to Scheme 3 from tert-butyl (S)-3-(iodomethyl)pyrrolidine-1-carboxylate, 2-bromo-5-fluoro-4-methylpyrimidine and N-(5-(chloromethyl)thiazol-2-yl)acetamide. LCMS (ESI): [M+H] 350. 1 HNMR (500MHz, CDCl 3)δ11.91(br s,1H),8.35(d,J=1.68Hz,1H),7.22(t,J=1.07Hz,1H),3.78(d,J=0.61H z,2H),2.98(dt,J=7.25,1.26Hz,2H),2.83-2.87(m,1H),2.70-2.82(m, 2H),2.58(td,J=8.66,6.03Hz,1H),2.51(d,J=2.44Hz,3H),2.29-2.35( m,4H),1.98-2.07(m,1H),1.60(ddt,J=12.51,8.32,6.14,6.14Hz,1H).

[0520] Example 3-12

[0521]

[0522] (R)-N-(5-((3-((4-methoxypyrimidin-2-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a manner analogous to Scheme 3 from tert-butyl (S)-3-(iodomethyl)pyrrolidine-1-carboxylate, 2-bromo-4-methoxypyrimidine and N-(5-(chloromethyl)thiazol-2-yl)acetamide. LCMS (ESI): [M+H] 348. 1 H NMR (500 MHz, CDCl 3 )δ12.17(br s,1H),8.24(d,J=5.80Hz,1H),7.13(t,J=1.07Hz,1H),6.41-6.48(m,1H),3. 83-3.92(m,3H),3.65-3.76(m,2H),2.78-2.88(m,3H),2.70-2.78(m,1H),2.6 5(td,J=8.39,5.80Hz,1H),2.50(td,J=8.66,6.18Hz,1H),2.24-2.29(m,1H), 2.23(s,3H),1.91-2.03(m,1H),1.53(ddt,J=12.59,8.28,6.05,6.05Hz,1H).

[0523] Example 3-13

[0524]

[0525] (R)-N-(5-((3-((5-methylpyrimidin-2-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a manner analogous to Scheme 3 from tert-butyl (S)-3-(iodomethyl)pyrrolidine-1-carboxylate, 2-bromo-5-methylpyrimidine and N-(5-(chloromethyl)thiazol-2-yl)acetamide. LCMS (ESI): [M+H] 332. 1 H NMR (500 MHz, CDCl 3 )δ11.95(br s,1H),8.48(s,2H),7.20(s,1H),2.94-3.03(m,2H),2.75-2.87(m,2H),2.72(td,J=8.32,5.80Hz,1H),2.57( td,J=8.54,6.26Hz,1H),2.30(s,4H),2.28(s,3H),1.95-2.07(m,1H),1.94-2.05(m,1H),1.54-1.65(m,1H).

[0526] Embodiment 3-14

[0527]

[0528] N-(5-((3-((5-fluoropyrimidin-2-yl)methyl)piperidin-1-yl)methyl)-1,3,4-thiadiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Scheme 3 using 5-fluoro-2-(piperidin-3-ylmethyl)pyrimidine HCl and N-(5-formyl-1,3,4-thiadiazol-2-yl)acetamide. LCMS: [M+H] 351. 1 H NMR (400 MHz, methanol-d4) δ 8.63 (d, J = 0.75 Hz, 2H), 3.75-3.90 (m, 2H), 2.87 (d, J = 7.28 Hz, 2H), 2.74-2.83 (m, 2H), 2.13-2.35 (m, 5H), 2.01 (t, J = 10.42 Hz, 1H), 1.50-1.80 (m, 3H), 0.99-1.19 (m, 1H).

[0529] Intermediate 10

[0530]

[0531] N-(5-(Hydroxymethyl-d2)thiazol-2-yl)acetamide: To a suspension of ethyl 2-acetamidothiazole-5-carboxylate (214 mg, 1.00 mmol) in THF (5 mL) was added LiAlD in THF (3 mL) at 0 °C. 4(250 mg, 5.96 mmol). The reaction mixture was stirred and slowly warmed to rt. Ice was added to the mixture followed by 1N aqueous HCl. The mixture was extracted with EtOAc (x5, solid NaCl was added to saturate the aqueous layer). MgSO 4 The combined organic phases were dried, filtered and concentrated. The residue was purified by normal phase column eluting with EtOAc to afford the title compound as a white solid (6.5 mg, 3.7%). LCMS: [M+H]175. 1 HNMR (400 MHz, methanol-d 4 )δ7.30(s,1H),2.22(s,3H).

[0532] Intermediate 11

[0533]

[0534] N-(5-(Chloromethyl-d2)thiazol-2-yl)acetamide: To a solution of N-(5-(hydroxymethyl-d2)thiazol-2-yl)acetamide (6.50 mg, 37.31 umol) in DCM (1.00 mL) was added thionyl chloride (0.15 mL, 2.06 mmol). The mixture was stirred at 50 °C for 10 min. The reaction mixture was concentrated to provide the title compound (7.2 mg, 100%).

[0535] Example 3-15

[0536]

[0537] N-(5-((3-((5-fluoropyrimidin-2-yl)methyl)piperidin-1-yl)methyl)-1,3,4-thiadiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 3 from 5-fluoro-2-(piperidin-3-ylmethyl)pyrimidine HCl and N-(5-(chloromethyl-d2)thiazol-2-yl)acetamide. LCMS: [M+H] 352. 1 H NMR (500 MHz, methanol-d4) δ 8.63 (s, 2H), 7.21 (s, 1H), 2.76-2.89 (m, 4H), 2.15-2.29 (m, 4H), 2.03-2.13 (m, 1H), 1.83-1.92 (m, 1H), 1.65-1.76 (m, 2H), 1.51-1.64 (m, 1H), 1.01-1.15 (m, 1H).

[0538] Intermediate 12

[0539]

[0540] 2-Acetylaminothiazole-5-carboxylic acid ethyl ester: To a stirred solution of 2-aminothiazole-5-carboxylic acid ethyl ester (10.00 g, 58.1 mmol), pyridine (9.47 mL, 117.3 mmol) and 4-dimethylaminopyridine (200.0 mg, 1.64 mmol) in dichloromethane (100. mL) at 0 ° C, acetic anhydride (8.23 mL, 87.1 mmol) was added. The reaction was heated to reflux and maintained for 2 hours. The reaction mixture was concentrated under reduced pressure and then hydrochloric acid solution (1.5 N in water, 50 mL) was added. The mixture was stirred for 10 min. The resulting precipitate was filtered and washed with water (250 mL) and heptane (50 mL) and then dried under high vacuum to obtain the title compound (11.82 g, 95.0% yield). LCMS: [M+H] 215.0. 1 H NMR: (400MHz, DMSO-d6) δ 12.55 (s, 1H), 8.12 (s, 1H), 4.27 (q, J = 7.11Hz, 2H), 2.19 (s, 3H), 1.28 (t, J = 7.15Hz, 3H).

[0541] Intermediate 13

[0542]

[0543] N-[5-(Hydroxymethyl)thiazol-2-yl]acetamide: To a stirred solution of ethyl 2-acetamidothiazole-5-carboxylate (1.00 g, 4.67 mmol) in toluene (24 mL) was slowly added triethylborohydride (1 M in tetrahydrofuran, 9.39 mL, 9.39 mmol) at 0°C. The reaction mixture was stirred at room temperature for 2.5 hours. The reaction was cooled to 0°C and more triethylborohydride (1 M in tetrahydrofuran, 9.39 mL, 9.39 mmol) was slowly added. The reaction was stirred at room temperature for 2 hours and then cooled to 0°C. Methanol (2 mL) was added very slowly, resulting in vigorous gas evolution. A 5% citric acid solution was added and the mixture was stirred at room temperature for 10 minutes. The mixture was extracted with ethyl acetate, washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, filtered and evaporated. Purification was performed by silica gel chromatography using 0-10% methanol in dichloromethane as eluent to obtain the title compound (319.7 mg, 39.8% yield). LCMS: [M+H] 172.9. 1 HNMR: (400MHz, DMSO-d6) δ 11.93 (s, 1H), 7.25 (s, 1H), 5.33 (t, J = 5.65Hz, 1H), 4.57 (dd, J = 0.88, 5.65Hz, 2H), 2.12 (s, 3H).

[0544] Intermediate 14

[0545]

[0546] N-[5-[[tert-butyl(dimethyl)silyl]oxymethyl]thiazol-2-yl]acetamide: To a stirred mixture of N-[5-(hydroxymethyl)thiazol-2-yl]acetamide (319.7 mg, 1.86 mmol), 4-dimethylaminopyridine (22.7 mg, 186 umol) and triethylamine (515 uL, 3.71 mmol) in dichloromethane (9.45 mL) at 0°C was added tert-butyl-chloro-dimethyl-silane (307.8 mg, 2.04 mmol). The reaction was stirred at room temperature overnight. The reaction was diluted with ethyl acetate, washed with 5% aqueous citric acid solution, washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, filtered, and evaporated. The residue was purified by silica gel chromatography using 0-100% ethyl acetate in heptane as eluent to obtain the title compound (451.6 mg, 84.8% yield). LCMS: [M+H] 286.9. 1 H NMR: (400MHz, DMSO-d6) δ 11.99 (s, 1H), 7.30 (s, 1H), 4.80 (d, J = 0.75Hz, 2H), 2.12 (s, 3H), 0.86 (s, 9H), 0.07 (s, 6H).

[0547] Intermediate 15

[0548]

[0549] N-[5-[[tert-butyl(dimethyl)silyl]oxymethyl]thiazol-2-yl]-N-methyl-acetamide: To a solution of N-[5-[[tert-butyl(dimethyl)silyl]oxymethyl]thiazol-2-yl]acetamide (584.7 mg, 2.04 mmol) in tetrahydrofuran (7.5 mL) was added lithium bis(trimethylsilyl)amide (1.0 M in tetrahydrofuran, 2.43 mL, 2.43 mmol) at 0°C. The resulting suspension was stirred at 0°C for 1 hour. To the mixture was added iodomethane (421 uL, 3.06 mmol) and the mixture was warmed to room temperature. After stirring for 4 hours, the mixture was diluted with ethyl acetate and then washed with saturated aqueous ammonium chloride solution. The organics were dried over magnesium sulfate, filtered and concentrated in vacuo. The material was purified on silica gel using 0-100% ethyl acetate in heptane as eluent to provide the title compound (335.2, 54.7% yield). LCMS: [M+H] 300.9. 1H NMR: (400 MHz, methanol-d4) δ 7.31 (s, 1H), 4.86 (d, J=1.00 Hz, 2H), 3.68 (s, 3H), 2.41 (s, 3H), 0.92 (s, 9H), 0.11 (s, 6H).

[0550] Intermediate 16

[0551]

[0552] N-[5-(Hydroxymethyl)thiazol-2-yl]-N-methyl-acetamide: N-[5-[[tert-butyl(dimethyl)silyl]

[0553] [(4-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-oxymethyl]thiazol-2-yl]-N-methyl-acetamide (335.2 mg, 1.12 mmol) was dissolved in tetrahydrofuran (6.4 mL). Tetrabutylammonium fluoride (1 M in tetrahydrofuran, 2.23 mL, 2.23 mmol) was added dropwise at 0 °C. After 30 min, the mixture was diluted with ethyl acetate, washed with saturated aqueous ammonium chloride solution, washed with brine, dried over magnesium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography using 0-10% methanol in dichloromethane as eluent to obtain the title compound (159.8 mg, 76.6% yield). LCMS: [M+H] 186.9. 1 H NMR: (400 MHz, methanol-d4) δ 7.35 (s, 1H), 4.71 (d, J = 0.75 Hz, 2H), 3.68 (s, 3H), 2.41 (s, 3H).

[0554] Intermediate 17

[0555]

[0556] N-[5-(Chloromethyl)thiazol-2-yl]-N-methyl-acetamide: To a stirred solution of N-[5-(hydroxymethyl)thiazol-2-yl]-N-methyl-acetamide (50.0 mg, 268 umol) in dichloromethane (5.0 mL) was slowly added thionyl chloride (60.0 uL, 822 umol) at 0 ° C. The reaction was heated to reflux and maintained for 1.5 hours. The reaction was concentrated under reduced pressure. The residue was dissolved in dichloromethane and then evaporated (repeatedly) to provide the title compound. LCMS for methyl ether: [M+H] 201.1 (MeOH as solvent for analytical samples).

[0557] Example 3-16

[0558]

[0559] N-[5-[[(3R)-3-[(5-fluoropyrimidin-2-yl)methyl]-1-piperidinyl]methyl]thiazol-2-yl]-N-methyl-acetamide: The title compound was prepared in a similar manner to Scheme 3 from 5-fluoro-2-(piperidin-3-ylmethyl)pyrimidine HCl and N-[5-(chloromethyl)thiazol-2-yl]-N-methyl-acetamide. LCMS: [M+H] 364.2. 1 H NMR (400 MHz, methanol-d4) δ 8.63 (d, J = 0.75 Hz, 2H), 7.28 (s, 1H), 3.67 (s, 2H), 3.66 (s, 3H), 2.78-2.87 (m, 4H), 2.41 (s, 3H), 2.23 (m, 1H), 2.02-2.10 (m, 1H), 1.86 (t, J = 10.67 Hz, 1H), 1.65-1.74 (m, 2H), 1.50-1.63 (m, 1H), 0.99-1.11 (m, 1H).

[0560] Example 3-17

[0561]

[0562] (R)-N-(4-fluoro-5-((3-((5-fluoropyrimidin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)propanamide: The title compound was prepared according to the general procedure described in Scheme 3 and using (R)-5-fluoro-2-(piperidin-3-ylmethyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)propanamide. LCMS (ESI): [M+H] 382. 1 HNMR: (400MHz, methanol-d 4 )δ8.64(d,J=0.75Hz,2H),3.64(s,2H),2.73-3.00(m,4H),2.46(q,J=7.53Hz,2H),2.08-2. 31(m,2H),1.91-2.04(m,1H),1.49-1.79(m,3H),1.19(t,J=7.53Hz,3H),0.98-1.13(m,1H).

[0563] Example 3-18

[0564]

[0565] (R)-N-(4-fluoro-5-((3-((2-methylpyridin-4-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Scheme 3 and using (R)-2-methyl-4-(piperidin-3-ylmethyl)pyridine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 363. 1 HNMR: (400MHz, methanol-d 4 )δ8.24(d,J=5.27Hz,1H),7.11(s,1H),7.04(dd,J=1.25,5.27Hz,1H),3.59(s,2H),2.69-2.92(m,2H),2.54(d,J=7.03Hz,2H ),2.47(s,3H),2.18(s,3H),2.07-2.22(m,1H),1.78-1.92(m,2H),1.62-1.78(m,2H),1.45-1.62(m,1H),0.93-1.15(m,1H).

[0566] Example 3-19

[0567]

[0568] (R)-N-(4-fluoro-5-((3-((2-methoxypyridin-4-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Scheme 3 and using (R)-2-methoxy-4-(piperidin-3-ylmethyl)pyridine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 379. 1 HNMR: (400MHz, methanol-d 4 )δ7.97(d,J=5.27Hz,1H),6.78(dd,J=1.38,5.40Hz,1H),6.60(s,1H),3.87(s,3H),3.56(s,2H),2.68-2.88(m,2H),2.43- 2.57(m,2H),2.18(s,3H),2.01-2.12(m,1H),1.76-1.96(m,2H),1.63-1.73(m,2H),1.46-1.61(m,1H),0.89-1.11(m,1H).

[0569] Example 3-20

[0570]

[0571] (R)-N-(4-fluoro-5-((3-((6-methylpyridin-3-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Scheme 3 and using (R)-2-methyl-5-(piperidin-3-ylmethyl)pyridine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 363. 1 HNMR: (400MHz, methanol-d 4 )δ8.19(d,J=1.76Hz,1H),7.54(dd,J=2.26,7.78Hz,1H),7.21(d,J=7.78Hz,1H),3.60(s,2H),2.71-2.92(m,2H),2.53(br d,J=5.52Hz,2H),2.48(s,3H),2.18(s,3H),2.04-2.13(m,1H),1.77-1.91(m,2H),1.60-1.74(m,2H),1.43-1.57(m,1H),0.85-1.10(m,1H).

[0572] Example 3-21

[0573]

[0574] (R)-N-(5-((3-((2,6-dimethylpyrimidin-4-yl)methyl)piperidin-1-yl)methyl)-4-fluorothiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Scheme 3 and using (R)-2,4-dimethyl-6-(piperidin-3-ylmethyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 378. 1 HNMR: (400MHz, methanol-d 4 )δ7.05(s,1H),3.48-3.67(m,2H),2.68-2.88(m,2H),2.52-2.65(m,2H),2.58(s,3H),2.43(s,3H),2.18 (s,3H),1.97-2.16(m,2H),1.78-1.90(m,1H),1.63-1.74(m,2H),1.47-1.61(m,1H),0.96-1.16(m,1H).

[0575] Example 3-22

[0576]

[0577] (R)-N-(4-Fluoro-5-((3-((6-methoxypyrimidin-4-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Scheme 3 and using (R)-4-methoxy-6-(piperidin-3-ylmethyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 380. 1 HNMR: (400MHz, methanol-d 4 )δ8.61(d,J=1.00Hz,1H),6.71(d,J=1.00Hz,1H),3.97(s,3H),3.52-3.66(m,2H),2.75-2.88(m,2H),2.4 8-2.66(m,2H),2.18(s,3H),1.99-2.12(m,2H),1.81-1.95(m,1H),1.47-1.78(m,3H),0.95-1.17(m,1H).

[0578] Example 3-23

[0579]

[0580] (R)-N-(5-((3-((6-methoxypyrimidin-4-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Scheme 3 and using (R)-4-methoxy-6-(piperidin-3-ylmethyl)pyrimidine. LCMS (ESI): [M+H] 362. 1 HNMR: (400MHz, methanol-d 4 )δ8.60(d,J=1.00Hz,1H),7.21(s,1H),6.71(d,J=1.00Hz,1H),3.96(s,3H),3.60-3.75(m,2H),2.67-2.90(m,2H ),2.44-2.67(m,2H),2..20(s,3H),1.96-2.16(m,2H),1.76-1.95(m,1H),1.46-1.76(m,3H),0.96-1.15(m,1H).

[0581] Example 3-24

[0582]

[0583] (S)-N-(5-((3-((2,6-dimethylpyridin-4-yl)methyl)pyrrolidin-1-yl)methyl)-4-fluorothiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 3 from (S)-2,6-dimethyl-4-(pyrrolidin-3-ylmethyl)pyridine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 363. 1 H NMR (400 MHz, methanol-d 4 )δ6.93(s,2H),3.62-3.77(m,2H),2.60-2.77(m,5H),2.48-2.58(m,1H),2.44 (s,6H),2.27-2.36(m,1H),2.18(s,3H),1.94-2.07(m,1H),1.47-1.58(m,1H).

[0584] Example 3-25

[0585]

[0586] (R)-N-(5-((3-((2,6-dimethylpyridin-4-yl)methyl)piperidin-1-yl)methyl)-4-fluorothiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 3 from (R)-2,6-dimethyl-4-(piperidin-3-ylmethyl)pyridine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 377. 1 H NMR (400 MHz, methanol-d 4 )δ6.89(s,2H),3.51-3.63(m,2H),2.82(br d,J=11.04Hz,1H),2.73(br d,J=9.79Hz,1H),2.49(d,J=7.03Hz,2H),2.43(s,6H),2.18(s,3H),2.05-2.15(m ,1H),1.76-1.94(m,2H),1.63-1.75(m,2H),1.49-1.62(m,1H),0.93-1.09(m,1H). LCMS(ESI):[M+H]377.

[0587] Example 3-26

[0588]

[0589] (R)-N-(4-fluoro-5-((3-((5-fluoropyrimidin-2-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 3 from (R)-5-fluoro-2-(pyrrolidin-3-ylmethyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 354. 1 H NMR (400 MHz, methanol-d 4 )δ8.64(d,J=0.75Hz,2H),3.65-3.79(m,2H),3.02(d,J=7.53Hz,2H),2.56-2.92(m,4H),2.40(d d,J=6.78,9.03Hz,1H),2.18(s,3H),1.96-2.10(m,1H),1.61(tdd,J=6.40,8.28,12.80Hz,1H).

[0590] Example 3-27

[0591]

[0592] (R)-N-(4-fluoro-5-((3-((5-fluoropyrimidin-2-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)propanamide: The title compound was prepared in an analogous manner to Scheme 3 from (R)-5-fluoro-2-(pyrrolidin-3-ylmethyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)propanamide. LCMS (ESI): [M+H] 368. 1 H NMR (400 MHz, methanol-d 4 )δ8.69(s,2H),4.52(s,2H),3.50-3.92(m,2H),3.35-3.49(m,1H),2.89-3.28(m,4H), 2.50(q,J=7.53Hz,2H),2.22-2.45(m,1H),1.70-2.01(m,1H),1.20(t,J=7.53Hz,3H).

[0593] Example 3-28

[0594]

[0595] (S)-N-(4-fluoro-5-((3-((5-fluoro-2-methylpyridin-4-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 3 from (S)-5-fluoro-2-methyl-4-(pyrrolidin-3-ylmethyl)pyridine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 367. 1 H NMR (400 MHz, methanol-d 4 )δ8.57(d,J=2.76Hz,1H),7.62(d,J=6.27Hz,1H),4.49-4.57(m,2H),3.44-3.78(m,3H), 2.97-3.08(m,2H),2.75-2.93(m,1H),2.64(s,3H),2.15-2.36(m,5H),1.80-2.00(m,1H).

[0596] Example 3-29

[0597]

[0598] (R)-N-(5-((3-((2,6-dimethylpyrimidin-4-yl)methyl)pyrrolidin-1-yl)methyl)-4-fluorothiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 3 from (R)-2,4-dimethyl-6-(pyrrolidin-3-ylmethyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 364. 1 H NMR (400 MHz, methanol-d 4 )δ7.42(s,1H),4.52(s,2H),3.36-3.85(m,4H),2.94-3.08(m,3H),2.74 (s,3H),2.60(s,3H),2.24-2.39(m,1H),2.21(s,3H),1.80-1.99(m,1H).

[0599] Example 3-30

[0600]

[0601] (S)-N-(5-((3-((5-chloro-2-methylpyridin-4-yl)methyl)pyrrolidin-1-yl)methyl)-4-fluorothiazol-2-yl)acetamide: The title compound was prepared in a similar manner to Scheme 3 from (S)-5-chloro-2-methyl-4-(pyrrolidin-3-ylmethyl)pyridine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 383.1 H NMR (400 MHz, methanol-d 4 )δ8.61(s,1H),7.55(s,1H),4.52(d,J=1.51Hz,2H),3.38-3.84(m,3H),3.22(br d,J=8.03Hz,1H),2.98-3.13(m,2H),2.72-2.96(m,1H),2.61(s,3H),2.14-2.34(m,4H),1.92(br d,J=16.06Hz,1H).

[0602] Example 3-31

[0603]

[0604] (R)-N-(4-fluoro-5-((3-((6-methoxypyrimidin-4-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 3 from (R)-4-methoxy-6-(pyrrolidin-3-ylmethyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 366. 1 H NMR (400 MHz, methanol-d 4 )δ8.63(d,J=0.75Hz,1H),6.75(d,J=0.75Hz,1H),3.97(s,3H),3.82(d,J=0.75Hz,2H),2.91(dd,J=7.53,9.54Hz,1H),2 .75-2.85(m,4H),2.65-2.73(m,1H),2.47(dd,J=7.15,9.66Hz,1H),2.19(s,3H),2.00-2.07(m,1H),1.55-1.66(m,1H).

[0605] Example 3-32

[0606]

[0607] (S)-N-(4-fluoro-5-((3-((2-methoxypyridin-4-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 3 from (S)-2-methoxy-4-(pyrrolidin-3-ylmethyl)pyridine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 365. 1 H NMR (400 MHz, methanol-d 4)δ7.99(d,J=5.27Hz,1H),6.81(dd,J=1.25,5.27Hz,1H),6.64(s,1H),3.87 (s,3H),3.83(d,J=2.51Hz,2H),2.89(dd,J=7.40,9.66Hz,1H),2.74-2.85(m ,2H),2.68(dd,J=2.38,7.65Hz,2H),2.56(td,J=7.87,15.12Hz,1H),2.44( dd,J=7.28,9.54Hz,1H),2.18(s,3H),1.96-2.03(m,1H),1.51-1.66(m,1H).

[0608] Example 3-33

[0609]

[0610] (S)-N-(4-fluoro-5-((3-((2-methylpyridin-4-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 3 from (S)-2-methoxy-4-(pyrrolidin-3-ylmethyl)pyridine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 349. 1 H NMR (400 MHz, methanol-d 4 )δ8.26(d,J=5.27Hz,1H),7.15(s,1H),7.08(dd,J=1.00,5.27Hz,1H),3.62-3.78(m,2H),2.62-2.79(m,5H),2.50- 2.60(m,1H),2.48(s,3H),2.31(dd,J=6.90,9.41Hz,1H),2.16-2.20(m,3H),1.94-2.05(m,1H),1.46-1.61(m,1H).

[0611] Example 3-34

[0612]

[0613] (S)-N-(4-Fluoro-5-((3-((6-methoxypyrimidin-4-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 3 from (S)-4-methoxy-6-(pyrrolidin-3-ylmethyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 366. 1 H NMR (400 MHz, methanol-d4 )δ8.62(d,J=1.00Hz,1H),6.75(d,J=1.00Hz,1H),3.97(s,3H),3.76(d,J=1.51Hz,2H),2.85(dd,J=7.53,9.54Hz,1H),2 .65-2.80(m,5H),2.40(dd,J=6.90,9.41Hz,1H),2.18(s,3H),1.96-2.08(m,1H),1.58(tdd,J=6.49,8.16,12.99Hz,1H).

[0614] Example 3-35

[0615]

[0616] (S)-N-(4-fluoro-5-((3-((6-methylpyridin-3-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 3 from (S)-4-methoxy-6-(pyrrolidin-3-ylmethyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 349. 1 H NMR (400 MHz, methanol-d 4 )δ8.23(d,J=2.01Hz,1H),7.58(dd,J=2.38,7.91Hz,1H),7.21(d,J=7.78Hz,1H),3.64-3.76(m,2H),2.61-2.80(m,5H),2 .43-2.55(m,4H),2.31(dd,J=6.78,9.29Hz,1H),2.18(s,3H),1.94-2.00(m,1H),1.54(tdd,J=6.53,8.22,12.86Hz,1H).

[0617] Example 3-36

[0618]

[0619] (S)-N-(4-fluoro-5-((3-((5-fluoropyrimidin-2-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 3 from (S)-5-fluoro-2-(pyrrolidin-3-ylmethyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 354. 1 H NMR (400 MHz, methanol-d 4)δ8.65(d,J=0.75Hz,2H),3.89(s,2H),3.01-3.10(m,3H),2.78-2.95(m,3H),2. 58(dd,J=7.53,10.04Hz,1H),2.19(s,3H),2.04-2.16(m,1H),1.60-1.74(m,1H).

[0620] Example 3-37

[0621]

[0622] (R)-N-(4-fluoro-5-((3-((5-fluoropyrimidin-2-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)-N-methylacetamide: To a mixture of N-[4-fluoro-5-[[(3R)-3-[(5-fluoropyrimidin-2-yl)methyl]pyrrolidin-1-yl]methyl]thiazol-2-yl]acetamide (25 mg, 71 umol) and methanol (34 mg, 1.06 mmol), triphenylphosphine (37 mg, 142 umol) in THF (0.5 mL) was added (NE)-N-isopropoxycarbonylimidocarbamic acid isopropyl ester (43 mg, 212 umol). The reaction mixture was then stirred at RT overnight. All solvents were removed. The crude was purified by chromatography on silica gel (solvent A: EtOAc, solvent B: 0-60% EtOAc-EtOH containing 2% NH4OH 3:1) to obtain the title compound as a white powder. LCMS (ESI): [M+H]368. 1 H NMR (400 MHz, methanol-d 4 )δ8.64(d,J=0.75Hz,2H),3.66-3.76(m,2H),3.59-3.64(m,3H),3.02(d,J=7.53Hz,2H),2.68-2.89(m,3H), 2.64(dt,J=6.02,8.78Hz,1H),2.35-2.44(m,4H),1.96-2.08(m,1H),1.61(tdd,J=6.31,8.28,12.74Hz,1H).

[0623] Example 3-38

[0624]

[0625] (S)-N-(4-chloro-5-((3-((2,6-dimethylpyridin-4-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 3 from 4-methoxy-6-(1-(pyrrolidin-3-yl)ethyl)pyrimidine and N-(4-chloro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 379. 1 H NMR (400 MHz, methanol-d 4 )δ6.94(s,2H),3.73-3.87(m,2H),2.70-2.78(m,3H),2.62-2.67(m,2H),2.49-2.57(m,1H),2 .44(s,6H),2.36(dd,J=6.65,9.41Hz,1H),2.19(s,3H),1.95-2.00(m,1H),1.47-1.60(m,1H).

[0626] Example 3-39

[0627]

[0628] N-(4-Fluoro-5-(((2R,4S)-4-((5-fluoropyrimidin-2-yl)methyl)-2-methylpyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was separated by chiral separation (CHIRALPAK IG 30x250mm, 5um; method: 0.1% DEA in 30% MeOH in CO 2 The mixture was separated from 5-fluoro-2-((5-methylpyrrolidin-3-yl)methyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide in a similar manner to Scheme 3 (flow rate: 100 mL / min, ABPR 120 bar, MBPR 40 psi, column temperature 40°C). LCMS (ESI): [M+H] 368. 1 H NMR (400 MHz, methanol-d 4 )δ8.63(d,J=0.75Hz,2H),3.86-3.96(m,1H),3.55(d,J=14.31Hz,1H),3.12(dd,J=7.28,9.29Hz,1H),2.95(d,J=7.28Hz,2H ),2.53-2.83(m,2H),2.11-2.24(m,4H),1.73-1.85(m,1H),1.64(ddd,J=8.28,9.79,12.80Hz,1H),1.15(d,J=6.02Hz,3H).

[0629] Example 3-40

[0630]

[0631] N-(4-Fluoro-5-(((2S,4S)-4-((5-fluoropyrimidin-2-yl)methyl)-2-methylpyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was separated by chiral separation (CHIRALPAK IG 30x250mm, 5um; method: 30% MeOH containing 0.1% DEA in CO 2 The mixture was separated from 5-fluoro-2-((5-methylpyrrolidin-3-yl)methyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide in a similar manner to Scheme 3 (flow rate: 100 mL / min, ABPR 120 bar, MBPR 40 psi, column temperature 40°C). LCMS (ESI): [M+H] 368. 1 H NMR (400 MHz, methanol-d 4 )δ8.63(d,J=0.75Hz,2H),3.90(dd,J=1.00,14.56Hz,1H),3.52(d,J=14.56Hz,1H),3.01(dd,J=2.26,7.28Hz,2H),2.87(dd,J=3.6 4,9.41Hz,1H),2.52-2.70(m,3H),2.18(s,3H),2.11(ddd,J=6.27,8.28,12.55Hz,1H),1.21-1.29(m,1H),1.16(d,J=6.02Hz,3H).

[0632] Example 3-41

[0633]

[0634] N-(4-Fluoro-5-(((2S,4R)-4-((5-fluoropyrimidin-2-yl)methyl)-2-methylpyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was separated by chiral separation (CHIRALPAK IG 30x250mm, 5um; method: 0.1% DEA in 30% MeOH in CO 2 The mixture was separated from 5-fluoro-2-((5-methylpyrrolidin-3-yl)methyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide in a similar manner to Scheme 3 (flow rate: 100 mL / min, ABPR 120 bar, MBPR 40 psi, column temperature 40°C). LCMS (ESI): [M+H] 368. 1 H NMR (400 MHz, methanol-d4 )δ8.63(d,J=0.75Hz,2H),3.91(dd,J=0.75,14.56Hz,1H),3.55(d,J=14.56Hz,1H),3.12(dd,J=7.03,9.29Hz,1H),2. 95(d,J=7.53Hz,2H),2.67-2.80(m,1H),2.57-2.67(m,1H),2.12-2.22(m,4H),1.79(ddd,J=5.77,7.65,13.18Hz,1H),

[0635] Example 3-42

[0636]

[0637] N-(4-Fluoro-5-(((2R,4R)-4-((5-fluoropyrimidin-2-yl)methyl)-2-methylpyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was separated by chiral separation (CHIRALPAK IG 30x250mm, 5um; method: 0.1% DEA in 30% MeOH in CO 2 The mixture was separated from 5-fluoro-2-((5-methylpyrrolidin-3-yl)methyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide in a similar manner to Scheme 3 (flow rate: 100 mL / min, ABPR 120 bar, MBPR 40 psi, column temperature 40°C). LCMS (ESI): [M+H] 368. 1 H NMR (400 MHz, methanol-d 4 )δ8.63(d,J=0.75Hz,1H),8.55-8.71(m,1H),3.90(dd,J=1.00,14.56Hz,1 H),3.52(d,J=14.31Hz,1H),3.01(dd,J=2.26,7.28Hz,2H),2.87(dd,J=3.7 6,9.54Hz,1H),2.59-2.71(m,1H),2.51-2.59(m,2H),2.18(s,3H),2.11(d dd,J=6.40,8.22,12.49Hz,1H),1.22-1.29(m,1H),1.16(d,J=6.02Hz,3H).

[0638] Example 3-43

[0639]

[0640] N-(4-Fluoro-5-(((2R,4S)-4-((6-methoxypyrimidin-4-yl)methyl)-2-methylpyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was separated by chiral separation (CHIRALPAK AD-H 30x250mm, 5um; method: 45% MeOH containing 0.1% DEA in CO 2 The mixture was separated from 4-methoxy-6-((5-methylpyrrolidin-3-yl)methyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide in a similar manner to Scheme 3 (flow rate: 100 mL / min, ABPR 120 bar, MBPR 40 psi, column temperature 40°C). LCMS (ESI): [M+H] 380. 1 H NMR (400 MHz, methanol-d 4 )δ8.61(d,J=1.00Hz,1H),6.73(d,J=1.00Hz,1H),3.97(s,3H),3.88-3.94(m,1H),3.55(d,J=14.56Hz,1H),3.07(dd,J=6.90,9. 16Hz,1H),2.53-2.73(m,4H),2.18(s,3H),2.12(t,J=9.03Hz,1H),1.68-1.79(m,1H),1.55-1.66(m,1H),1.14(d,J=6.02Hz,3H).

[0641] Example 3-44

[0642]

[0643] N-(4-Fluoro-5-(((2S,4S)-4-((6-methoxypyrimidin-4-yl)methyl)-2-methylpyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was separated by chiral separation (CHIRALPAK AD-H 30x250mm, 5um; method: 45% MeOH containing 0.1% DEA in CO 2 The mixture was separated from 4-methoxy-6-((5-methylpyrrolidin-3-yl)methyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide in a similar manner to Scheme 3 (flow rate: 100 mL / min, ABPR 120 bar, MBPR 40 psi, column temperature 40°C). LCMS (ESI): [M+H] 380. 1 HNMR (400 MHz, methanol-d 4)δ8.61(d,J=1.00Hz,1H),6.72(d,J=1.00Hz,1H),3.96(s,3H),3.91(dd,J=1.00,14.56Hz,1H),3.51(d,J=14.31Hz,1 H),2.67-2.82(m,3H),2.46-2.63(m,3H),2.19(s,3H),2.04-2.16(m,1H),1.20-1.25(m,1H),1.18(d,J=6.02Hz,3H).

[0644] Example 3-45

[0645]

[0646] N-(4-Fluoro-5-(((2R,4R)-4-((6-methoxypyrimidin-4-yl)methyl)-2-methylpyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was separated by chiral separation (CHIRALPAK AD-H 30x250mm, 5um; method: 45% MeOH containing 0.1% DEA in CO 2 The mixture was separated from 4-methoxy-6-((5-methylpyrrolidin-3-yl)methyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide in a similar manner to Scheme 3 (flow rate: 100 mL / min, ABPR 120 bar, MBPR 40 psi, column temperature 40°C). LCMS (ESI): [M+H] 380. 1 H NMR (400 MHz, methanol-d 4 )δ8.61(d,J=1.00Hz,1H),6.72(d,J=1.00Hz,1H),3.96(s,3H),3.91(dd,J=1.13,14.43Hz,1H),3.51(d,J=14.31Hz,1 H),2.68-2.81(m,3H),2.46-2.61(m,3H),2.19(s,3H),2.05-2.15(m,1H),1.19-1.24(m,1H),1.17(d,J=6.02Hz,3H).

[0647] Example 3-46

[0648]

[0649] N-(4-Fluoro-5-(((2S,4R)-4-((6-methoxypyrimidin-4-yl)methyl)-2-methylpyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was separated by chiral separation (CHIRALPAK AD-H 30x250mm, 5um; method: 45% MeOH containing 0.1% DEA in CO 2 The mixture was separated from 4-methoxy-6-((5-methylpyrrolidin-3-yl)methyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide in a similar manner to Scheme 3 (flow rate: 100 mL / min, ABPR 120 bar, MBPR 40 psi, column temperature 40°C). LCMS (ESI): [M+H] 380. 1 H NMR (400 MHz, methanol-d 4 )δ8.61(d,J=1.00Hz,1H),6.73(d,J=1.00Hz,1H),3.97(s,3H),3.88-3.94(m,1H),3.55(d,J=14.56Hz,1H),3.07(dd,J=6.90,9. 16Hz,1H),2.56-2.72(m,4H),2.18(s,3H),2.12(t,J=9.16Hz,1H),1.69-1.79(m,1H),1.56-1.67(m,1H),1.14(d,J=6.02Hz,3H).

[0650] Example 3-47

[0651]

[0652] (S)-N-(5-((3-((2,6-dimethylpyridin-4-yl)methyl)pyrrolidin-1-yl)methyl)-1,3,4-thiadiazol-2-yl)acetamide: To a mixture of 2,6-dimethyl-4-[[(3S)-pyrrolidin-3-yl]methyl]pyridine (200 mg, 0.31 mmol, trifluoroacetic acid) and 5-(chloromethyl)-1,3,4-thiadiazol-2-amine (91 mg, 0.37 mmol, methanesulfonic acid) in acetonitrile (2.00 mL) and DMF (1.0 mL) was added diisopropylethylamine (320 mg, 2.48 mmol). The reaction was stirred at room temperature for 2 h. The mixture was concentrated in vacuo, diluted with EtOAc, washed with brine, and chromatographed on silica gel (containing 2% NH 4The crude residue was purified by 20-100% EtOAc-EtOH (20-100% EtOAc-EtOH 3:1 in heptane) to obtain 5-[[(3S)-3-[(2,6-dimethyl-4-pyridinyl)methyl]pyrrolidin-1-yl]methyl]-1,3,4-thiadiazol-2-amine (26 mg, LCMS (ESI): [M+H]304), which was dissolved in dichloromethane (1.0 mL) stirred at room temperature, then diisopropylethylamine (21 mg, 0.17 mmol) was added, followed by acetic anhydride (10 mg, 0.99 mmol), and the mixture was stirred at room temperature overnight. The mixture was concentrated in vacuo and the residue was purified by preparative TLC to provide the title compound (6 mg, 26% yield). LCMS (ESI): [M+H]346. 1 H NMR (400 MHz, methanol-d 4 )δ7.21(br s,2H),4.09-4.25(m,2H),3.72(br d,J=4.77Hz,1H),2.93(br d,J=6.78Hz,2H),2.80(d,J=7.28Hz,2H),2.57-2.71(m,2H),2.55(s,6H ),2.25(s,2H),2.24-2.26(m,1H),2.03-2.11(m,1H),1.60-1.68(m,1H).

[0653] Example 3-48

[0654]

[0655] (R)-N-(4-fluoro-5-((3-((5-fluoropyrimidin-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Scheme 3 and using (R)-5-fluoro-2-(piperidin-3-ylmethyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 368. 1 HNMR: (400MHz, methanol-d 4 )δ8.63(d,J=0.75Hz,2H),3.56(s,2H),2.70-2.95(m,4H),2.14-2.29(m,1H),2.18(s,3H),2. 02-2.12(m,1H),1.82-1.94(m,1H),1.64-1.78(m,2H),1.46-1.62(m,1H),0.92-1.15(m,1H).

[0656] Example 3-49

[0657]

[0658] (R)-N-(4-Fluoro-5-((3-((6-methoxypyrimidin-4-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)propanamide: The title compound was prepared according to the general procedure described in Scheme 3 and using (R)-4-methoxy-6-(piperidin-3-ylmethyl)pyrimidine and N-(4-fluoro-5-formylthiazol-2-yl)propanamide. LCMS (ESI): [M+H] 394. 1 HNMR: (400MHz, methanol-d 4 )δ8.61(d,J=1.00Hz,1H),6.72(d,J=1.00Hz,1H),3.97(s,3H),3.60(s,2H),2.70-2.91(m,2H),2.51-2.67(m,2H),2. 39-2.52(m,2H),2.00-2.23(m,2H),1.82-1.97(m,1H),1.44-1.77(m,3H),1.19(t,J=7.53Hz,3H),0.89-1.09(m,1H).

[0659] Solution 4

[0660]

[0661] Intermediate 18

[0662]

[0663] tert-Butyl 3-((4-fluoro-1H-pyrazol-1-yl)methyl)piperidine-1-carboxylate: 4-fluoro-1H-pyrazole (0.10 g, 1.16 mmol), cesium carbonate (1.14 g, 3.50 mmol) and tert-butyl 3-(bromomethyl)piperidine-1-carboxylate (0.323 g, 1.16 mmol) were suspended in DMF (5.00 mL) and the mixture was heated to 100 ° C and maintained for 16 h. The reaction mixture was cooled to room temperature, filtered, and concentrated in vacuo to provide the title compound in the form of a crude mixture. LCMS (ESI): [M+H] 284.

[0664] Intermediate 19

[0665]

[0666] 3-((4-Fluoro-1H-pyrazol-1-yl)methyl)piperidine hydrochloride: A solution of HCl in dioxane (4.0 M, 4.76 mL, 27.0 mmol) was added to the crude mixture of tert-butyl 3-((4-fluoro-1H-pyrazol-1-yl)methyl)piperidine-1-carboxylate from the previous step and the mixture was stirred at room temperature for 4 h. The mixture was concentrated in vacuo to provide the title compound as a crude mixture. LCMS (ESI): [M+H] 184.

[0667] Example 4-1

[0668]

[0669] N-(5-((3-((4-fluoro-1H-pyrazol-1-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide

[0670] The crude mixture of 3-((4-fluoro-1H-pyrazol-1-yl)methyl)piperidine hydrochloride from the previous step was dissolved in MeCN (4.00 mL). Triethylamine (0.46 g, 4.56 mmol, 0.63 mL) and N-[5-(chloromethyl)thiazol-2-yl]acetamide (0.145 mg, 0.760 mmol) were added to the mixture. The mixture was stirred at room temperature for 16 h. The reaction mixture was filtered and concentrated in vacuo. The residue was purified by preparative HPLC {(column: Waters Sunfire OBD 50x100 mm, 5 um; conditions: 95% water / 5% ACN 20 minutes in 0.1% TFA (flow rate: 80 mL / min))} to provide the title compound. LCMS (ESI): [M+H] 338. 1 HNMR: (500MHz, methanol-d4) δ7.58(d,J=4.6Hz,1H),7.32-7.34(m,1H),7.21(s,1H),3.96(d,J=7.3Hz,2H),3.68(s,2H),2.78(br d,J=11.0Hz,1H),2.64(br d,J=9.8Hz,1H),2.12-2.21(m,5H),1.90(br t,J=10.4Hz,1H),1.69-1.77(m,1H),1.52-1.64(m,2H),1.01-1.10(m,1H).

[0671] Example 4-2

[0672]

[0673] N-(5-((3-((4-ethyl-1H-pyrazol-1-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 4 from tert-butyl 3-(bromomethyl)piperidine-1-carboxylate, 4-ethyl-1H-pyrazole and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 348. 1 HNMR: (500MHz, methanol-d4) δ7.55(s,1H),7.41(s,1H),7.32-7.36(m,1H),4.52(q,J=14.4Hz,2H),4.13(br dd,J=14.0,5.5Hz,1H),4.02(br dd,J=14.0,7.9Hz,1H),3.53(br d,J=12.2Hz,1H),3.22(brd,J=11.6Hz,1H),2.82-2.95(m,1H),2.73(br t,J=12.2Hz,1H),2.44-2.50(m,2H),2.30(br s,1H),2.22-2.24(m,3H),1.92-2.10(m,1H),1.68-1.87(m,2H),1.14-1.19(t,3H).

[0674] Example 4-3

[0675]

[0676] N-(5-((3-((4-(trifluoromethyl)-1H-pyrazol-1-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 4 from tert-butyl 3-(bromomethyl)piperidine-1-carboxylate, 4-(trifluoromethyl)-1H-pyrazole and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 388.

[0677] Example 4-4

[0678]

[0679] N-(5-((3-((3,4,5-trimethyl-1H-pyrazol-1-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 4 from tert-butyl 3-(bromomethyl)piperidine-1-carboxylate, 3,4,5-trimethyl-1H-pyrazole and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 363.

[0680] Embodiment 4-5

[0681]

[0682] N-(5-((3-((4-cyclobutyl-1H-pyrazol-1-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 4 from tert-butyl 3-(bromomethyl)piperidine-1-carboxylate, 4-cyclobutyl-1H-pyrazole and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 375. 1 HNMR: (500MHz, methanol-d4) δ7.38(s,1H),7.29(s,1H),7.19(s,1H),3.94-4.02(m,2H),3.60-3.68(m,2H),3.32-3.39(m,1H),2.76(br d,J=10.4Hz,1H),2.57(br d,J=10.4Hz,1H),2.23-2.34(m,2H),2.19(s,3H),2.12-2.16(m,2H),1.91-2.02(m ,3H),1.81-1.90(m,2H),1.73(dt,J=12.8,4.0Hz,1H),1.52-1.65(m,2H),1.06(br d, J = 11.0 Hz, 1H).

[0683] Embodiment 4-6

[0684]

[0685] N-(5-((3-((4-cyclopropyl-1H-pyrazol-1-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 4 from tert-butyl 3-(bromomethyl)piperidine-1-carboxylate, 4-cyclopropyl-1H-pyrazole and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 360.

[0686] Embodiment 4-7

[0687]

[0688] N-(5-((3-((4-isopropyl-1H-pyrazol-1-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 4 from tert-butyl 3-(bromomethyl)piperidine-1-carboxylate, 4-isopropyl-1H-pyrazole and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 363. 1HNMR: (500MHz, methanol-d4) δ7.30(s,1H),7.22(s,1H),7.19(s,1H),3.91-4.00(m,2H),3.61-3.67(m,2H),2.75(br d,J=10.4Hz,1H),2.56(br d,J=9.8Hz,1H),2.20(s,3H),2.10-2.12(m,2H),1.84(br t,J=10.1Hz,1H),1.52-1.74(m,4H),1.05(br d,J=11.0Hz,1H),0.78-0.83(m,2H),0.41-0.46(m,2H).

[0689] Embodiment 4-8

[0690]

[0691] N-(5-((3-((4-methoxy-1H-pyrazol-1-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 4 from tert-butyl 3-(bromomethyl)piperidine-1-carboxylate, 4-methoxy-1H-pyrazole and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 350.

[0692] Embodiment 4-9

[0693]

[0694] N-(5-((3-((4-bromo-1H-pyrazol-1-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 4 from tert-butyl 3-(bromomethyl)piperidine-1-carboxylate, 4-bromo-1H-pyrazole and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 399.

[0695] Embodiment 4-10

[0696]

[0697] N-(5-((3-((4-methyl-1H-pyrazol-1-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in an analogous manner to Scheme 4 from tert-butyl 3-(bromomethyl)piperidine-1-carboxylate, 4-methyl-1H-pyrazole and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 334.

[0698] Embodiment 4-11

[0699]

[0700] N-(5-((3-((4-acetyl-1H-pyrazol-1-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared in a similar manner to Scheme 4 from tert-butyl 3-(bromomethyl)piperidine-1-carboxylate, 1-(1H-pyrazol-4-yl)ethan-1-one and N-[5-(chloromethyl)thiazol-2-yl]acetamide. LCMS (ESI): [M+H] 362.

[0701] Intermediate A

[0702]

[0703] (S)-tert-butyl(5-(dimethyl(oxo)-16-sulfanylidene)-4-oxopentan-2-yl)carbamate: A suspension of (S)-3-((tert-butoxycarbonyl)amino)butanoic acid (19 g, 93.5 mmol) and HATU (38.4 g, 101 mmol) in THF (370 mL) was treated with TEA (55 mL, 390 mmol) and the resulting solution was stirred at rt for 16 h. In another flask, a suspension of potassium tert-butoxide (37.8 g, 337 mmol) and trimethylsulfoxonium chloride (43.3 g, 337 mmol) in THF (370 mL) was heated at 60 °C for 2 h and then cooled in an ice-water bath for 15 min. The solution of the activated ester was then added dropwise at 0 °C over a period of 45 min. The reaction mixture was stirred for an additional 1 h and the reaction was then concentrated under reduced pressure. The residue was partitioned between dichloromethane (1000 mL) and water (1000 mL). After separation of the layers, the organic phase was washed with saturated aqueous NaCl solution (1000 mL) and then purified by Na 2 SO 4 Dry, filter, and concentrate under reduced pressure.The crude material was purified on silica gel column chromatography using a 0-5% MeOH gradient in dichloromethane to provide the title compound (14 g, 56% yield).

[0704] Intermediate B

[0705]

[0706] (S)-tert-butyl 2-methyl-4-oxopyrrolidine-1-carboxylate: (S)-tert-butyl (5-(dimethyl (oxo)-16-sulfanylidene)-4-oxopentan-2-yl) carbamate (14 g, 50.5 mmol) was dissolved in 1,2-dichloroethane (500 mL). After degassing, di-μ-chlorobis-[(η-cycloocta-1,5-diene)]diiridium (I) (1 g) was added under an argon atmosphere, and then the temperature was raised and reacted at 70° C. for 2 h. The solvent of the reaction mixture was distilled off under reduced pressure, and the resulting residue was subjected to silica gel column chromatography (hexane:ethyl acetate=2:1) ​​to provide the title compound (6.12 g, 62% yield).

[0707] Intermediate C

[0708]

[0709] (S)-tert-butyl 4-(cyanomethylene)-2-methylpyrrolidine-1-carboxylate: A solution of diethyl cyanomethylphosphonate (5.5 g, 31 mmol) in anhydrous tetrahydrofuran (100 mL) was degassed with nitrogen. Subsequently, potassium tert-butoxide (3.5 g, 31 mmol) was added at room temperature, and the reaction mixture was degassed with nitrogen and stirred for 20 minutes. (S)-tert-butyl 2-methyl-4-oxopyrrolidine-1-carboxylate (6.12 g, 31 mmol) in anhydrous tetrahydrofuran (20 mL) was added. After stirring for 20 hours, the reaction mixture was concentrated to provide a brown oil. The residue was suspended in chloroform (500 mL) and saturated with NaHCO 3 (3 × 250 mL), washed with Na 2 SO 4 Drying and concentration in vacuo afforded the title compound as a brown oil (5.16 g, 75% yield).

[0710] Intermediate D

[0711]

[0712] (2S)-tert-butyl 4-(cyanomethyl)-2-methylpyrrolidine-1-carboxylate: A solution of (S,)-tert-butyl 4-(cyanomethylene)-2-methylpyrrolidine-1-carboxylate (5.16 g, 23 mmol) in methanol (500 mL) containing 10% Pd on carbon (2 g) was stirred under hydrogen at 60 psi for 24 h. The suspension was filtered through celite, concentrated in vacuo, and the residue was purified by silica gel chromatography eluting with 15% EtOAc-hexanes to provide the title compound (4.43 g, 86% yield).

[0713] Intermediate E

[0714]

[0715] Tert-butyl (2S)-4-((Z)-2-amino-2-(hydroxyimino)ethyl)-2-methylpyrrolidine-1-carboxylate: A mixture of tert-butyl (2S)-4-(cyanomethyl)-2-methylpyrrolidine-1-carboxylate (4.43 g, 20 mmol) and hydroxylamine hydrochloride (2.76 g, 40 mmol) was dissolved in EtOH (100 mL) to obtain a colorless suspension. DIPEA (5 g, 47 mmol) was then added and the resulting mixture was stirred at 100 °C for 6 h. The crude reaction mixture was concentrated in vacuo and washed with hexanes (50 mL) to provide the title compound (3.96 g, 77% yield).

[0716] Intermediate F

[0717]

[0718] Tert-butyl (2S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)pyrrolidine-1-carboxylate: Tert-butyl (2S)-4-((Z)-2-amino-2-(hydroxyimino)ethyl)-2-methylpyrrolidine-1-carboxylate (3.96 g, 15.4 mmol) was dissolved in pyridine (50 mL), acetic anhydride (1.5 g, 15 mmol) was added and then heated at 90 °C for 24 h. The residue was partitioned between dichloromethane (1000 mL) and water (1000 mL). After separation of the layers, the organic phase was washed with saturated aqueous NaCl solution (1000 mL), washed with Na 2 SO 4 Dry, filter and concentrate under reduced pressure.The residue obtained was subjected to column chromatography on silica gel with DCM:MeOH as eluent to obtain the title compound (0.65 g, 17% yield).

[0719] Intermediate G

[0720]

[0721] 5-Methyl-3-(((5S)-5-methylpyrrolidin-3-yl)methyl)-1,2,4-oxadiazole

[0722] To a solution of tert-butyl (2S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)pyrrolidine-1-carboxylate (0.65 g, 2.3 mmol) in EtOAc (20 mL) was added 18 M HCl in EtOAc (10 mL) dropwise. After stirring at room temperature for 4 h, the formed precipitate was collected by filtration, washed with EtOAc (20 mL), and dried in vacuo to provide the title compound (0.305 g, 61% yield). LC-MS (ESI) m / z [M+H] + 182. 1 H NMR (400MHz, d 2 o)δ1.25(dd,J=6.6,3.2Hz,1.5H),1.29*(dd,J=6.4,3.1Hz,1.5H),1.35(m,0.5H),1.85(m,1H),2. 28*(m,0.5H),2.47(s,3H),2.80(m,3H),2.94(m,1H),3.45(m,1H),3.61(m,0.5H),3.76*(m,0.5H)

[0723] Embodiment 4-12

[0724]

[0725] N-(4-fluoro-5-(((2S,4R)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide and N-(4-fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Example 1-1 and using 5-methyl-3-(((5S)-5-methylpyrrolidin-3-yl)methyl)-1,2,4-oxadiazole and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. SiO 2 (ethyl acetate 100%) to provide two isomers (trans or cis) which were arbitrarily assigned as:

[0726] Peak 1: LCMS (ESI): [M+H]354. 1 HNMR: (400MHz, methanol-d 4)δ3.91(dd,J=1.13,14.43Hz,1H),3.52(d,J=14.31Hz,1H),2.83(dd,J=3.26,9.54Hz,1H),2.70-2.78(m,2H ),2.54(s,3H),2.43-2.59(m,3H),2.18(s,3H),2.09-2.24(m,1H),1.19-1.27(m,1H),1.17(d,J=6.27Hz,3H)

[0727] Peak 2: LCMS (ESI): [M+H]354. 1 HNMR: (400MHz, methanol-d 4 )δ3.86-3.96(m,1H),3.54(d,J=14.56Hz,1H),3.11-3.21(m,1H),2.67-2.73(m,2H),2.54-2.66(m ,2H),2.53(s,3H),2.18(s,3H),2.12(t,J=9.16Hz,1H),1.59-1.82(m,2H),1.15(d,J=6.27Hz,3H).

[0728] Examples 4-13 and 4-14

[0729]

[0730] N-(5-(((2S,4R)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide and N-(5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compounds were prepared according to the general procedures described in Examples 1-2 and using 5-methyl-3-(((5S)-5-methylpyrrolidin-3-yl)methyl)-1,2,4-oxadiazole. SiO 2 The resulting isomer was purified by (EtOAc / EtOH 3 / 1) to provide two isomers (trans or cis):

[0731] N-(5-(((2S,4R)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide (early fraction): LCMS (ESI): [M+H]336. 1 HNMR: (400MHz, methanol-d 4)δ7.23(s,1H),4.07(dd,J=0.88,14.18Hz,1H),3.47-3.57(m,1H),2.72-2.84(m,3H),2.41-2.61 (m,3H),2.53(s,3H),2.10-2.24(m,1H),2.19(s,3H),1.20-1.32(m,1H),1.17(d,J=6.02Hz,3H).

[0732] N-(5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide (late fraction): LCMS (ESI): [M+H]336. 1 HNMR: (400MHz, methanol-d 4 )δ7.24(s,1H),4.07(dd,J=0.88,14.18Hz,1H),3.56(d,J=14.31Hz,1H),3.13(dd,J=7.03,9.29Hz,1H),2.5 3-2.72(m,4H),2.53(s,3H),2.19(s,3H),2.08(t,J=9.29Hz,1H),1.63-1.83(m,2H),1.15(d,J=6.02Hz,3H).

[0733] Examples 4-15 and 4-16

[0734]

[0735] N-(4-fluoro-5-(((2S,5S)-2-methyl-5-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide and N-(4-fluoro-5-(((2S,5R)-2-methyl-5-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Example 1-1 and using 5-methyl-3-(((6S)-6-methylpiperidin-3-yl)methyl)-1,2,4-oxadiazole and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. SiO 2 The resulting isomer was purified by (EtOAc 100%) to provide two isomers (cis and trans):

[0736] N-(4-Fluoro-5-(((2S,5S)-2-methyl-5-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide (early fraction): LCMS (ESI): [M+H]368. 1 HNMR: (400MHz, methanol-d 4 )δ3.59-3.81(m,2H),2.68-2.76(m,3H),2.43-2.60(m,2H),2.53(s,3H),2.18(s,3H),2.04-2 .13(m,1H),1.60-1.75(m,1H),1.49-1.58(m,2H),1.35-1.47(m,1H),1.11(d,J=6.27Hz,3H).

[0737] N-(4-Fluoro-5-(((2S,5R)-2-methyl-5-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide (late fraction): LCMS (ESI): [M+H]368. 1 HNMR: (400MHz, methanol-d 4 )δ3.73-3.96(m,2H),2.90-2.95(m,1H),2.51-2.60(m,2H),2.54(s,3H),2.23-2.34(m,1H),2.19(s,3H ),1.96-2.07(m,2H),1.64-1.80(m,2H),1.26-1.42(m,1H),1.20(d,J=6.27Hz,3H),0.95-1.14(m,1H).

[0738] Example 4-17

[0739]

[0740] N-(5-(((2S)-2-methyl-5-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Examples 1-2 and using 5-methyl-3-(((6S)-6-methylpiperidin-3-yl)methyl)-1,2,4-oxadiazole. LCMS (ESI): [M+H] 350. 1 H NMR (400 MHz, methanol-d 4)δ7.24(s,1H),3.96-4.07(m,1H),3.77-3.90(m,1H),2.87-2.96(m,1H),2.51-2.58(m,2H),2.53(s,3H),2.23-2.32(m,1H),2.2 0(s,3H),1.98-2.11(m,1H),1.89-1.96(m,1H),1.64-1.79(m,2H),1.29-1.43(m,1H),1.22(d,J=6.02Hz,3H),0.93-1.10(m,1H).

[0741] Embodiment 4-18

[0742]

[0743] N-(4-fluoro-5-((3-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Example 1-1 and using 5-methyl-3-(piperidin-3-ylmethyl)-1,2,4-oxadiazole and N-(4-fluoro-5-formylthiazol-2-yl)acetamide. LCMS (ESI): [M+H] 354. 1 HNMR: (400MHz, methanol-d 4 )δ3.64(s,2H),2.78-2.95(m,2H),2.62(d,J=7.28Hz,2H),2.54(s,3H),2.18(s,3H),2.03 -2.16(m,2H),1.89-2.00(m,1H),1.67-1.79(m,2H),1.50-1.65(m,1H),0.95-1.14(m,1H).

[0744] Embodiment 4-19

[0745]

[0746] N-(5-((3-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Example 1-1 and using 5-methyl-3-(piperidin-3-ylmethyl)-1,2,4-oxadiazole. LCMS (ESI): [M+H] 336. 1 HNMR: (400MHz, DMSO-d 6)δ11.80(s,1H),7.09(s,1H),3.58(q,J=13.9Hz,2H),2.81-2.73(m,1H),2.74-2.66(m,1H),2.57-2.52(m,5H),2.11 (s,3H),1.99(s,2H),1.85(t,J=10.2Hz,1H),1.66(t,J=14.0Hz,2H),1.50(d,J=12.1Hz,1H),1.02(t,J=11.7Hz,1H).

[0747] Embodiment 4-20

[0748]

[0749] N-(5-((3-((1H-1,2,3-triazol-1-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Example 1-1 and using 3-((1H-1,2,3-triazol-1-yl)methyl)piperidine. LCMS (ESI): [M+H] 321.

[0750] Example 4-21

[0751]

[0752] N-(5-((3-((1H-1,2,4-triazol-1-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Example 1-1 and using 3-((1H-1,2,4-triazol-1-yl)methyl)piperidine. LCMS (ESI): [M+H] 321. 1 HNMR: (400MHz, chloroform-d) δ12.25(s,1H),8.01(s,1H),7.91(s,1H),7.15(s,1H),4.18(dd,J=13.7,7.5Hz,1H),4.09(dd,J=13.7,6.8Hz,1H), 3.69-3.53(m,2H),2.66-2.48(m,2H),2.35-2.16(m,4H),2.03(t,J=9.6Hz,1H),1.73-1.64(m,1H),1.64-1.49(m,2H),1.22-1.07(m,2H).

[0753] Example 4-22

[0754]

[0755] N-(5-((3-((1-methyl-1H-imidazol-2-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Example 1-1 and using 3-((1-methyl-1H-imidazol-2-yl)methyl)piperidine. LCMS (ESI): [M+H] 334. 1 HNMR: (400 MHz, chloroform-d) δ12.48 (s, 1H), 7.15 (s, 1H), 6.94-6.85 (m, 1H), 6.81-6.72 (m, 1H), 3.71-3.58 (m, 2H), 3.57 (s, 3H), 2.83-2.50 (m, 4H), 2.29 (s, 3H), 2.14-2.00 (m, 2H), 1.94 (t, J=10.0 Hz, 1H), 1.76-1.58 (m, 2H), 1.59-1.43 (m, 1H), 1.12-1.00 (m, 1H).

[0756] Example 4-23

[0757]

[0758] N-(5-((3-([1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Example 1-1 and using 3-(piperidin-3-ylmethyl)-[1,2,4]triazolo[4,3-a]pyridine. LCMS (ESI): [M+H] 371. 1 HNMR: (400MHz, DMSO-d 6 )δ11.82(s,1H),8.35(d,J=7.0Hz,1H),7.62(d,J=9.3Hz,1H),7.25(dd,J=9.2,6.5Hz,1 H),7.09(s,1H),6.87(t,J=6.7Hz,1H),3.65-3.51(m,2H),3.14-3.01(m,2H),2.79(d,J =10.7Hz,1H),2.66(d,J=10.6Hz,1H),2.26-2.15(m,1H),2.11(s,3H),2.10-2.03(m,1H ), 1.98 (t, J = 10.0Hz, 1H), 1.76-1.56 (m, 2H), 1.59-1.42 (m, 1H), 1.13 (d, J = 10.5Hz, 1H).

[0759] Example 4-24

[0760]

[0761] N-(5-((3-((1H-Benzo[d]imidazol-1-yl)methyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Example 1-1 and using 1-(piperidin-3-ylmethyl)-1H-benzo[d]imidazole. LCMS (ESI): [M+H]370. 1 HNMR: (400 MHz, chloroform-d) δ12.28 (s, 1H), 7.84 (s, 1H), 7.78 (d, J = 7.1 Hz, 1H), 7.39 (d, J = 7.8 Hz, 1H), 7.33-7.19 (m, 2H), 7.14 (s, 1H), 4.19 (dd, J = 14.3, 7.7 Hz, 1H), 4.05 (dd, J = 14.3, 7 .0Hz,1H),3.61(s,2H),3.47(s,3H),2.69-2.42(m,1H),2.29(s,2H),2.27-2.14(m,1H), 2.10-1.93(m,1H),1.75-1.62(m,1H),1.59(s,1H),1.56-1.40(m,1H),1.22-1.07(m,1H).

[0762] Example 4-25

[0763]

[0764] N-(5-((3-(4-chlorobenzyl)piperidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Example 1-1 using 3-(4-chlorobenzyl)piperidine. LCMS (ESI): [M+H]364. 1 HNMR: (400MHz, DMSO-d 6 )δ11.80(s,1H),7.20(d,J=8.0Hz,2H),7.10(d,J=8.2Hz,2H),7.07(s,1H) ,3.54(q,J=13.8Hz,2H),2.76-2.61(m,2H),2.59-2.46(m,1H),2.42(dd,J= 13.6,6.4Hz,1H),2.12(s,3H),2.03-1.88(m,1H),1.87-1.69(m,2H),1.69 -1.53(m,2H),1.44(dd,J=23.5,11.1Hz,1H),0.93(dd,J=20.1,8.6Hz,1H).

[0765] Example 4-26

[0766]

[0767] N-(5-((3-(3,4-difluorobenzyl)pyrrolidin-1-yl)methyl)thiazol-2-yl)acetamide: The title compound was prepared according to the general procedure described in Example 1-1 and using 3-(3,4-difluorobenzyl)pyrrolidine. LCMS (ESI): [M+H]352.

[0768] Biological data

[0769] OGA enzyme inhibition biochemical assay

[0770] Recombinant full-length human OGA enzyme was purchased from Origene. 4-MUGlCNAc substrate was purchased from Sigma. All other reagents were purchased from Sigma or Fisher. The assay buffer consisted of the McIlvaine buffer system (pH 6.4) (0.2 M Na 2 HPO 4 The reaction consisted of 1 nM OGA, 100 μM 4-MUGlcNAc (K m ) and compound in a final volume of 10 μl. The reaction was incubated at room temperature for 90 minutes and quenched with 40 μl 3M glycine (pH 10) and read on a PerkinElmer Envision plate reader (Ex: 355nm / Em: 460nm). Starting from 20 μM, a 10-point dose-response of the test compound was tested with 4-fold dilutions. Data were fitted using GraphPad Prism using a 4-parameter fit and a variable slope.

[0771] Table 1 below shows the activity data of some compounds of the present invention.

[0772]

[0773]

[0774]

[0775]

[0776] Although we have described many embodiments, it should be apparent that our basic examples can be altered to provide other embodiments that utilize the compounds and methods of the present disclosure. It should be understood, therefore, that the scope of the present disclosure will be limited by the appended claims rather than by the specific embodiments that have been shown by way of example.

[0777] The entire contents of all references cited throughout this application (including references, issued patents, published patent applications, and co-pending patent applications) are expressly incorporated herein by reference. Unless otherwise defined, all technical and scientific terms used herein have the meanings commonly known to those of ordinary skill in the art.

Claims

1. A compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof, in: Ar is optionally substituted 5- to 10-membered heteroaryl, optionally substituted phenyl, or optionally substituted phenyl fused to an optionally substituted non-aromatic 5- to 6-membered heterocyclic ring; Y 1 and Y 2 Each is CR c or N, where Y 1 or Y 2 At least one of them is N; Z is CR 2 R 2 、 C(=O), (CR 2 R 2 ) 2 、 CH 2 C(=O) or C(=O)CH 2 ; R a , R b and R c are independently -H, halogen, C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl or C 1 -C 4 Alkoxy, or R a and R b Together with its intervening carbon atom, it forms C 3 -C 6 Cycloalkyl; m is 0 or 1; n is 0 or an integer from 1 to 7; When n is not 0, R 1 is independently at each occurrence a halo, C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 1 -C 4 Alkoxy or C 1 -C 4 Haloalkoxy; R 2 is independently at each occurrence -H, halo, C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 3 -C 10 Cycloalkyl or C 3 -C 10 Halogenated cycloalkyl; Or alternatively, two R 2 Together with the carbon atom to which it is attached, it forms C 3 -C 10 Cycloalkyl; R 3 Yes - H or C 1 -C 4 alkyl; and R 4 Yes - H, C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl or C 3 -C 6 Cycloalkyl; Or alternatively, R 3 and R 4 Together with their intervening atoms they form an optionally substituted 5- to 7-membered heterocyclyl.

2. The compound according to claim 1, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof, in: Ar is optionally substituted 5- to 10-membered heteroaryl, optionally substituted phenyl, or optionally substituted phenyl fused to an optionally substituted non-aromatic 5- to 6-membered heterocyclic ring; Y 1 and Y 2 Each is CR c or N, where Y 1 or Y 2 At least one of them is N; Z is CR 2 R 2 、 C(=O), (CR 2 R 2 ) 2 、 CH 2 C(=O) or C(=O)CH 2 ; R a , R b and R c are independently -H, halogen, C 1 -C 4 Alkyl or C 1 -C 4 A haloalkyl group, or R a and R b Together with its intervening carbon atom, it forms C 3 -C 6 Cycloalkyl; m is 0 or 1; n is 0 or an integer from 1 to 7; When n is not 0, R 1 is independently at each occurrence a halo, C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 1 -C 4 Alkoxy or C 1 -C 4 Haloalkoxy; R 2 is independently at each occurrence -H, halo, C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 3 -C 10 Cycloalkyl or C 3 -C 10 Halogenated cycloalkyl; Or alternatively, two R 2 Together with the carbon atom to which it is attached, it forms C 3 -C 10 Cycloalkyl; R 3 Yes - H or C 1 -C 4 alkyl; and R 4 Yes - H, C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl or C 3 -C 6 Cycloalkyl; Or alternatively, R 3 and R 4 Together with their intervening atoms they form an optionally substituted 5- to 7-membered heterocyclyl.

3. The compound according to any one of claims 1 and 2, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

4. The compound according to any one of claims 1 to 3, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof; wherein R a and R b Each independently is -H or C 1 -C 4 alkyl; and R 2 is independently at each occurrence -H, halo, C 1 -C 4 alkyl.

5. The compound according to any one of claims 1 to 3, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof; wherein R a and R b Each independently is -H or C 1 -C 4 alkyl; and R 2 is independently at each occurrence -H, halo, C 1 -C 4 alkyl.

6. The compound according to any one of claims 1 to 3, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof; wherein R 2 is independently at each occurrence -H, halo, C 1 -C 4 alkyl.

7. The compound according to any one of claims 1 to 3, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof; wherein R 2 is independently at each occurrence -H, halo, C 1 -C 4 alkyl.

8. The compound according to any one of claims 1 to 4, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof; wherein R a and R b Each is independently -H or methyl; R 1 Is a halogen, C 1 -C 4 Alkyl or C 1 -C 4 haloalkyl; and R 2 -H or C independently at each occurrence 1 -C 4 alkyl.

9. The compound according to any one of claims 1 to 3 and 5, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof; wherein R a and R b Each is independently -H or methyl; R 1 Is a halogen, C 1 -C 4 Alkyl or C 1 -C 4 haloalkyl; and R 2 -H or C independently at each occurrence 1 -C 4 alkyl.

10. The compound according to any one of claims 1 to 4 and 8, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof; wherein R a and R b Each is independently -H or methyl; R 2 is independently at each occurrence -H or methyl; and R 1 It is -F or methyl.

11. The compound according to any one of claims 1 to 3, 5 and 9, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof; wherein R a and R b Each is independently -H or methyl; R 2 is independently at each occurrence -H or methyl; and R 1 It is -F or methyl.

12. The compound according to any one of claims 1 to 4, 8 and 10, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

13. The compound according to any one of claims 1 to 3, 5, 9 and 11, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

14. The compound according to any one of claims 1 to 3 and 6, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

15. The compound according to any one of claims 1 to 3 and 6, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

16. The compound according to any one of claims 1 and 2, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

17. The compound according to any one of claims 1, 2 and 16, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof; wherein R a and R b Each independently is -H or C 1 -C 4 alkyl; and R 2 is independently at each occurrence -H, halo, C 1 -C 4 alkyl.

18. The compound according to any one of claims 1, 2 and 16, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof; wherein R 2 is independently at each occurrence -H, halo, C 1 -C 4 alkyl.

19. The compound according to any one of claims 1, 2, 16 and 17, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof; wherein R a and R b Each is independently -H or methyl; R 1 Is a halogen, C 1 -C 4 Alkyl or C 1 -C 4 haloalkyl; and R 2 -H or C independently at each occurrence 1 -C 4 alkyl.

20. The compound according to any one of claims 1, 2, 16, 18 and 19, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof; wherein R a and R b Each is independently -H or methyl; R 2 is independently at each occurrence -H or methyl; and R 1 It is -F or methyl.

21. The compound according to any one of claims 1, 2, 16, 17, 19 and 20, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

22. The compound according to any one of claims 1, 2, 16 and 18, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

23. The compound of any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein Ar is optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted thiazolyl, optionally substituted phenyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted pyrazinyl, optionally substituted imidazo[1,2-a]pyridinyl, optionally substituted thieno[2,3-d]pyrimidinyl, or optionally substituted thieno[3,2-d]pyrimidinyl.

24. A compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein Ar is optionally substituted oxadiazolyl, optionally substituted 1,2,3-triazol-1-yl, optionally substituted triazolo[4,3-a]pyridin-3-yl, or optionally substituted 1H-benzo[d]imidazol-1-yl.

25. A compound according to any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein Ar is optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted or optionally substituted 26. A compound according to any one of claims 1 to 23 and 25, or a pharmaceutically acceptable salt thereof, wherein Ar is optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted or optionally substituted 27. A compound according to any one of claims 1 to 22 and 24, or a pharmaceutically acceptable salt thereof, wherein Ar is optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted or optionally substituted 28. A compound according to any one of claims 1 to 22, 24 and 27, or a pharmaceutically acceptable salt thereof, wherein Ar is optionally substituted 29. A compound according to any one of claims 1 to 28 or a pharmaceutically acceptable salt thereof, in: Ar is optionally substituted with one or more groups selected from: C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 3 -C 6 Cycloalkyl, halogen, -CN, -NO 2 、-OR z 、-NR x R y 、-S(O) i R x 、-NR x S(O) i R y 、-S(O) i NR x R y 、-C(=O)OR x 、-OC(=O)OR x 、-C(=S)OR y 、-O(C=S)R x 、-C(=O)NR x R y 、-NR x C(=O)R y 、-C(=S)NR x R y 、-NR x C(=S)R y 、-NR x (C=O)OR y 、-O(C=O)NR x R y 、-NR x (C=S)OR y 、-O(C=S)NR x R y 、-NR x (C=O)NR x R y 、-NR x (C=S)NR x R y 、-C(=S)R x 、-C(=O)R x , phenyl and monocyclic heteroaryl; in Ar on the C 1 -C 4 The alkyl substituents are optionally substituted with -CN, -NO 2 、-OR z 、-NR x R y 、-S(O) i R x 、-NR x S(O) i R y 、-S(O) i NR x R y 、-C(=O)OR x 、-OC(=O)OR x 、-C(=S)OR x ,-O(C=S)R x 、-C(=O)NR x R y 、-NR x C(=O)R y 、-C(=S)NR x R y -NR x C(=S)R y 、-NR x (C=O)OR y 、-O(C=O)NR x R y 、-NR x (C=S)OR y 、-O(C=S)NR x R y 、-NR x (C=O)NR x R y 、-NR x (C=S)NR x R y 、-C(=S)R x and -C(=O)R y , C 3 -C 6 Cycloalkyl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy and halomethoxy), monocyclic heteroaryl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy or halomethoxy) and phenyl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy, and halomethoxy); Ar on the C 3 -C 6 Cycloalkyl, phenyl and monocyclic heteroaryl substituents are optionally and independently substituted with: C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, halogen, -CN, -NO 2 、-OR z 、-NR x R y 、-S(O) i R x 、-NR x S(O) i R y 、-S(O) i NR x R y 、-C(=O)OR x 、-OC(=O)OR x 、-C(=S)OR x 、-O(C=S)R y 、-C(=O)NR x R y 、-NR x C(=O)R y 、-C(=S)NR x R y 、-NR x C(=S)R y 、-NR x (C=O)OR y 、-O(C=O)NR x R y 、-NR x (C=S)OR y 、-O(C=S)NR x R y 、-NR x (C=O)NR x R y 、-NR x (C=S)NR x R y 、-C(=S)R x and -C(=O)R x ; Each R x and each R y Independently -H, C 1 -C 4 Alkyl or C 3 -C 8 Cycloalkyl; wherein R x or R y The C 1 -C 4 Alkyl or C 3 -C 8 The cycloalkyl group is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, C 3 -C 6 Cycloalkyl and phenyl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy or halomethoxy); R z Yes - H, C 1 -C 4 Alkyl or C 3 -C 8 Cycloalkyl; wherein R z The C 1 -C 4 Alkyl or C 3 -C 8 The cycloalkyl group is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, C 3 -C 6 Cycloalkyl and phenyl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy, and halomethoxy); and i is 0, 1 or 2.

30. A compound according to any one of claims 1 to 29, or a pharmaceutically acceptable salt thereof, wherein Ar is optionally substituted with one or more groups selected from the group consisting of: C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 3 -C 6 Cycloalkyl, halogen, -CN, -OR z 、-NR x R y 、-C(=O)NR x R y 、-C(=S)NR x R y 、-O(C=O)NR x R y 、-O(C=S)NR x R y 、-C(=O)OR x 、-NR x C(=O)R y Phenyl, -C(=O)R x and optionally substituted monocyclic heteroaryl.

31. A compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, wherein Ar is optionally substituted with one or more groups selected from the group consisting of: C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 3 -C 6 Cycloalkyl, halogen, -OR z 、-C(=O)R x and optionally C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, halogen-substituted monocyclic heteroaryl.

32. A compound according to any one of claims 1 to 31 or a pharmaceutically acceptable salt thereof, wherein Ar is optionally substituted with one or more groups selected from: -CH 3、 -CH 2 CH 3 , halomethyl, cyclopentyl, cyclobutyl, halogen, -OR z 、-C(=O)R x and containing one or two heteroatoms selected from S and N and optionally C 1 -C 4 Alkyl-substituted 5-membered or 6-membered monocyclic heteroaryl; wherein R x Yes - H or C 1 -C 4 alkyl; and wherein R z is an optionally substituted C 1 -C 4 alkyl.

33. A compound according to any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein Ar is optionally substituted with one or more groups selected from: -CH 3 、-CH 2 CH 3 , -CHF 2 , -CF 3 , cyclopentyl, cyclobutyl, -F, -Cl, -Br, -OCH 3 、-C(=O)CH 3 and thiazolyl.

34. The compound according to claim 1, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof; wherein : Y 1 and Y 2 Each is CR c or N, where Y 1 or Y 2 At least one of them is N; Z is CR 2 R 2 、C(=O)、(CR 2 R 2 ) 2 、CH 2 C(=O) or C(=O)CH 2 ; R a , R b and R c are independently -H, halogen, C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl or C 1 -C 4 Alkoxy, or R a and R b Together with its intervening carbon atom, it forms C 3 -C 6 Cycloalkyl; m is 0 or 1; n is 0 or an integer from 1 to 7; When n is not 0, R 1 is independently at each occurrence a halo, C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 1 -C 4 Alkoxy or C 1 -C 4 Haloalkoxy; R 2 is independently at each occurrence -H, halo, C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 3 -C 10 Cycloalkyl or C 3 -C 10 Halogenated cycloalkyl; Or alternatively, two R 2 Together with the carbon atom to which it is attached, it forms C 3 -C 10 Cycloalkyl; R 3 Yes - H or C 1 -C 4 alkyl; and R 4 Yes - H, C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl or C 3 -C 6 Cycloalkyl; Or alternatively, R 3 and R 4 and together with their intervening atoms form an optionally substituted 5- to 7-membered heterocyclyl; R 5 Select C at each occurrence 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 3 -C 6 Cycloalkyl, halogen, -CN, -NO 2 、-OR z 、-NR x R y 、-S(O) i R x 、-NR x S(O) i R y 、-S(O) i NR x R y 、-C(=O)OR x 、-OC(=O)OR x 、-C(=S)OR y ,-O(C=S)R x 、-C(=O)NR x R y 、-NR x C(=O)R y 、-C(=S)NR x R y 、-NR x C(=S)R y 、-NR x (C=O)OR y 、-O(C=O)NR x R y 、-NR x (C=S)OR y 、-O(C=S)NR x R y 、-NR x (C=O)NR x R y 、-NR x (C=S)NR x R y 、-C(=S)R x 、-C(=O)R x , phenyl and monocyclic heteroaryl; in When R 5 It is C 1 -C 4 When the C 1 -C 4 The alkyl group is optionally and independently substituted with: -CN, -NO 2 、-OR z 、-NR x R y 、-S(O) i R x 、-NR x S(O) i R y 、-S(O) i NR x R y 、-C(=O)OR x 、-OC(=O)OR x 、-C(=S)OR x ,-O(C=S)R x 、-C(=O)NR x R y 、-NR x C(=O)R y 、-C(=S)NR x R y -NR x C(=S)R y 、-NR x (C=O)OR y 、-O(C=O)NR x R y 、-NR x (C=S)OR y 、-O(C=S)NR x R y 、-NR x (C=O)NR x R y 、-NR x (C=S)NR x R y 、-C(=S)R x and -C(=O)R y , C 3 -C 6 Cycloalkyl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy and halomethoxy), monocyclic heteroaryl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy or halomethoxy) and phenyl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy, and halomethoxy); When R 5 It is C 3 -C 6 When the cycloalkyl, phenyl or monocyclic heteroaryl group is substituted, the cycloalkyl, phenyl or monocyclic heteroaryl group is optionally and independently substituted by the following groups: 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, halogen, -CN, -NO 2 、-OR z 、-NR x R y 、-S(O) i R x 、-NR x S(O) i R y 、-S(O) i NR x R y 、-C(=O)OR x 、-OC(=O)OR x 、-C(=S)OR x 、-O(C=S)R y 、-C(=O)NR x R y 、-NR x C(=O)R y 、-C(=S)NR x R y 、-NR x C(=S)R y 、-NR x (C=O)OR y 、-O(C=O)NR x R y 、-NR x (C=S)OR y 、-O(C=S)NR x R y 、-NR x (C=O)NR x R y 、-NR x (C=S)NR x R y 、-C(=S)R x and -C(=O)R x ; Each R x and each R y Independently -H, C 1 -C 4 Alkyl or C 3 -C 8 Cycloalkyl; wherein R x or R y The C 1 -C 4 Alkyl or C 3 -C 8 The cycloalkyl group is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, C 3 -C 6 Cycloalkyl and phenyl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy or halomethoxy); R z Yes - H, C 1 -C 4 Alkyl or C 3 -C 8 Cycloalkyl; wherein R z The C 1 -C 4 Alkyl or C 3 -C 8 The cycloalkyl group is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, C 3 -C 6 Cycloalkyl and phenyl (optionally substituted with one or more groups selected from: -CH 3 , halomethyl, halo, methoxy, and halomethoxy); and i is 0, 1 or 2; and q is 0, 1, 2, or 3.

35. The compound according to claim 34, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

36. The compound according to claim 35, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof; wherein q is 0, 1, 2 or 3.

37. The compound of claim 34, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

38. The compound of claim 34, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

39. The compound according to claim 34, wherein the compound is represented by the formula: or a pharmaceutically acceptable salt thereof.

40. The compound of claim 34, wherein the compound is represented by the formula: or a pharmaceutically acceptable salt thereof; wherein q is 0, 1, 2 or 3.

41. The compound of claim 34, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

42. The compound of claim 34, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

43. The compound according to claim 34, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

44. The compound of claim 34, wherein the compound is represented by the formula: or a pharmaceutically acceptable salt thereof; wherein q is 0, 1, 2 or 3.

45. The compound according to claim 34, wherein the compound is represented by the formula: or a pharmaceutically acceptable salt thereof.

46. ​​The compound of claim 34, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

47. The compound of claim 34, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

48. The compound of claim 34, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

49. The compound of claim 34, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

50. The compound of claim 34, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

51. A compound according to any one of claims 1 to 50, or a pharmaceutically acceptable salt thereof, wherein R 3 Yes -H.

52. A compound according to any one of claims 1 to 51 or a pharmaceutically acceptable salt thereof, wherein R 4 Yes-CH 3 .

53. A compound according to any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, wherein R 5 Selected from C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 3 -C 6 Cycloalkyl, halogen, -CN, -OR z 、-NR x R y 、-C(=O)NR x R y 、-C(=S)NR x R y 、-O(C=O)NR x R y 、-O(C=S)NR x R y 、-C(=O)OR x 、-NR x C(=O)R y Phenyl, -C(=O)R x and optionally substituted monocyclic heteroaryl.

54. A compound according to any one of claims 1 to 53, or a pharmaceutically acceptable salt thereof, wherein R 5 Selected from C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 3 -C 6 Cycloalkyl, halogen, -OR z 、-C(=O)R x and optionally C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, halogen-substituted monocyclic heteroaryl.

55. A compound according to any one of claims 1 to 54, or a pharmaceutically acceptable salt thereof, wherein R 5 Selected from -CH 3 、-CH 2 CH 3 , halomethyl, cyclopentyl, cyclobutyl, halogen, -OR z 、-C(=O)R x and containing one or two heteroatoms selected from S and N and optionally C 1 -C 4 Alkyl-substituted 5-membered or 6-membered monocyclic heteroaryl; wherein R x Yes - H or C 1 -C 4 alkyl; and wherein R z is an optionally substituted C 1 -C 4 alkyl.

56. A compound according to any one of claims 1 to 55, or a pharmaceutically acceptable salt thereof, wherein R 5 Selected from -CH 3、 -CH 2 CH 3 , -CHF 2 , -CF 3 , cyclopentyl, cyclobutyl, -F, -Br, Cl, -OCH 3 、-C(=O)CH 3 and thiazolyl.

57. A compound according to any one of claims 1 to 56, or a pharmaceutically acceptable salt thereof, wherein R 5 Selected from -F, -Br and Cl.

58. A compound according to any one of claims 1 to 57, or a pharmaceutically acceptable salt thereof, wherein R a and R b One of them is -H and the other is selected from -CH 3 , -CF 3 and -OCH 3 .

59. A compound according to any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof, wherein n is 0 or 1.

60. A compound according to any one of claims 1 to 59, or a pharmaceutically acceptable salt thereof, wherein n is 0.

61. A pharmaceutical composition comprising a compound according to any one of claims 1 to 60 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

62. A method of treating a subject having a disease or disorder selected from a neurodegenerative disease, a tauopathy, diabetes, cancer, and stress, the method comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 60 or an effective amount of a pharmaceutical composition according to claim 61.

63. The method of claim 62, wherein the disease or condition is selected from acute ischemic stroke (AIS), Alzheimer's disease, dementia, amyotrophic lateral sclerosis (ALS), amyotrophic lateral sclerosis with cognitive impairment (ALSci), argyrophilic grain dementia, Britt's disease, corticobasal degeneration (CBP), dementia pugilistica, diffuse neurofibrillary tangles with calcifications, Down syndrome, epilepsy, familial English dementia, familial Danish dementia, frontotemporal dementia with Parkinsonism associated with chromosome 17 (FTDP-17), Jakobs-Straussler disease, Guadeloupe Parkinsonism, Habermann-Straussler disease (neurodegeneration with type 1 brain iron accumulation), ischemic stroke, mild cognitive impairment (MCI), multiple system atrophy, myotonic dystrophy, Nieto-Pitt disease (type C), globus pallidus-ponto-nigral degeneration, Guam Parkinsonism-dementia complex, Pick disease (PiD), postencephalitic parkinsonism (PEP), prion diseases (including Creutzfeldt-Jakob disease (GJD), variant Creutzfeldt-Jakob disease (vCJD), familial fatal insomnia, kuru, progressive supranuclear gliosis, progressive supranuclear palsy (PSP), Stein-Lee-Osborn syndrome, subacute sclerosing panencephalitis, pure entanglement dementia, Huntington's disease, and Parkinson's disease.

64. The method of any one of claims 62 and 63, wherein the disease or disorder is selected from acute ischemic stroke (AIS), Alzheimer's disease, dementia, amyotrophic lateral sclerosis (ALS), amyotrophic lateral sclerosis with cognitive impairment (ALSci), argyrophilic grain dementia, epilepsy, ischemic stroke, mild cognitive impairment (MCI), Huntington's disease, and Parkinson's disease.

65. The method of any one of claims 62 to 64, wherein the disease or disorder is Alzheimer's disease.

66. 1 kind suppresses the method for O-GlcNAcase in the experimenter in need, and described method comprises using an effective amount of the compound according to any one of claims 1 to 60 or an effective amount of the pharmaceutical composition according to claim 61 to described experimenter.

67. A method of treating a disease or disorder characterized by tau hyperphosphorylation in the brain, the method comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 60 or an effective amount of a pharmaceutical composition according to claim 61.